| AC451 |
Multiple organ condyloma acuminatum tissue array, 45 cases_45 cores |
|
331-Eur |
US Biomax |
tissue |
| AC451 |
Multiple organ condyloma acuminatum tissue array, 45 cases_45 cores; ihc Anti-Human Papilloma Virus (HPV) confimed |
|
210-Eur |
US Biomax |
tissue |
| AD2081 |
Adrenal gland disease spectrum (adrenal cancer progression) tissue array, 100 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| AD2081 |
Adrenal gland disease spectrum (adrenal cancer progression) tissue array, 100 cases_200 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| AG801 |
Adrenal tumor tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| AG801 |
Adrenal tumor tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| AMS541 |
Mouse(FBV strain) normal tissue array, cover 22 organs_anatomic sites, 3 cases_54 cores |
|
225-Eur |
US Biomax |
tissue |
| AMS541 |
Mouse(FBV strain) normal tissue array, cover 22 organs_anatomic sites, 3 cases_54 cores; ihc H&E |
|
238-Eur |
US Biomax |
tissue |
| AMS542 |
Mouse(KM strain) normal tissue array, cover 22 organs_anatomic sites, 3 cases_54 cores |
|
225-Eur |
US Biomax |
tissue |
| AMS542 |
Mouse(KM strain) normal tissue array, cover 22 organs_anatomic sites, 3 cases_54 cores; ihc H&E |
|
238-Eur |
US Biomax |
tissue |
| AMS543 |
Skin squamous cell carcinoma (SCC) tissue array, 80 cases_80 cores, no overlaps with SK801; ihc Anti-Cytokeratin (High MW) confirmed |
|
215-Eur |
US Biomax |
tissue |
| AMS544 |
Mouse normal tissue array, covering 22 organ_anatomic sites, 3 cases_54 cores |
|
225-Eur |
US Biomax |
tissue |
| AMS544 |
Mouse normal tissue array, covering 22 organ_anatomic sites, 3 cases_54 cores; ihc H&E |
|
238-Eur |
US Biomax |
tissue |
| ART661 |
Rat(Wistar strain) normal tissue array, covering all major organs, non-overlapping with ART662, 22 cases_66 cores |
|
225-Eur |
US Biomax |
tissue |
| ART661 |
Rat(Wistar strain) normal tissue array, covering all major organs, non-overlapping with ART662, 22 cases_66 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| ASM221 |
Cyno monkey normal tissue array, 22 cases_22 cores |
|
225-Eur |
US Biomax |
tissue |
| ASM221 |
Cyno monkey normal tissue array, 22 cases_22 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| BB01011 |
Gastric ulcer tissue array, 14 cases _24 cores |
|
160-Eur |
US Biomax |
tissue |
| BB01011 |
Gastric ulcer tissue array, 14 cases _24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC000110 |
Colorectal cancer tissue array, 85 cases_170 cores |
|
397-Eur |
US Biomax |
recombinant |
| BC000110 |
Colorectal cancer tissue array, 85 cases_170 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
recombinant |
| BC000111 |
Multiple organ cancer tissue array, 39 cases_39 cores |
|
189-Eur |
US Biomax |
tissue |
| BC000111 |
Multiple organ cancer tissue array, 39 cases_39 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC000119 |
Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| BC000119 |
Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases_200 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BC00012 |
Multiple organ diseased tissue array, 30 cases_60 cores, replaced by MC801 |
|
160-Eur |
US Biomax |
tissue |
| BC00012 |
Multiple organ diseased tissue array, 30 cases_60 cores, replaced by MC801; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC000120 |
Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| BC000120 |
Multi-organ carcinoma tissue array, including TNM, clinical stage and pathology grade, 200 cases_200 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BC00014 |
Multiple organ diseased tissue array, 63 cases_63 cores, replaced by MC631 |
|
160-Eur |
US Biomax |
tissue |
| BC00014 |
Multiple organ diseased tissue array, 63 cases_63 cores, replaced by MC631; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC00016 |
Multiple organ diseased tissues, 54 cases_54 cores, replaced by MC541 |
|
160-Eur |
US Biomax |
tissue |
| BC00016 |
Multiple organ diseased tissues, 54 cases_54 cores, replaced by MC541; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC00019 |
Multiple organ squamous cell carcinoma tissue array, 63 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC00019 |
Multiple organ squamous cell carcinoma tissue array, 63 cases_63 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC00111 |
Multiple organ normal and diseased tissue array (replaced by MCN601), 54 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| BC00111 |
Multiple organ normal and diseased tissue array (replaced by MCN601), 54 cases_60 cores; ihc Anti-SMA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC001111 |
Multiple organ normal and diseased tissue array, 58 cases_60 cores, replaced by MCN601 |
|
231-Eur |
US Biomax |
tissue |
| BC001111 |
Multiple organ normal and diseased tissue array, 58 cases_60 cores, replaced by MCN601; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC001113 |
Esophageal adenocarcinoma, cardia adenocarcinoma, normal esophageal and cardia tissue array, 50 cases_50 cores (previously cat# ES501) |
|
189-Eur |
US Biomax |
tissue |
| BC001113 |
Esophageal adenocarcinoma, cardia adenocarcinoma, normal esophageal and cardia tissue array, 50 cases_50 cores (previously cat# ES501); ihc Anti-Cytokeratin (Low MW) confirmed Certified pathologist c |
|
267-Eur |
US Biomax |
tissue |
| BC00112 |
Multiple organ paired normal and cancer (8 types) tissue array, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BC00112 |
Multiple organ paired normal and cancer (8 types) tissue array, 48 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC001128 |
Top five cancer tissue array, including TNM and pathology grade, 148 cases_175 cores |
|
485-Eur |
US Biomax |
tissue |
| BC001128 |
Top five cancer tissue array, including TNM and pathology grade, 148 cases_175 cores |
|
397-Eur |
US Biomax |
tissue |
| BC001128 |
Top five cancer tissue array, including TNM and pathology grade, 148 cases_175 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC00113 |
Multiple organs tumor and normal tissue, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BC00113 |
Multiple organs tumor and normal tissue, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BC001130 |
Pancreatic carcinoma and multi-organ adjacent tissue array, including TNM, clinical stage and pathology grade, 81 cases_121 cores |
|
278-Eur |
US Biomax |
tissue |
| BC001130 |
Pancreatic carcinoma and multi-organ adjacent tissue array, including TNM, clinical stage and pathology grade, 81 cases_121 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC001134 |
Multiple organs tumor and normal tissue array, including TNM, clinical stage and pathology grade, 150 cases_150 cores |
|
397-Eur |
US Biomax |
tissue |
| BC001134 |
Multiple organs tumor and normal tissue array, including TNM, clinical stage and pathology grade, 150 cases_150 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| BC00114 |
Multiple organ normal and diseased tissue array, 36 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| BC00114 |
Multiple organ normal and diseased tissue array, 36 cases_60 cores; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC00115 |
Multiple organ normal and diseased tissue array, 44 cases_64 cores, replaced by MC802 |
|
231-Eur |
US Biomax |
tissue |
| BC00115 |
Multiple organ normal and diseased tissue array, 44 cases_64 cores, replaced by MC802; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC00116 |
Carcinoma with adjacent-tissue combined panel tissue array, 44 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| BC00116 |
Carcinoma with adjacent-tissue combined panel tissue array, 44 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC00119 |
Multiple organ diseased tissue array, 32 cases_32 cores, replaced by MC483 |
|
160-Eur |
US Biomax |
tissue |
| BC00119 |
Multiple organ diseased tissue array, 32 cases_32 cores, replaced by MC483; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC00432 |
Multiple organ tumor and adjacent normal tissue array, 39 cases_43 cores |
|
160-Eur |
US Biomax |
tissue |
| BC00432 |
Multiple organ tumor and adjacent normal tissue array, 39 cases_43 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC01001 |
Tissue array of gastric diseases biopsied from gastroscope, including TNM, clinical stage and pathology grade, 18 cases_18 cores |
|
231-Eur |
US Biomax |
tissue |
| BC01001 |
Tissue array of gastric diseases biopsied from gastroscope, including TNM, clinical stage and pathology grade, 18 cases_18 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC01011 |
Stomach carcinoma (multi-tissue combined panel) tissue array, 24 cases _72 cores, replaced by ST721 |
|
160-Eur |
US Biomax |
tissue |
| BC01011 |
Stomach carcinoma (multi-tissue combined panel) tissue array, 24 cases _72 cores, replaced by ST721; ihc Anti-Cytokeratin (CK) confirmed |
|
162-Eur |
US Biomax |
tissue |
| BC01014 |
Stomach carcinoma tissue array (multi-tissue combined panel), 71 cases _72 cores, replaced by ST807 |
|
231-Eur |
US Biomax |
tissue |
| BC01014 |
Stomach carcinoma tissue array (multi-tissue combined panel), 71 cases _72 cores, replaced by ST807; ihc CgA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC01022 |
Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases _63 cores |
|
160-Eur |
US Biomax |
tissue |
| BC01022 |
Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases _63 cores; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC01023 |
Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases _63 cores |
|
160-Eur |
US Biomax |
tissue |
| BC01023 |
Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases _63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC01024 |
Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases _63 cores |
|
160-Eur |
US Biomax |
tissue |
| BC01024 |
Stomach adenocarcinoma (combination of adjacent and normal) tissue array, 21 cases _63 cores, replaced by ST722; ihc Anti-Cytokeratin (CK) confirmed |
|
162-Eur |
US Biomax |
tissue |
| BC01071 |
Carcinoma of stomach, liver and rectum tissue array, 45 cases _48 cores |
|
160-Eur |
US Biomax |
recombinant |
| BC01071 |
Carcinoma of stomach, liver and rectum tissue array, 45 cases _48 cores, replaced by BC01071a; ihc Anti-P53 confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BC01071a |
Multiple organ cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores, replacing BC01071; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC01081 |
Adenocarcinoma of stomach, colon and rectum high density tissue array, 556 cases_616 cores |
|
456-Eur |
US Biomax |
recombinant |
| BC01081 |
Adenocarcinoma of stomach, colon and rectum high density tissue array, 556 cases_616 cores; ihc Anti-EMA confirmed |
|
487-Eur |
US Biomax |
recombinant |
| BC01114 |
Stomach adenocarcinoma with matched adjacent tissue and normal tissue array, including TNM, clinical stage and pathology grade, 55 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| BC01114 |
Stomach adenocarcinoma with matched adjacent tissue and normal tissue array, including TNM, clinical stage and pathology grade, 55 cases_100 cores, replaced by ST1004; ihc Anti-Cytokeratin (CK) confi |
|
258-Eur |
US Biomax |
tissue |
| BC02011 |
Multiple esophageal cancer tissue array, 69 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC02011 |
Multiple esophageal cancer tissue array, 69 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC02012 |
Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC02012 |
Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC02013 |
Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC02013 |
Esophageal carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC02021 |
Esophagus squamous carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores |
|
160-Eur |
US Biomax |
tissue |
| BC02021 |
Esophagus squamous carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC02022 |
Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores |
|
160-Eur |
US Biomax |
tissue |
| BC02022 |
Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC02023 |
Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases_54cores, replaced by ES722 |
|
160-Eur |
US Biomax |
tissue |
| BC02023 |
Esophagus squamous cell carcinoma (combination of adjacent and normal) tissue array, 18 cases_54cores, replaced by ES722 ; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC02111 |
Esophagus adenocarcinoma and normal tissue array, 23 cases_80 cores |
|
189-Eur |
US Biomax |
tissue |
| BC02111 |
Esophageal adenocarcinoma tissue array with matched normal adjacent tissue, 21 cases_80 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC03002 |
Liver disease spectrum tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BC03002 |
Liver disease spectrum tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC03011 |
Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by LV8010 |
|
160-Eur |
US Biomax |
tissue |
| BC03011 |
Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by LV8010; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC03013 |
Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by LV723 |
|
160-Eur |
US Biomax |
tissue |
| BC03013 |
Liver carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by LV723; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC03021 |
Liver carcinoma (combination of adjacent and normal) tissue array, 42 cases_63 cores, replaced by LV803 |
|
231-Eur |
US Biomax |
tissue |
| BC03021 |
Liver carcinoma (combination of adjacent and normal) tissue array, 42 cases_63 cores, replaced by LV803; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC03116 |
Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 70 cases_70 cores |
|
231-Eur |
US Biomax |
tissue |
| BC03116 |
Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 70 cases_70 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC03118 |
Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| BC03118 |
Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases_200 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| BC03119 |
Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores |
|
278-Eur |
US Biomax |
tissue |
| BC03119 |
Liver carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC04002 |
Lung disease spectrum tissue array, including TNM, clinical stage and pathology grade, 99 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BC04002 |
Lung disease spectrum tissue array, including TNM, clinical stage and pathology grade, 99 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC04011 |
Lung cancer tissue array, including pathology grade, 23 cases_63 cores, replaced by LC721; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC04012 |
Lung carcinoma (multi-tissue combined panel) tissue array, 68 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC04012 |
Lung carcinoma (multi-tissue combined panel) tissue array, 68 cases_72 cores, replaced by BC04016; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC04013 |
Non-small cell lung carcinoma tissue array, 63 cases_63 core, replaced by LC806 |
|
160-Eur |
US Biomax |
tissue |
| BC04013 |
Non-small cell lung carcinoma tissue array, 63 cases_63 core, replaced by LC806; ihc CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC04014 |
Non-small cell lung carcinoma (NSCLC) tissue array, 63 cases_63 cores, replaced by LC807 |
|
160-Eur |
US Biomax |
tissue |
| BC04014 |
Non-small cell lung carcinoma (NSCLC) tissue array, 63 cases_63 cores, replaced by LC807; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC04015 |
Lung carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BC04015 |
Lung carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
162-Eur |
US Biomax |
tissue |
| BC04016 |
Lung carcinoma tissue array, 72 cases_72 cores, replaced by LC726 |
|
160-Eur |
US Biomax |
tissue |
| BC04016 |
Lung carcinoma tissue array, 72 cases_72 cores, replaced by LC726; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC04021 |
Lung carcinoma (multi-tissue combined panel) tissue array, 72 cases _72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC04021 |
Lung carcinoma (multi-tissue combined panel) tissue array, 72 cases _72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC04022 |
Non-small cell lung carcinoma (NSCLC)(combination of adjacent and normal) tissue array, 18 cases_54 cores |
|
160-Eur |
US Biomax |
tissue |
| BC04022 |
Non-small cell lung carcinoma (NSCLC)(combination of adjacent and normal) tissue array, 18 cases_54 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC041114 |
Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| BC041114 |
Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases_200 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BC041115 |
Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores |
|
278-Eur |
US Biomax |
tissue |
| BC041115 |
Lung carcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores, replaced by BC041115a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC041115a |
Lung cancer tissue array with normal lung tissue, including TNM, clinical stage and pathology grade, 120 cases_120 cores, replacing BC041115; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC04118 |
Lung squamous cell carcinoma and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| BC04118 |
Lung squamous cell carcinoma and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC04119 |
Lung adenocarcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 30 cases_40 cores, replaced by BC04119b |
|
231-Eur |
US Biomax |
tissue |
| BC04119 |
Lung adenocarcinoma and normal tissue array, including TNM, clinical stage and pathology grade, 30 cases_40 cores, replaced by BC04119b; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC04119b |
Lung adenocarcinoma tissue array with normal lung tissue, including TNM and pathology grade,30 cases_40 cores, replacing BC04119 |
|
336-Eur |
US Biomax |
tissue |
| BC04119b |
Lung adenocarcinoma tissue array with normal lung tissue, including TNM and pathology grade,30 cases_40 cores, replacing BC04119 |
|
278-Eur |
US Biomax |
tissue |
| BC04119b |
Lung adenocarcinoma tissue array with normal lung tissue, including TNM and pathology grade,30 cases_40 cores, replacing BC04119; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC05002 |
Colon disease spectrum tissue array, including TNM, clinical stage and pathology grade, 79 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BC05002 |
Colon disease spectrum tissue array, including TNM, clinical stage and pathology grade, 79 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC05011 |
Multiple types of colon carcinoma tissue array, 72 cases_72 cores, replaced by CO804 |
|
231-Eur |
US Biomax |
tissue |
| BC05011 |
Multiple types of colon carcinoma tissue array, 72 cases_72 cores, replaced by CO804; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC050112 |
Colon metastatic carcinoma tissue array, 23 cases_63 cores, replaced by CO726 |
|
231-Eur |
US Biomax |
tissue |
| BC050112 |
Colon metastatic carcinoma tissue array, 23 cases_63 cores, replaced by CO726; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC05012 |
Colon carcinoma (multi-tissue combined panel) tissue array, 70 cases_72 cores. |
|
231-Eur |
US Biomax |
tissue |
| BC05012 |
Colon carcinoma (multi-tissue combined panel) tissue array, 70 cases_72 cores.; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC05021 |
Colon adenocarcinoma (combination of adjacent and adjacent normal) tissue array, 18 cases_54 cores, no overlapping with BC05022, replaced by CO722 |
|
231-Eur |
US Biomax |
tissue |
| BC05021 |
Colon adenocarcinoma (combination of adjacent and adjacent normal) tissue array, 18 cases_54 cores, no overlapping with BC05022, replaced by CO722; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC05022 |
Colon adenocarcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores, no overlapping with BC05021 |
|
231-Eur |
US Biomax |
tissue |
| BC05022 |
Colon adenocarcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores, no overlapping with BC05021; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC05023 |
Colon adenocarcinoma (combination of adjacent and normal) tissue array, with grade and stage (TNM) info, 18 cases_54 cores |
|
231-Eur |
US Biomax |
tissue |
| BC05023 |
Colon adenocarcinoma (combination of adjacent and normal) tissue array, with grade and stage (TNM) info, 18 cases_54 cores; ihc Anti-Epithelial Membrane Antigen (EMA) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC051110 |
Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores |
|
278-Eur |
US Biomax |
tissue |
| BC051110 |
Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC051111 |
Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| BC051111 |
Colon cancer and normal tissue array, including TNM, clinical stage and pathology grade, 100 cases_200 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BC05115 |
Colon cancer, metastasize to lymph node and liver, and normal tissue array, including TNM, clinical stage and pathology grade, 68 cases_69 cores, replaced by CO702 |
|
231-Eur |
US Biomax |
tissue |
| BC05115 |
Colon cancer, metastasize to lymph node and liver, and normal tissue array, including TNM, clinical stage and pathology grade, 68 cases_69 cores, replaced by CO702; ihc Anti-Cytokeratin (Low-MW) conf |
|
258-Eur |
US Biomax |
tissue |
| BC05118 |
Colon cancer and matched adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BC05118 |
Colon cancer and matched adjacent normal tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replaced by BC05118a; ihc Anti-actin confirmed Certified pathologist code |
|
296-Eur |
US Biomax |
tissue |
| BC05118a |
Colon cancer tissue array with matched adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replacing BC05118; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC06002 |
Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases_72 cores |
|
321-Eur |
US Biomax |
recombinant |
| BC06002 |
Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases_72 cores |
|
266-Eur |
US Biomax |
recombinant |
| BC06002 |
Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases_72 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
recombinant |
| BC06011 |
Rectum carcinoma (multi-tissue combined panel) tissue array, 71 cases_72 cores |
|
160-Eur |
US Biomax |
recombinant |
| BC06011 |
Rectum carcinoma (multi-tissue combined panel) tissue array, 71 cases_72 cores; ihc Anti-CEA confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BC06022 |
Rectum carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores, replaced by RE722 |
|
160-Eur |
US Biomax |
recombinant |
| BC06022 |
Rectum carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores, replaced by RE722; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BC07001 |
Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases_80 cores |
|
321-Eur |
US Biomax |
tissue |
| BC07001 |
Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BC07001 |
Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BC07011 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores, replaced by BC07013 |
|
160-Eur |
US Biomax |
tissue |
| BC07011 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores, replaced by BC07013; ihc Anti-EMA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC07012 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores, replaced by BC07015 |
|
160-Eur |
US Biomax |
tissue |
| BC07012 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores, replaced by BC07015; ihc Anti-EMA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC07013 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores, replacing BC07011 |
|
160-Eur |
US Biomax |
tissue |
| BC07013 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores, replacing BC07011; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC07014 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC07014 |
Kidney carcinoma (multi-tissue combined panel) tissue array, 72 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC07014a |
Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replacing BC07014; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC07015 |
Multiple type kidney cancer tissue array with normal tissues, 71 cases_72 cores, replacing BC07012 |
|
231-Eur |
US Biomax |
tissue |
| BC07015 |
Multiple type kidney cancer tissue array with normal tissues, 71 cases_72 cores, replacing BC07012; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC07114 |
Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 100 cases_200 cores |
|
558-Eur |
US Biomax |
tissue |
| BC07114 |
Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 100 cases_200 cores |
|
456-Eur |
US Biomax |
tissue |
| BC07114 |
Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 100 cases_200 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BC07115 |
Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 120 cases_120 cores |
|
321-Eur |
US Biomax |
tissue |
| BC07115 |
Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 120 cases_120 cores |
|
266-Eur |
US Biomax |
tissue |
| BC07115 |
Kidney clear cell carcinoma tissue array, including TNM and pathology grade, 120 cases_120 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC08013 |
Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by BC08014 |
|
160-Eur |
US Biomax |
tissue |
| BC08013 |
Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by BC08014; ihc Anti-ER confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC08014 |
Breast cancer (multiple types of breast cancer) tissue array, 63 cases_63 cores, replaced by BR8018 |
|
160-Eur |
US Biomax |
tissue |
| BC08014 |
Breast cancer (multiple types of breast cancer) tissue array, 63 cases_63 cores, replaced by BR8018; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC08015 |
Breast carcinoma (multi-tissue combined panel) tissue array, 22 cases_63 cores, replaced by BR728 |
|
160-Eur |
US Biomax |
tissue |
| BC08015 |
Breast carcinoma (multi-tissue combined panel) tissue array, 22 cases_63 cores, replaced by BR728; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC08016 |
Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by BR803 |
|
160-Eur |
US Biomax |
tissue |
| BC08016 |
Breast carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by BR803; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC08022 |
Breast carcinoma (combination of adjacent and normal) tissue array, 53 cases_63 cores, replacing BN08021 |
|
160-Eur |
US Biomax |
tissue |
| BC08022 |
Breast carcinoma (combination of adjacent and normal) tissue array, 53 cases_63 cores, replacing BN08021; ihc Anti-ER confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC08023 |
Breast carcinoma (combination of adjacent and normal) tissue array, 57 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC08023 |
Breast carcinoma (combination of adjacent and normal) tissue array, 57 cases_63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC08032 |
Infiltrating duct carcinoma (combination of adjacent and normal) tissue array, 57 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC08032 |
Infiltrating duct carcinoma (combination of adjacent and normal) tissue array, 57 cases_63 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC081115 |
Breast cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases_110 cores, replaced by BC081120 |
|
278-Eur |
US Biomax |
tissue |
| BC081115 |
Breast cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases_110 cores, replaced by BC081120; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC081116 |
Breast cancer (IDC) tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases_110 cores |
|
278-Eur |
US Biomax |
tissue |
| BC081116 |
Breast cancer (IDC) tissue array, with adjacent normal tissue, including TNM and pathology grade, 110 cases_110 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC081120 |
Breast cancer and adjacent normal tissue array, including TNM and pathology grade, 110 cases_110 cores, replacing BC081115 |
|
266-Eur |
US Biomax |
tissue |
| BC081120 |
Breast cancer and adjacent normal tissue array, including TNM and pathology grade, 110 cases_110 cores, replacing BC081115; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC08118 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases_100 cores |
|
321-Eur |
US Biomax |
tissue |
| BC08118 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BC08118 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases_100 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BC09012 |
Endometrial carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC09012 |
Endometrial carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC10021 |
Cervix carcinoma (combination of margin and normal tissues) tissue array, 64 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| BC10021 |
Cervix carcinoma (combination of margin and normal tissues) tissue array, 64 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC10025 |
Cervical cancer and normal tissue array, 54 cases_54 cores |
|
231-Eur |
US Biomax |
tissue |
| BC10025 |
Cervical cancer and normal tissue array, 54 cases_54 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC11011 |
Ovarian carcinoma (multi-tissue combined panel) tissue array (replaced by OV802), 70 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC11011 |
Ovarian carcinoma (multi-tissue combined panel) tissue array (replaced by OV802), 70 cases_72 cores; ihc Anti-EMA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC110118 |
Ovarian cancer tissue array, including TNM and pathology grade, 72 cases_72 cores, replacing BC11012 |
|
231-Eur |
US Biomax |
tissue |
| BC110118 |
Ovarian cancer tissue array, including TNM and pathology grade, 72 cases_72 cores, replacing BC11012; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| BC11012 |
Ovarian carcinoma (multi-tissue combined panel) tissue array, 70 cases_72 cores |
|
160-Eur |
US Biomax |
tissue |
| BC11012 |
Ovarian carcinoma (multi-tissue combined panel) tissue array, 70 cases_72 cores, replaced by BC11012a; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC11012a |
Ovary cancer tissue array, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replacing BC11012; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC111109 |
Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases_70 cores |
|
231-Eur |
US Biomax |
tissue |
| BC111109 |
Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases_70 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| BC111110 |
Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases_70 cores |
|
231-Eur |
US Biomax |
tissue |
| BC111110 |
Ovary cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 70 cases_70 cores, replaced by OV701; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| BC11115 |
Ovary serous papillary adenocarcinoma, lymph node metastasis with adjacent normal ovary tissue array, including TNM and pathology grade, 100 cases_100 cores |
|
321-Eur |
US Biomax |
tissue |
| BC11115 |
Ovary serous papillary adenocarcinoma, lymph node metastasis with adjacent normal ovary tissue array, including TNM and pathology grade, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BC11115 |
Ovary serous papillary adenocarcinoma, lymph node metastasis with adjacent normal ovary tissue array, including TNM and pathology grade, 100 cases_100 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BC12011a |
Bladder cancer tissue array, including TNM, clinical stage and pathology grade, 63 cases_63 cores, replacing BC12011; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| BC12012 |
Bladder carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by BL802 |
|
231-Eur |
US Biomax |
tissue |
| BC12012 |
Bladder carcinoma (multi-tissue combined panel) tissue array, 63 cases_63 cores, replaced by BL802; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC14012 |
Pancreatic cancer (multi-tissue combined panel), 24 cases_63 cores, replaced by PA721 |
|
231-Eur |
US Biomax |
tissue |
| BC14012 |
Pancreatic cancer (multi-tissue combined panel), 24 cases_63 cores, replaced by PA721; ihc Anti-Cytokeration (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC15012 |
Thyroid carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC15012 |
Thyroid carcinoma (multi-tissue combined panel) tissue array, 23 cases_63 cores; ihc Anti-Thyroglobulin (TG) antibody confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC17012 |
Medulloblastoma of brain tissue array, 100 cases_100 cores |
|
277-Eur |
US Biomax |
tissue |
| BC17012 |
Medulloblastoma of brain tissue array, 100 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| BC17012 |
Medulloblastoma of brain tissue array, 20 cases_60 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| BC17013 |
Brain astrocytoma and meningioma tissue array, 120 cases_120 cores |
|
321-Eur |
US Biomax |
tissue |
| BC17013 |
Brain astrocytoma and meningioma tissue array, 120 cases_120 cores |
|
266-Eur |
US Biomax |
tissue |
| BC17013 |
Brain astrocytoma and meningioma tissue array, 120 cases_120 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC19012 |
Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases_63 cores, replaced by PR808 |
|
231-Eur |
US Biomax |
tissue |
| BC19012 |
Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases_63 cores, replaced by PR808; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC19013 |
Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC19013 |
Prostate carcinoma (multi-tissue combined panel) tissue array, 33 cases_63 cores; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC19014 |
Prostate carcinoma tissue array, 31 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC19014 |
Prostate carcinoma tissue array, 31 cases_63 cores; ihc Anti-PTEN confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC19015 |
Prostate carcinoma tissue array, 9 cases_27 cores |
|
160-Eur |
US Biomax |
tissue |
| BC19015 |
Prostate carcinoma tissue array, 9 cases_27 cores; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC19017 |
Prostate carcinoma tissue array, 33 cases_63 cores, replaced by PR809 |
|
160-Eur |
US Biomax |
tissue |
| BC19017 |
Prostate carcinoma tissue array, 33 cases_63 cores, replaced by PR809; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC19019 |
Prostate cancer and hyperplasia tissue array, 33 cases_63 cores, replacing BC19011 |
|
231-Eur |
US Biomax |
tissue |
| BC19019 |
Prostate cancer and hyperplasia tissue array, 33 cases_63 cores, replacing BC19011; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC19021 |
Prostate cancer, adjacent normal tissue and normal tissue array, including TNM, clinical stage and pathology grade, 20 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| BC19021 |
Prostate cancer, adjacent normal tissue and normal tissue array, including TNM, clinical stage and pathology grade, 20 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BC19111 |
Normal prostate tissue array, with prostate tumor and hyperplasia, 11 cases_30 cores |
|
160-Eur |
US Biomax |
tissue |
| BC19111 |
Normal prostate tissue array, with prostate tumor and hyperplasia, 11 cases_30 cores; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC21011 |
Skin malignant tumor tissue array, 78 cases_78 cores (squamous carcinoma, adenocarcinoma, basal cell carcinoma, sarcoma, melanoma), replaced by BC21014 |
|
231-Eur |
US Biomax |
tissue |
| BC21011 |
Skin malignant tumor tissue array, 78 cases_78 cores (squamous carcinoma, adenocarcinoma, basal cell carcinoma, sarcoma, melanoma), replaced by BC21014; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC21014 |
Skin malignant tumor tissue array, 78 cases_78 cores, replacing BC21011 |
|
231-Eur |
US Biomax |
tissue |
| BC21014 |
Skin malignant tumor tissue array, 78 cases_78 cores, replacing BC21011; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC23011 |
Testis tumor combination, 24 cases_72 cores |
|
231-Eur |
US Biomax |
assays |
| BC23011 |
Testis tumor combination, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
assays |
| BC23012 |
Testis tumor tissue array, 23 cases_63 cores |
|
231-Eur |
US Biomax |
assays |
| BC23012 |
Testis tumor tissue array, 23 cases_63 cores; ihc Anti-LCA confirmed |
|
267-Eur |
US Biomax |
assays |
| BC24011 |
Soft tissue tumor (multi-tissue combined panel) tissue array, 63 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BC24011 |
Soft tissue tumor (multi-tissue combined panel) tissue array, 63 cases_63 cores; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC24021 |
Leiomyosarcoma and Rhabdomyosarcoma tissue array with normal muscles controls, 39 cases_75 cores |
|
231-Eur |
US Biomax |
tissue |
| BC24021 |
Leiomyosarcoma and Rhabdomyosarcoma tissue array with normal muscles controls, 39 cases_75 cores, replaced by SO751; ihc Anti-Des confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC27011 |
Multiple organs, diseased tissue array of oral cavity, 47 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BC27011 |
Multiple organs, diseased tissue array of oral cavity, 47 cases_48 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC30011 |
Heart tissue array, 13 cases_34 cores, replaced by BC30013 |
|
231-Eur |
US Biomax |
tissue |
| BC30011 |
Heart tissue array, 13 cases_34 cores, replaced by BC30013; ihc Anti-Vimentin (Vim) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC30013 |
Heart disease and normal tissue array, replacing BC30011, 18 cases_36 cores |
|
231-Eur |
US Biomax |
tissue |
| BC30013 |
Heart disease and normal tissue array, replacing BC30011, 18 cases_36 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BC34011 |
Head and neck squamous cell carcinoma tissue array, 24 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BC34011 |
Head and neck squamous cell carcinoma tissue array, 24 cases_63 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BC34111 |
Multiple head and neck squamous cell carcinoma tissue array with normal tissue, 36 cases_72 cores, replaced by HN811 |
|
160-Eur |
US Biomax |
tissue |
| BC34111 |
Multiple head and neck squamous cell carcinoma tissue array with normal tissue, 36 cases_72 cores, replaced by HN811; ihc Anti-H-CK confirmed |
|
228-Eur |
US Biomax |
tissue |
| BC35111 |
Retinoblastoma and normal adjacent tissue array, 17 cases_34 cores |
|
189-Eur |
US Biomax |
tissue |
| BC35111 |
Retinoblastoma and normal adjacent tissue array, 17 cases_34 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| BCN721 |
Multiple cancer (12 common types) tissue array with unmatched normal adjacent tissue, 71 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| BCN721 |
Multiple cancer (12 common types) tissue array with unmatched normal adjacent tissue, 71 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BCN801 |
Multiple organ cancer with adjacent tissue combined panel tissue array, 48 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| BCN801 |
Multiple organ cancer with adjacent tissue combined panel tissue array, 48 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BCN961 |
Multiple organ cancer tissue array with adjacent cancer tissue control tissue array, 57 cases_96 cores, replaced by BCN963 |
|
231-Eur |
US Biomax |
elisa |
| BCN961 |
Multiple organ cancer tissue array with adjacent cancer tissue control tissue array, 57 cases_96 cores, replaced by BCN963; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
elisa |
| BCN962 |
Combined multiple normal and cancer tissue array, containing germline, embryonic tumors and normal adjacent tissue, 60 cases_96 cores |
|
231-Eur |
US Biomax |
elisa |
| BCN962 |
Combined multiple normal and cancer tissue array, containing germline, embryonic tumors and normal adjacent tissue, 60 cases_96 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
elisa |
| BCN963 |
Multiple organ cancer and adjacent normal tissue array, including TNM and pathology grade, 78 cases_96 cores, replacing BCN961 |
|
266-Eur |
US Biomax |
elisa |
| BCN963 |
Multiple organ cancer and adjacent normal tissue array, including TNM and pathology grade, 78 cases_96 cores, replaced by BCN963a; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| BCN963a |
Multiple organ tumor and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 81 cases_96 cores, replacing BCN963; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| BE01014 |
Multiple organ, normal fetus tissue array, 26 cases_78 cores |
|
189-Eur |
US Biomax |
tissue |
| BE01014 |
Multiple organ, normal fetus tissue array, 26 cases_78 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BE01015 |
Multiple organ, normal fetus tissue array, 50 cases_50 cores |
|
189-Eur |
US Biomax |
tissue |
| BE01015 |
Multiple organ, normal fetus tissue array, 50 cases_50 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BL1001 |
Bladder cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BL1001 |
Bladder cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL1002 |
Bladder cancer and normal tissue array, including TNM and pathology grade, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BL1002 |
Bladder cancer and normal tissue array, including TNM and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL1501 |
Bladder cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BL1921 |
Mid-advanced stage bladder cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| BL1921 |
Mid-advanced stage bladder cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
elisa |
| BL208 |
Tissue microarray of bladder cancer and normal tissue, high density (69 cases_208 cores) with grade and stage data |
|
456-Eur |
US Biomax |
tissue |
| BL208 |
Tissue microarray of bladder cancer and normal tissue, high density (69 cases_208 cores) with grade and stage data; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BL2081 |
Bladder cancer high density tissue array, 203 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BL2081 |
Bladder cancer high density tissue array, 203 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BL2082 |
Bladder disease spectrum (bladder cancer progression) tissue array, 202 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BL2082 |
Bladder disease spectrum (bladder cancer progression) tissue array, 202 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BL241 |
Bladder cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| BL241 |
Bladder cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| BL242 |
Bladder cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BL242 |
Bladder cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BL243 |
Bladder cancer tissue array with normal tissues from autopsy, 12 cases_24 cores with stage and grade data |
|
100-Eur |
US Biomax |
tissue |
| BL243 |
Bladder cancer tissue array with normal tissues from autopsy, 12 cases_24 cores with stage and grade data; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
tissue |
| BL244 |
Bladder cancer tissue array with matched adjacent bladder tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BL481 |
Bladder cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with stage and grade data |
|
189-Eur |
US Biomax |
tissue |
| BL481 |
Bladder cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with stage and grade data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| BL482 |
Bladder cancer tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BL482 |
Bladder cancer tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BL801 |
Bladder cancer tissue array, with adjacent normal tissue, pathology grade and TNM stage, 53 cases_80 cores, replaced by BL806 |
|
266-Eur |
US Biomax |
tissue |
| BL801 |
Bladder cancer tissue array, with adjacent normal tissue, pathology grade and TNM stage, 53 cases_80 cores, replaced by BL806; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL802 |
Bladder cancer tissue array with normal tissue, 80 cases_80 cores, replacing BC12012 |
|
266-Eur |
US Biomax |
tissue |
| BL802 |
Bladder cancer tissue array with normal tissue, 80 cases_80 cores, replacing BC12012; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL803 |
Bladder cancer and normal tissue array with TNM and grade data, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BL803 |
Bladder cancer and normal tissue array with TNM and grade data, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL804 |
Bladder disease spectrum (urocystic cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BL804 |
Bladder disease spectrum (urocystic cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL805 |
Mid-advanced stage bladder cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BL805 |
Mid-advanced stage bladder cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BL806 |
Bladder cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 80 cases_80 cores, replacing BL801 |
|
266-Eur |
US Biomax |
tissue |
| BL806 |
Bladder cancer tissue array, with matched adjacent normal tissue (NAT), including TNM and pathology grade, 80 cases_80 cores, replacing BL801; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BLC1501 |
Bladder cancer mid-density tissue array, 75 cases_150 cores |
|
261-Eur |
US Biomax |
tissue |
| BLC1501 |
Bladder cancer mid-density tissue array, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
281-Eur |
US Biomax |
tissue |
| BLC241 |
Bladder cancer tissue array, 12 cases_24 cores |
|
189-Eur |
US Biomax |
tissue |
| BLC241 |
Bladder cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| BLC661 |
Bladder cancer tissue array, 33 cases_66 cores |
|
225-Eur |
US Biomax |
tissue |
| BLC661 |
Bladder cancer tissue array, 33 cases_66 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| BM01011 |
Liver, kidney, lung, muscle, brain, heart, stomach, spleen tissue array, 160 cases_160 cores, replaced by MO1601 |
|
278-Eur |
US Biomax |
tissue |
| BM01011 |
Liver, kidney, lung, muscle, brain, heart, stomach, spleen tissue array, 160 cases_160 cores, replaced by MO1601; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BM241 |
Bone marrow tissue array, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| BM241 |
Bone marrow tissue array, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BM481 |
Normal bone marrow tissue array, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BM481 |
Normal bone marrow tissue array, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BM482 |
Multiple myeloma tissue microarray with normal tissue as control, 24 cases_48 cores, replaced by BM483 |
|
397-Eur |
US Biomax |
tissue |
| BM482 |
Multiple myeloma tissue microarray with normal tissue as control, 24 cases_48 cores, replaced by BM483; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BM483 |
Bone marrow tumor and adjacent normal tissue array, including TNM and pathology grade, 24 cases_48 cores, replacing BM482 |
|
266-Eur |
US Biomax |
tissue |
| BM483 |
Bone marrow tumor and adjacent normal tissue array, including TNM and pathology grade, 24 cases_48 cores, replacing BM482; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| BN00011 |
Multiple organ normal tissue array, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BN00011 |
Multiple organ normal tissue array, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN00015 |
Multiple organ normal tissue array, 47 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BN00015 |
Multiple organ normal tissue array, 47 cases_48 cores; ihc Anti-SMA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN00112 |
Multiple organ normal tissue array, 40cases_40 cores, replaced by BN00119 |
|
160-Eur |
US Biomax |
tissue |
| BN00112 |
Multiple organ normal tissue array, 40cases_40 cores, replaced by BN00119; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN00119 |
Multiple organ normal tissue array, 40 cases_40 cores, replacing BN00112 |
|
266-Eur |
US Biomax |
tissue |
| BN00119 |
Multiple organ normal tissue array, 40 cases_40 cores, replacing BN00112; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BN01011 |
Normal stomach tissue (multi-sites) array, 21 cases _63 cores, replaced by BN01011b |
|
160-Eur |
US Biomax |
tissue |
| BN01011 |
Normal stomach tissue (multi-sites) array, 21 cases _63 cores, replaced by BN01011b; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN01011b |
Normal stomach tissue array, 24 cases_72 cores, replacing BN01011 |
|
277-Eur |
US Biomax |
tissue |
| BN01011b |
Normal stomach tissue array, 24 cases_72 cores, replacing BN01011 |
|
231-Eur |
US Biomax |
tissue |
| BN01011b |
Normal stomach tissue array, 24 cases_72 cores, replacing BN01011; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| BN01013 |
Normal stomach tissue (multi-sites) array, 70 cases _72 cores |
|
160-Eur |
US Biomax |
tissue |
| BN01013 |
Normal stomach tissue (multi-sites) array, 70 cases _72 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN03011 |
Normal liver tissue array (multi-sites), 20 cases_63 cores, replaced by LVN801 |
|
160-Eur |
US Biomax |
tissue |
| BN03011 |
Normal liver tissue array (multi-sites), 20 cases_63 cores, replaced by LVN801; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN04011 |
Normal lung tissue (multi-sites) tissue array, 22 cases_63 cores, replaced by LC725 |
|
160-Eur |
US Biomax |
tissue |
| BN04011 |
Normal lung tissue (multi-sites) tissue array, 22 cases_63 cores, replaced by LC725; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN05011 |
Normal colon tissue (multi-site) array, 23 cases_63 cores, replaced by BN05014 |
|
160-Eur |
US Biomax |
tissue |
| BN05011 |
Normal colon tissue (multi-site) array, 23 cases_63 cores, replaced by BN05014; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN05014 |
Colon normal tissue array, including TNM and pathology grade of 3 cases adenocarcinoma, 24 cases_72 cores, replacing BN05011 |
|
160-Eur |
US Biomax |
tissue |
| BN05014 |
Colon normal tissue array, including TNM and pathology grade of 3 cases adenocarcinoma, 24 cases_72 cores, replacing BN05011; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| BN06011 |
Normal rectum tissue (multi-sites) tissue array, 23 cases_63 cores |
|
160-Eur |
US Biomax |
recombinant |
| BN06011 |
Normal rectum tissue (multi-sites) tissue array, 23 cases_63 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BN06012 |
Normal rectum tissue (multi-sites) tissue array, 70 cases_72 cores |
|
160-Eur |
US Biomax |
recombinant |
| BN06012 |
Normal rectum tissue (multi-sites) tissue array, 70 cases_72 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BN07011 |
Normal kidney tissue array (multi-sites), 20 cases_54 cores |
|
160-Eur |
US Biomax |
tissue |
| BN07011 |
Normal kidney tissue array (multi-sites), 20 cases_54 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN07012 |
Normal kidney tissue (multi-sites) tissue array, 70 cases_72 cores, replaced by KD803 |
|
160-Eur |
US Biomax |
tissue |
| BN07012 |
Normal kidney tissue (multi-sites) tissue array, 70 cases_72 cores, replaced by KD803; ihc Anti-Villin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN08013 |
Normal breast tissue (multi-sites) array, 71 cases_72 cores, replaced by BRN801 |
|
160-Eur |
US Biomax |
tissue |
| BN08013 |
Normal breast tissue (multi-sites) array, 71 cases_72 cores, replaced by BRN801; ihc anti-Cytokeratin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN08111 |
Breast hyperplasia and normal tissue array, 10 cases_30 cores |
|
231-Eur |
US Biomax |
tissue |
| BN08111 |
Breast hyperplasia and normal tissue array, 10 cases_30 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BN1002 |
Multiple organ (20) normal tissue array, 100 cases_100 cores, replacing BN1001 |
|
266-Eur |
US Biomax |
tissue |
| BN1002 |
Multiple organ (20) normal tissue array, 100 cases_100 cores, replaced by BN1002a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BN1002a |
Multiple organ normal tissue array, 100 cases_100 cores, replacing BN1002; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BN113 |
Multiple organ normal tissue array, replaced by BN126, 45 cases_45 cores |
|
189-Eur |
US Biomax |
tissue |
| BN113 |
Multiple organ normal tissue array, replaced by BN126, 45 cases_45 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN114 |
Multiple normal human organ tissue array, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BN114 |
Multiple normal human organ tissue array, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN115 |
Multiple organ normal tissue array, 46 cases_46 cores |
|
189-Eur |
US Biomax |
tissue |
| BN115 |
Multiple organ normal tissue array, 46 cases_46 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN116 |
Multiple organ normal tissue array, 48 cases_48 cores, replaced by BN129 |
|
189-Eur |
US Biomax |
tissue |
| BN116 |
Multiple organ normal tissue array, 48 cases_48 cores, replaced by BN129; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN117 |
Multiple organ normal tissue array, 45 cases_45 cores |
|
189-Eur |
US Biomax |
tissue |
| BN117 |
Multiple organ normal tissue array, 45 cases_45 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN126 |
Multiple organ normal tissue array, replacing BN113, 45 cases_45 cores |
|
231-Eur |
US Biomax |
tissue |
| BN126 |
Multiple organ normal tissue array, replacing BN113, 45 cases_45 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BN129 |
Multiple organ adjacent normal tissue array, 48 cases_48 cores, replacing BN116 |
|
160-Eur |
US Biomax |
tissue |
| BN129 |
Multiple organ adjacent normal tissue array, 48 cases_48 cores, replacing BN116; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN242 |
Multiple normal (12 type) tissue array, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| BN242 |
Multiple normal (12 type) tissue array, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BN243 |
Multiple normal (12 type) tissue array, 12 cases_24 cores, replacing BN241 |
|
88-Eur |
US Biomax |
tissue |
| BN243 |
Multiple normal (12 type) tissue array, 12 cases_24 cores, replaced by BN243a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| BN243a |
Multiple organ normal tissue array, 12 cases_24 cores, replacing BN243; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BN29011 |
Normal bone marrow tissue array, 60 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| BN29011 |
Normal bone marrow tissue array, 60 cases_60 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BN481 |
Multiple human normal organ (12 type) tissue microarray, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BN481 |
Multiple human normal organ (12 type) tissue microarray, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN482 |
Normal human tissue microarray from 12 organs from autopsy, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BN482 |
Normal human tissue microarray from 12 organs from autopsy, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN484 |
Multiple organ normal tissue array, 24 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| BN484 |
Multiple organ normal tissue array, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BN501 |
Normal human top 10 organ tissue array, 50 cases_50 cores, replacing BN00012 and BN00013 |
|
160-Eur |
US Biomax |
tissue |
| BN501 |
Normal human top 10 organ tissue array, 50 cases_50 cores, replacing BN00012 and BN00013; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BN961 |
Normal human tissue panel (24 organs) with two serial tissue array sections in parallel, 24 cases_102 cores, replacing BN861 |
|
266-Eur |
US Biomax |
tissue |
| BN961 |
Normal human tissue panel (24 organs) with two serial tissue array sections in parallel, 24 cases_102 cores, replacing BN861; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BO2081 |
Bone disease spectrum (bone tumor progression) tissue array, 104 cases_208 cores |
|
516-Eur |
US Biomax |
tissue |
| BO2081 |
Bone disease spectrum (bone tumor progression) tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BO241 |
Bone and cartilage cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| BO241 |
Bone and cartilage cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Vimentin (Vim) confirmed |
|
105-Eur |
US Biomax |
tissue |
| BO242 |
Human normal bone tissue array, 12 cases_24 cores, replaced by BO243 |
|
100-Eur |
US Biomax |
tissue |
| BO242 |
Human normal bone tissue array, 12 cases_24 cores, replaced by BO243 ; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
tissue |
| BO243 |
Human normal bone and osteosarcoma tissue array, 12 cases_24 cores, replaced by BO244 |
|
88-Eur |
US Biomax |
tissue |
| BO243 |
Human normal bone and osteosarcoma tissue array, 12 cases_24 cores, replaced by BO244; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BO244 |
Human normal bone and osteosarcoma tissue array, 12 cases_24 cores, replacing BO243 |
|
100-Eur |
US Biomax |
tissue |
| BO244 |
Human normal bone and osteosarcoma tissue array, 12 cases_24 cores, replaced by BO244b; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BO244a |
Human normal bone and osteosarcoma tissue array, including TNM and clinical stage, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BO244b |
Human normal bone and osteosarcoma tissue array, including TNM and clinical stage, 12 cases_24 cores, replacing BO244; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BO481 |
Bone and cartilage tumor tissue array with unmatched normal tissue, 48 cases_48 cores with TNM data |
|
189-Eur |
US Biomax |
tissue |
| BO481 |
Bone and cartilage tumor tissue array with unmatched normal tissue, 48 cases_48 cores with TNM data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| BO601 |
Bone giant cell tumor tissue array, 30 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| BO601 |
Bone giant cell tumor tissue array, 30 cases_60 cores; ihc Anti-Vimtin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BO801 |
Bone and cartilage disease spectrum (bone and cartilage cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BO801 |
Bone and cartilage disease spectrum (bone and cartilage cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR01015 |
Multiple organ, normal tissue array, 8 normal tissues, 160 cases_160 cores, replacing BR01011 |
|
278-Eur |
US Biomax |
tissue |
| BR01015 |
Multiple organ, normal tissue array, 8 normal tissues, 160 cases_160 cores, replacing BR01011; ihc Anti-EMA confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR041 |
Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases_4 cores, replaced by BR042a |
|
88-Eur |
US Biomax |
tissue |
| BR041 |
Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases_4 cores, replaced by BR042a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BR042a |
Breast cancer tissue array, including TNM and pathology grade, 4 cases_4 cores |
|
88-Eur |
US Biomax |
tissue |
| BR042a |
Breast cancer tissue array, including TNM and pathology grade, 4 cases_4 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR082 |
Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases_8 cores |
|
112-Eur |
US Biomax |
tissue |
| BR082 |
Breast cancer tissue array with HER2 IHC control, including TNM and pathology grade, 4 cases_8 cores; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
tissue |
| BR1001 |
Breast cancer tissue array with matched carcinoma metastasis to lymph nodes, 50 cases_100 cores, replaced by BR1004 |
|
314-Eur |
US Biomax |
tissue |
| BR1001 |
Breast cancer tissue array with matched carcinoma metastasis to lymph nodes, 50 cases_100 cores, replaced by BR1004; ihc Anti-Cytokeratin (Low MW) confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR10010 |
Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, 50 cases_100 cores, replacing BR1004 |
|
314-Eur |
US Biomax |
tissue |
| BR10010 |
Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, with ER, PR and Her-2 (neu) IHC results, 50 cases_100 cores, replaced by BR10010a; ihc Anti-Actin confi |
|
296-Eur |
US Biomax |
tissue |
| BR10010a |
Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, with ER, PR and Her-2 (neu) IHC results, 50 cases_100 cores, replacing BR10010; ihc Anti-Actin confirme |
|
296-Eur |
US Biomax |
tissue |
| BR1002 |
Tissue microarray of breast cancer and normal tissue, 97 cases _100 cores, with stage and grade information |
|
266-Eur |
US Biomax |
tissue |
| BR1002 |
Tissue microarray of breast cancer and normal tissue, 97 cases _100 cores, with stage and grade information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1003 |
Breast pre-cancerous disease and cancer tissue array (100 cases_101 cores), with clinical stage and pathology grade data |
|
266-Eur |
US Biomax |
tissue |
| BR1003 |
Breast pre-cancerous disease and cancer tissue array (100 cases_101 cores), with clinical stage and pathology grade data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1004 |
Tissue array of breast carcinoma and matched metastasis in lymph nodes tissue arrays, 50 cases_100 cores, replaced by BR10010 |
|
314-Eur |
US Biomax |
tissue |
| BR1004 |
Tissue array of breast carcinoma and matched metastasis in lymph nodes tissue arrays, 50 cases_100 cores, replaced by BR10010; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1005 |
Breast cancer and matched metastatic carcinoma of lymph node, 50 cases_100 cores, no overlaps with BR1001 or BR1004 |
|
314-Eur |
US Biomax |
|
| BR1005 |
Breast cancer and matched metastatic carcinoma of lymph node, 50 cases_100 cores, no overlaps with BR1001 or BR1004, replaced by BR1005a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
|
| BR1005a |
Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replacing BR1005; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1006 |
Breast tumor tissue array of varieties and normal adjacent tissue (NAT), 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BR1006 |
Breast tumor tissue array of varieties and normal adjacent tissue (NAT), 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1007 |
Breast cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BR1007 |
Breast cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1008 |
Breast cancer, carcinoma metastasize to lymph nodes and adjacent normal tissue array, including TNM and pathology grade, 100 cases_100 cores, replacing BC08212 |
|
266-Eur |
US Biomax |
tissue |
| BR1008 |
Breast cancer, carcinoma metastasize to lymph nodes and adjacent normal tissue array, including TNM and pathology grade, 100 cases_100 cores, replacing BC08212; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1009 |
Breast cancer tissue array for antibody screening , including TNM and pathology grade, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| BR1009 |
Breast cancer tissue array for antibody screening , including TNM and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1502 |
Breast cancer mid-density tissue array, wiht AR_ER_PR_Her-2_P53_EGFR_Ki67 IHC results, 75 cases_150 cores, replaced by BR1503 |
|
278-Eur |
US Biomax |
tissue |
| BR1502 |
Breast cancer mid-density tissue array, wiht AR_ER_PR_Her-2_P53_EGFR_Ki67 IHC results, 75 cases_150 cores, replaced by BR1503; ihc Anti-Vimentin_Cytokeratin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1503 |
Breast cancer tissue array, including TNM and pathology grade, with IHC results of Her-2, ER, PR, P53 and Ki-67, 75 cases_150 cores, replacing BR1502 |
|
278-Eur |
US Biomax |
tissue |
| BR1503 |
Breast cancer tissue array, including TNM and pathology grade, 75 cases_150 cores, replaced by BR1503a; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1503a |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores, with IHC results of Her-2, ER, PR, AR, P53 and Ki67, 75 cases_150 cores, replacing BR1503; ihc Anti- |
|
296-Eur |
US Biomax |
tissue |
| BR1504 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| BR1504 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| BR1504 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR1505 |
Breast cancer tissue array, including TNM, clinical stage, pathology grade and IHC markers (ER, PR, Her-2, AR and Ki67) results, 75 cases_150 cores, no overlaps with BR1503 or BR1504; ihc Anti-Actin |
|
296-Eur |
US Biomax |
tissue |
| BR1921 |
High-density breast invasive ductal and lobular carcinoma tissue array with normal tissues, grading and staging data,192 cases_192 cores |
|
456-Eur |
US Biomax |
tissue |
| BR1921 |
High-density breast invasive ductal and lobular carcinoma tissue array with normal tissues, grading and staging data,192 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR1922 |
Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| BR1922 |
Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
elisa |
| BR2001 |
Breast cancer high-density tissue array, 196 cases_200 cores, replaced by BR2086 |
|
456-Eur |
US Biomax |
elisa |
| BR2001 |
Breast cancer high-density tissue array, 196 cases_200 cores, replaced by BR2086; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
487-Eur |
US Biomax |
elisa |
| BR208 |
High-density, multiple breast cancer (1-3 grade) and normal breast tissue array, 70 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR208 |
High-density, multiple breast cancer (1-3 grade) and normal breast tissue array, 70 cases_208 cores, replaced by BR208b; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20810 |
Breast tumor survey tissue array (4 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20810 |
Breast tumor survey tissue array (4 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20811 |
Breast tumor survey tissue array (5 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20811 |
Breast tumor survey tissue array (5 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20812 |
Breast tumor survey tissue array (6 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20812 |
Breast tumor survey tissue array (6 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20813 |
Breast tumor survey tissue array (7 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20813 |
Breast tumor survey tissue array (7 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20814 |
Breast tumor survey tissue array (8 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20814 |
Breast tumor survey tissue array (8 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20815 |
Breast tumor survey tissue array (9 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20815 |
Breast tumor survey tissue array (9 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20816 |
Breast tumor survey tissue array (10 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20816 |
Breast tumor survey tissue array (10 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20817 |
Breast tumor survey tissue array (11 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20817 |
Breast tumor survey tissue array (11 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20818 |
Breast tumor survey tissue array (12 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20818 |
Breast tumor survey tissue array (12 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20819 |
Breast tumor survey tissue array (13 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20819 |
Breast tumor survey tissue array (13 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR2082 |
Breast disease spectrum (breast cancer progression) tissue array, 206 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR2082 |
Breast disease spectrum (breast cancer progression) tissue array, 206 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR20820 |
Breast tumor survey tissue array (14 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20820 |
Breast tumor survey tissue array (14 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20821 |
Breast tumor survey tissue array (15 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20821 |
Breast tumor survey tissue array (15 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20822 |
Breast tumor survey tissue array (16 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20822 |
Breast tumor survey tissue array (16 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20823 |
Breast tumor survey tissue array (17 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20823 |
Breast tumor survey tissue array (17 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20824 |
Breast tumor survey tissue array (18 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20824 |
Breast tumor survey tissue array (18 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20825 |
Breast tumor survey tissue array (19 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20825 |
Breast tumor survey tissue array (19 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20826 |
Breast tumor survey tissue array (20 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20826 |
Breast tumor survey tissue array (20 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20827 |
Breast tumor survey tissue array (21 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20827 |
Breast tumor survey tissue array (21 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20828 |
Breast tumor survey tissue array (22 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20828 |
Breast tumor survey tissue array (22 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20829 |
Breast tumor survey tissue array (23 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20829 |
Breast tumor survey tissue array (23 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR2083 |
High-density breast cancer tissue array with normal tissue, stage and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR2083 |
High-density breast cancer tissue array with normal tissue, stage and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20830 |
Breast tumor survey tissue array (24 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20830 |
Breast tumor survey tissue array (24 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20831 |
Breast tumor survey tissue array (25 of 25), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20831 |
Breast tumor survey tissue array (25 of 25), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR20832 |
Breast tumor survey tissue array (1 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20832 |
Breast tumor survey tissue array (1 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR20833 |
Breast tumor survey tissue array (2 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20833 |
Breast tumor survey tissue array (2 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR20834 |
Breast tumor survey tissue array (3 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20834 |
Breast tumor survey tissue array (3 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR20835 |
Breast tumor survey tissue array (4 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20835 |
Breast tumor survey tissue array (4 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR20836 |
Breast tumor survey tissue array (5 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR20836 |
Breast tumor survey tissue array (5 of 5), with adjacent normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR2085a |
High-density (188 cases_208 cores), multiple types of breast cancer of infiltrating ductal, lobular carcinoma and normal breast tissue array, replaced by BR2085c. |
|
456-Eur |
US Biomax |
tissue |
| BR2085a |
High-density (188 cases_208 cores), multiple types of breast cancer of infiltrating ductal, lobular carcinoma and normal breast tissue array, replaced by BR2085c.; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR2085b |
High-density (188 cases_208 cores), multiple types of breast cancer tissue array of infiltrating ductal, lobular carcinoma and normal breast |
|
456-Eur |
US Biomax |
tissue |
| BR2085b |
High-density (188 cases_208 cores), multiple types of breast cancer tissue array of infiltrating ductal, lobular carcinoma and normal breast; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR2085c |
Breast cancer tissue array, with normal tissue and adjacent normal tissue, including TNM and pathology grade, 188 cases_208 cores, replacing BR2085a |
|
456-Eur |
US Biomax |
tissue |
| BR2085c |
Breast cancer tissue array, with normal tissue and adjacent normal tissue, including TNM and pathology grade, 188 cases_208 cores, replacing BR2085a; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR2086 |
Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 208 cases_208 cores, replacing BR2001 |
|
456-Eur |
US Biomax |
tissue |
| BR2086 |
Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 208 cases_208 cores, replacing BR2001; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR2087 |
Breast tumor survey tissue array (1 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR2087 |
Breast tumor survey tissue array (1 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR2088 |
Breast tumor survey tissue array (2 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR2088 |
Breast tumor survey tissue array (2 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR2089 |
Breast tumor survey tissue array (3 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| BR2089 |
Breast tumor survey tissue array (3 of 25), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR208b |
TMA block of high-density (70 cases_208 cores), multiple breast cancer (I-3 grade) and normal breast tissue |
|
40981-Eur |
US Biomax |
tissue |
| BR208b |
TMA block of high-density (70 cases_208 cores), multiple breast cancer (I-3 grade) and normal breast tissue, replacing BR208; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| BR2161 |
Breast cancer tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
456-Eur |
US Biomax |
tissue |
| BR2161 |
Breast cancer tissue array, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| BR241 |
Breast cancer test tissue array with self-matched or unmatched normal adjacent tissues, 6 cases_24 cores. |
|
88-Eur |
US Biomax |
assays |
| BR241 |
Breast cancer test tissue array with self-matched or unmatched normal adjacent tissues, 6 cases_24 cores.; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| BR242 |
Multiple breast cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores, replaced by BR244 |
|
88-Eur |
US Biomax |
assays |
| BR242 |
Multiple breast cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores, replaced by BR244; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| BR243 |
Breast cancer and adjacent normal tissue array, 6 cases_24 cores, replaced by BR243a |
|
88-Eur |
US Biomax |
tissue |
| BR243 |
Breast cancer and adjacent normal tissue array, 6 cases_24 cores, replacing BR241; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR243a |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 |
|
99-Eur |
US Biomax |
tissue |
| BR243a |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 |
|
88-Eur |
US Biomax |
tissue |
| BR243a |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replaced by BR243f; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR243b |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR243c |
Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by BR243d; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR243d |
Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243c; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR243e |
Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR243f |
Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| BR244 |
Breast cancer tissue array with adjacent normal tissues, with TNM and grade info, 12 cases_24 cores, replaced by BR245 |
|
88-Eur |
US Biomax |
tissue |
| BR244 |
Breast cancer tissue array with adjacent normal tissues, with TNM and grade info, 12 cases_24 cores, replaced by BR245; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BR245 |
Breast carcinoma tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by BR246 |
|
88-Eur |
US Biomax |
tissue |
| BR245 |
Breast carcinoma tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by BR246; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BR246 |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by BR246a |
|
88-Eur |
US Biomax |
tissue |
| BR246 |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by BR246a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BR246a |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 12 cases_24 cores, replacing BR246 |
|
99-Eur |
US Biomax |
tissue |
| BR246a |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 12 cases_24 cores, replacing BR246 |
|
88-Eur |
US Biomax |
tissue |
| BR246a |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 12 cases_24 cores, replacing BR246; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| BR247 |
Breast cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores, 2 sections_sllide |
|
189-Eur |
US Biomax |
tissue |
| BR247 |
Breast cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores, 2 sections_sllide; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BR451 |
Breast cancer tissue microarray with matched normal adjacent tissue and metastatic lymph nodes, 45cases_45 cores, with ER, PR and P53 IHC results |
|
160-Eur |
US Biomax |
tissue |
| BR451 |
Breast cancer tissue microarray with matched normal adjacent tissue and metastatic lymph nodes, 45cases_45 cores, with ER, PR and P53 IHC results; ihc Anti-Cytokeratin (CK) confirmed |
|
162-Eur |
US Biomax |
tissue |
| BR480 |
Breast disease spectrum tissue array - progression array, 48 cases_48 cores |
|
314-Eur |
US Biomax |
tissue |
| BR480 |
Breast disease spectrum tissue array - progression array, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR481 |
Breast infiltrating ductal carcinoma not otherwise specified (NOS) and matched adjacent, 12 cases_48 cores |
|
160-Eur |
US Biomax |
rat |
| BR481 |
Breast infiltrating ductal carcinoma not otherwise specified (NOS) and matched adjacent, 12 cases_48 cores; ihc Anti-actin confirmed Certified pathologist code Certified pathologist code |
|
185-Eur |
US Biomax |
rat |
| BR482 |
Multiple breast cancer tissue array with normal tissues from autopsy, 24 cases_48 cores, with stage and grade info |
|
160-Eur |
US Biomax |
tissue |
| BR482 |
Multiple breast cancer tissue array with normal tissues from autopsy, 24 cases_48 cores, with stage and grade info; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| BR483 |
Multiple breast cancer tissue array with normal tissues from autopsy, with TNM, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| BR483 |
Multiple breast cancer tissue array with normal tissues from autopsy, with TNM, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| BR484 |
Breast cancer tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| BR484 |
Breast cancer tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR485 |
Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases_96 cores |
|
397-Eur |
US Biomax |
elisa |
| BR485 |
Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
elisa |
| BR486 |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| BR486 |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BR486 |
Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BR601 |
Breast fibroma and sclerosing adenosis tissue microarray, 30 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| BR601 |
Breast fibroma and sclerosing adenosis tissue microarray, 30 cases_60 cores; ihc Anti-Smooth Muscle Actin (SMA) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR602 |
Breast tumor and normal tissue array, with TNM data, 25 cases_60 cores |
|
----Eur |
US Biomax |
tissue |
| BR6161 |
High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| BR6161 |
High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| BR641 |
Breast cancer tissue array, 64 cases_66 cores, with TNM data |
|
----Eur |
US Biomax |
tissue |
| BR701 |
Breast cancer tissue array, 70 cases_70 cores, with TNM data plus ER, PR and Her-2 (C-erbB-2, neu<_em>) IHC results, replaced by BR962 |
|
231-Eur |
US Biomax |
elisa |
| BR701 |
Breast cancer tissue array, 70 cases_70 cores, with TNM data plus ER, PR and Her-2 (C-erbB-2, neu<_em>) IHC results, replaced by BR962; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
elisa |
| BR721 |
Breast cancer tissue array with self-matching adjacent tissue and normal tissue, 24 cases_72 cores, no overlaps with other BR TMAs |
|
231-Eur |
US Biomax |
tissue |
| BR721 |
Breast cancer tissue array with self-matching adjacent tissue and normal tissue, 24 cases_72 cores, no overlaps with other BR TMAs; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR722 |
Breast disease spectrum tissue array, 66 cases_72 cores, including normal, precancerous and cancer in different stages |
|
231-Eur |
US Biomax |
recombinant |
| BR722 |
Breast disease spectrum tissue array, 66 cases_72 cores, including normal, precancerous and cancer in different stages; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
recombinant |
| BR723 |
Breast various pathology developmental process tissue array, including TNM and pathology grade, 71 cases_72 cores |
|
314-Eur |
US Biomax |
tissue |
| BR723 |
Breast various pathology developmental process tissue array, including TNM and pathology grade, 71 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR724 |
Breast cancer, adjacent and adjacent normal tissue array, 66 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| BR724 |
Breast cancer, adjacent and adjacent normal tissue array, 66 cases_72 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR725 |
Breast cancer, adjacent and adjacent normal tissue array, 68 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| BR725 |
Breast cancer, adjacent and adjacent normal tissue array, 68 cases_72 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR726 |
Breast cancer tissue array and normal tissue array, with TNM and grade, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| BR726 |
Breast cancer tissue array and normal tissue array, with TNM and grade, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR727 |
Breast cancer and normal tissue array, with TNM, stage and grade info, 24 cases_72 cores, replacing BS08011 |
|
231-Eur |
US Biomax |
tissue |
| BR727 |
Breast cancer and normal tissue array, with TNM, stage and grade info, 24 cases_72 cores, replacing BS08011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR728 |
Breast carcinoma tissue array, with stage and grade info, 24 cases_72 cores, replacing BC08015 |
|
231-Eur |
US Biomax |
tissue |
| BR728 |
Breast carcinoma tissue array, with stage and grade info, 24 cases_72 cores, replacing BC08015; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR801 |
Breast tumor tissue array, with matched tumor and adjacent normal tissue, 40 cases_80 cores, replaced by BR804 |
|
231-Eur |
US Biomax |
tissue |
| BR801 |
Breast tumor tissue array, with matched tumor and adjacent normal tissue, 40 cases_80 cores, replaced by BR804; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR8010 |
Breast fibroadenoma tissue array (including normal, lobular, invasive carcinoma and metastasis in lymph nodes), 71 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| BR8010 |
Breast fibroadenoma tissue array (including normal, lobular, invasive carcinoma and metastasis in lymph nodes), 71 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR8011 |
Breast intraductal carcinoma tissue microarray with normal adjacent tissue, 80 cases_80 cores |
|
314-Eur |
US Biomax |
tissue |
| BR8011 |
Breast intraductal carcinoma tissue microarray with normal adjacent tissue, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR8012 |
Breast cancer and normal tissue array with stage and grade info, 40 cases_80 cores, replaced by BR8014 |
|
231-Eur |
US Biomax |
tissue |
| BR8012 |
Breast cancer and normal tissue array with stage and grade info, 40 cases_80 cores, replaced by BR8014; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR8013 |
Advanced breast cancer and normal tissue array, with stage, TNM and pathology grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| BR8013 |
Advanced breast cancer and normal tissue array, with stage, TNM and pathology grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR8014 |
Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores, replacing BR8012 |
|
231-Eur |
US Biomax |
tissue |
| BR8014 |
Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores, replacing BR8012; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR8015 |
Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases_80 cores, replacing BC08014 |
|
231-Eur |
US Biomax |
tissue |
| BR8015 |
Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases_80 cores, replacing BC08014; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR8016 |
Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BR8016 |
Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BR8017 |
Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BR8017 |
Middle-advanced stage breast cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BR8018 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing BR808, BC08014 |
|
266-Eur |
US Biomax |
tissue |
| BR8018 |
Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing BR808, BC08014; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BR802 |
Breast cancer tissue array, with matched or unmatched adjacent normal tissue array, 40 cases_80 cores, no overlaps with BR801, BR803 and BR1001, replaced by BR802b |
|
231-Eur |
US Biomax |
tissue |
| BR802 |
Breast cancer tissue array, with matched or unmatched adjacent normal tissue array, 40 cases_80 cores, no overlaps with BR801, BR803 and BR1001, replaced by BR802b; ihc Anti-Cytokeratin (High MW) con |
|
267-Eur |
US Biomax |
tissue |
| BR802b |
Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 |
|
266-Eur |
US Biomax |
tissue |
| BR802b |
Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BR803 |
Breast carcinoma (multi-tissue combined panel) tissue array, 79 cases_80 cores, replacing BC08016 |
|
189-Eur |
US Biomax |
tissue |
| BR803 |
Breast carcinoma (multi-tissue combined panel) tissue array, 79 cases_80 cores, replaced by BR803a; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BR803a |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing BR803; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BR804 |
Breast tumor tissue array, with matched tumor and adjacent normal tissue, replacing BR801, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| BR804 |
Breast tumor tissue array, with matched tumor and adjacent normal tissue, 40 cases_80 cores, replaced by BR804a; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR804a |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores, replacing BR804; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR805 |
Breast infiltrating lobular carcinoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BR805 |
Breast infiltrating lobular carcinoma tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| BR806 |
Breast hyperplasia tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| BR806 |
Breast hyperplasia tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR807 |
Medullary carcinoma of breast tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| BR807 |
Medullary carcinoma of breast tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR808 |
Tissue array of multiple types of breast cancer and normal breast tissue, 80 cases_80 cores, replaced by BR8018 |
|
231-Eur |
US Biomax |
tissue |
| BR808 |
Tissue array of multiple types of breast cancer and normal breast tissue, 80 cases_80 cores, replaced by BR8018; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR809 |
Breast invasive lobular carcinoma tissue array with adjacent normal tissue, 79 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| BR809 |
Breast invasive lobular carcinoma tissue array with adjacent normal tissue, 79 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BR811 |
Breast cancer tissue array with normal tissues from autopsy, 80 cases_80 cores, with grade and stage data |
|
231-Eur |
US Biomax |
tissue |
| BR811 |
Breast cancer tissue array with normal tissues from autopsy, 80 cases_80 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR812 |
Breast cancer tissue array with normal tissues from autopsy, 40 cases_80 cores, with TNM data |
|
231-Eur |
US Biomax |
tissue |
| BR812 |
Breast cancer tissue array with normal tissues from autopsy, 40 cases_80 cores, with TNM data; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BR951 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, to be replaced by BR95 |
|
456-Eur |
US Biomax |
tissue |
| BR951 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replaced by BR952; ihc |
|
429-Eur |
US Biomax |
tissue |
| BR952 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores |
|
456-Eur |
US Biomax |
tissue |
| BR952 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores; ihc Anti-Actin confir |
|
429-Eur |
US Biomax |
tissue |
| BR953 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replacing BR952 |
|
456-Eur |
US Biomax |
tissue |
| BR953 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replaced by BR954; ihc |
|
429-Eur |
US Biomax |
tissue |
| BR954 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replacing BR953; ihc |
|
429-Eur |
US Biomax |
tissue |
| BR961 |
Breast cancer array with normal and other non-malignant breast tissues, with AR, ER, PR, Her-2 (neu) IHC results, 48 cases_96 cores, replaced by BR962 |
|
----Eur |
US Biomax |
elisa |
| BR962 |
Breast cancer array with normal and other non-malignant breast tissues, with AR, ER, PR, Her-2 (neu) IHC results, 48 cases_96 cores, replacing BR961, BR701 |
|
231-Eur |
US Biomax |
elisa |
| BR962 |
Breast cancer array with normal and other non-malignant breast tissues, with AR, ER, PR, Her-2 (neu) IHC results, 48 cases_96 cores, replaced by BR963; ihc Anti-Vimentin_Cytokeratin confirmed |
|
296-Eur |
US Biomax |
elisa |
| BR963 |
Breast disease spectrum tissue array, including TNM and pathology grade, stage, TNM and IHC markers (AR, PR, ER, Her-2, Ki67, CK14 and p53), 48 cases_96 cores, replacing BR962 |
|
314-Eur |
US Biomax |
elisa |
| BR963 |
Breast disease spectrum tissue array, including TNM and pathology grade, stage, TNM and IHC markers (AR, PR, ER, Her-2, Ki67, CK14 and p53), 48 cases_96 cores, replaced by BR963a; ihc Anti-Actin conf |
|
296-Eur |
US Biomax |
elisa |
| BR963a |
Breast disease spectrum tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores, replacing BR963; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
elisa |
| BR964 |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
elisa |
| BRC1021 |
Breast cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| BRC1021 |
Breast cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| BRC1501 |
Breast cancer mid-density tissue array, non-overlapping with either BRC1502 or BRC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| BRC1501 |
Breast cancer mid-density tissue array, non-overlapping with either BRC1502 or BRC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| BRC1502 |
Breast cancer mid-density tissue array, non-overlapping with either BRC1501 or BRC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| BRC1502 |
Breast cancer mid-density tissue array, non-overlapping with either BRC1501 or BRC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| BRC1503 |
Breast cancer mid-density tissue array, non-overlapping with BRC1501 or BRC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| BRC1503 |
Breast cancer mid-density tissue array, non-overlapping with BRC1501 or BRC1502, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| BRC2281 |
High density breast cancer tissue array, 228 cases_228 cores |
|
----Eur |
US Biomax |
tissue |
| BRC2281 |
High density breast cancer tissue array, 228 cases_228 cores; ihc H&E, IHC anti-Cytokeratin |
|
434-Eur |
US Biomax |
tissue |
| BRC481 |
Breast cancer and normal tissue array, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BRC481 |
Breast cancer and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| BRC491 |
Human breast invasive ductal carcinoma (IDC) tissue array, non-overlapping with BRC711, 49 cases_49 cores |
|
142-Eur |
US Biomax |
tissue |
| BRC491 |
Human breast invasive ductal carcinoma (IDC) tissue array, non-overlapping with BRC711, 49 cases_49 cores; ihc H&E, IHC anti- Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| BRC51 |
Breast cancer tissue array BLOCK, Her-2 IHC marker; ihc Anti-Cytokeratin (CK) confirmed |
|
4878-Eur |
US Biomax |
tissue |
| BRC711 |
Human breast invasive ductal cancer tissue array, non-overlapping with BRC491, 71 cases_72 cores |
|
142-Eur |
US Biomax |
tissue |
| BRC711 |
Human breast invasive ductal cancer tissue array, non-overlapping with BRC491, 71 cases_72 cores; ihc H&E, IHC anti-Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| BRC961 |
Breast cancer array with normal and other non-malignant breast tissues, non-overlapping with BRC962, with AR_ER_PR_Her-2(neu) IHC results, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| BRC961 |
Breast cancer array with normal and other non-malignant breast tissues, non-overlapping with BRC962, with AR_ER_PR_Her-2(neu) IHC results, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| BRC962 |
Breast cancer and normal tissue array, non-overlapping with BRC961, with TNM data, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| BRC962 |
Breast cancer and normal tissue array, non-overlapping with BRC961, with TNM data, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| BRD181 |
Breast disease tissue array, 18 cases_18 cores |
|
118-Eur |
US Biomax |
tissue |
| BRD181 |
Breast disease tissue array, 18 cases_18 cores; ihc H&E, IHC anti-Cytokeratin |
|
123-Eur |
US Biomax |
tissue |
| BRF401 |
Breast cancer frozen tissue array, with normal tissue, 40 cases_40 cores, Her-2 and ER_PR IHC are supplied when purchase; ihc Anti-Actin confirmed |
|
742-Eur |
US Biomax |
tissue |
| BRF401i |
Breast cancer frozen tissue array, with normal tissue, 40 cases_40 cores, Her-2 and ER_PR IHC are supplied when purchase; ihc Anti-Actin confirmed |
|
742-Eur |
US Biomax |
tissue |
| BRF404 |
Breast invasive ductal carcinoma forzen tissue array, 20 cases_40 cores |
|
167-Eur |
US Biomax |
tissue |
| BRF404 |
Breast invasive ductal carcinoma forzen tissue array, 20 cases_40 cores; ihc Anti-Actin confirmed |
|
742-Eur |
US Biomax |
tissue |
| BRM481 |
Tissue array of breast carcinoma metastasis in lymph nodes, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| BRM481 |
Tissue array of breast carcinoma metastasis in lymph nodes, 24 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| BRM961 |
Breast cancer tissue array containing primary and matched metastatic tumors (in lymph nodes) and adjacent normal breast tissue, 48 casea_96 cores |
|
314-Eur |
US Biomax |
elisa |
| BRM961 |
Breast cancer tissue array containing primary and matched metastatic tumors (in lymph nodes) and adjacent normal breast tissue, 48 casea_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
281-Eur |
US Biomax |
elisa |
| BRN801 |
Breast normal adjacent tissue and cancer tissue array, 80 cases_80 cores, replacing BN08013 |
|
231-Eur |
US Biomax |
tissue |
| BRN801 |
Breast normal adjacent tissue (NAT) and cancer tissue array, 80 cases_80 cores, replaced by BRN801a; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BRN801a |
Breast adjacent normal tissue array with breast cancer tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing BRN801; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| BS01011 |
Stomach cancer tissue array, 72 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| BS01011 |
Stomach cancer tissue array, 72 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS01012 |
Stomach adenocarcinoma tissue array, 72 cases _72 cores |
|
160-Eur |
US Biomax |
tissue |
| BS01012 |
Stomach adenocarcinoma tissue array, 72 cases _72 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS01032 |
Stomach adenocarcinoma (grade II) tissue array, 63 cases _63 cores, replaced by ST808 |
|
160-Eur |
US Biomax |
tissue |
| BS01032 |
Stomach adenocarcinoma (grade II) tissue array, 63 cases _63 cores, replaced by ST808; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS01041 |
Stomach adenocarcinoma (grade III) tissue array, 22 cases _63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS01041 |
Stomach adenocarcinoma (grade III) tissue array, 22 cases _63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS01042 |
Stomach adenocarcinoma (grade III) tissue array, 22 cases _63 cores, replaced by ST723 |
|
160-Eur |
US Biomax |
tissue |
| BS01042 |
Stomach adenocarcinoma (grade III) tissue array, 22 cases _63 cores, replaced by ST723; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS02021 |
Esophagus squamous cell carcinoma (grade I) tissue array, 21 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS02021 |
Esophagus squamous cell carcinoma (grade I) tissue array, 21 cases_63 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS02031 |
Esophagus squamous cell carcinoma (grade II) tissue array, 22 cases_63 cores, replaced by ES723 |
|
160-Eur |
US Biomax |
tissue |
| BS02031 |
Esophagus squamous cell carcinoma (grade II) tissue array, 22 cases_63 cores, replaced by ES723; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS02041 |
Esophagus squamous cell carcinoma (grade III) tissue array, 23 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS02041 |
Esophagus squamous cell carcinoma (grade III) tissue array, 23 cases_63 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS02051 |
Esophagus adenocarcinoma tissue array, 33 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS02051 |
Esophagus adenocarcinoma tissue array, 33 cases_63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS03011 |
Hepatocellular carcinoma tissue array, 21 cases_63 cores, replaced by LV804 |
|
160-Eur |
US Biomax |
tissue |
| BS03011 |
Hepatocellular carcinoma tissue array, 21 cases_63 cores, replaced by LV804; ihc Anti-PCNA confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS03013 |
Hepatocellular carcinoma tissue array, 22 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS03013 |
Hepatocellular carcinoma tissue array, 22 cases_63 cores; ihc Anti-AFP confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS03014 |
Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809 |
|
160-Eur |
US Biomax |
tissue |
| BS03014 |
Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809; ihc Anti-AFP confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS04011 |
Lung squamous carcinoma (combination of adjacent and normal) tissue array, 18 cases_54 cores, replaced by LC808 |
|
160-Eur |
US Biomax |
tissue |
| BS04011 |
Lung cancer tissue array, including pathology grade, 64 cases_64 core, replaced by LC808; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS04031 |
Lung squamous cell carcinoma tissue array, 63 cases_64 cores, replaced by LC724 |
|
160-Eur |
US Biomax |
tissue |
| BS04031 |
Lung squamous cell carcinoma tissue array, 63 cases_64 cores, replaced by LC724; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS04041 |
Lung squamous cell carcinoma (grade II) tissue array, 21 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS04041 |
Lung squamous cell carcinoma (grade II) tissue array, 21 cases_63 cores; ihc Anti-H-CK confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS04071 |
Lung squamous cell carcinoma (grade III) tissue array, 21 cases_63 cores, replaced by LC723 |
|
160-Eur |
US Biomax |
tissue |
| BS04071 |
Lung squamous cell carcinoma (grade III) tissue array, 21 cases_63 cores, replaced by LC723; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS04081 |
Lung adenocarcinoma (grade II) tissue array, 21 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS04081 |
Lung adenocarcinoma (grade II) tissue array, 21 cases_63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
162-Eur |
US Biomax |
tissue |
| BS04102 |
Large cell carcinoma of lung tissue array, 21 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BS04102 |
Large cell carcinoma of lung tissue array, 21 cases_63 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS04111 |
Lung small cell carcinoma tissue array, 33 cases_63 cores |
|
160-Eur |
US Biomax |
tissue |
| BS04111 |
Lung small cell carcinoma tissue array, 33 cases_63 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS05011 |
Colon adenocarcinoma tissue array, 23 cases_63 cores. |
|
160-Eur |
US Biomax |
tissue |
| BS05011 |
Colon adenocarcinoma tissue array, 23 cases_63 cores.; ihc Anti-P53 confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS05021 |
Colon adenocarcinoma (grade I) tissue array, 23 cases_63 cores, replaced by CO723 |
|
160-Eur |
US Biomax |
tissue |
| BS05021 |
Colon adenocarcinoma (grade I) tissue array, 23 cases_63 cores, replaced by CO723; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS05031 |
Colon adenocarcinoma (grade II) tissue array, 21 cases_63 cores, replaced by CO724 |
|
160-Eur |
US Biomax |
tissue |
| BS05031 |
Colon adenocarcinoma (grade II) tissue array, 21 cases_63 cores, replaced by CO724; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS05041 |
Colon adenocarcinoma (grade III) tissue array, 23 cases_63 cores, replaced by CO725 |
|
189-Eur |
US Biomax |
tissue |
| BS05041 |
Colon adenocarcinoma (grade III) tissue array, 23 cases_63 cores, replaced by CO725; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS06011 |
Rectum adenocarcinoma tissue array, 22 cases_63 cores |
|
160-Eur |
US Biomax |
recombinant |
| BS06011 |
Rectum adenocarcinoma tissue array, 22 cases_63 cores; ihc Anti-CEA confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BS06021 |
Rectum adenocarcinoma (grade I) tissue array, 21 cases_63 cores |
|
160-Eur |
US Biomax |
recombinant |
| BS06021 |
Rectum adenocarcinoma (grade I) tissue array, 21 cases_63 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BS06031 |
Rectum adenocarcinoma (grade II) tissue array, 21 cases_63 cores, replaced by RE723 |
|
160-Eur |
US Biomax |
recombinant |
| BS06031 |
Rectum adenocarcinoma (grade II) tissue array, 21 cases_63 cores, replaced by RE723; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BS06041 |
Rectum adenocarcinoma (grade III) tissue array, 21 cases_63 cores, replaced by RE724 |
|
160-Eur |
US Biomax |
recombinant |
| BS06041 |
Rectum adenocarcinoma (grade III) tissue array, 21 cases_63 cores, replaced by RE724; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
185-Eur |
US Biomax |
recombinant |
| BS08011 |
Breast infiltrating ductal carcinoma tissue array, 22 cases_63 cores, replaced by BR727 |
|
160-Eur |
US Biomax |
tissue |
| BS08011 |
Breast infiltrating ductal carcinoma tissue array, 22 cases_63 cores, replaced by BR727 ; ihc Anti-ER confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS09011 |
Uteral leiomyoma (hysteromyoma) tissue array, 30 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| BS09011 |
Uteral leiomyoma (hysteromyoma) tissue array, 30 cases_60 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS17011 |
Brain glioblastoma tissue array, 21 cases_63 cores, replaced by GL811 |
|
231-Eur |
US Biomax |
tissue |
| BS17011 |
Brain glioblastoma tissue array, 21 cases_63 cores, replaced by GL811; ihc Anti-GFAP confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS17015 |
Brain glioma tissue array, 63 cases_63 cores, replaced by GL803 |
|
231-Eur |
US Biomax |
tissue |
| BS17015 |
Brain glioma tissue array, 63 cases_63 cores, replaced by GL803; ihc Anti-GFAP confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS17016 |
Brain glioma tissue array, 33 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BS17016 |
Brain glioma tissue array, 33 cases_63 cores, replaced by BS17016a; ihc Anti-GFAP confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS17016a |
Brain glioblastoma tissue array, including pathology grade, 40 cases_80 cores, replacing BS17016; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS17017 |
Brain gliocytoma tissue array, 63 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| BS17017 |
Brain gliocytoma tissue array, 63 cases_63 cores; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS17018 |
Brain glioblastoma tissue array, 33 cases_63 cores, replaced by GL805 |
|
231-Eur |
US Biomax |
tissue |
| BS17018 |
Brain glioblastoma tissue array, 33 cases_63 cores, replaced by GL805; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS20011 |
Lymphoma tissue array, 30 cases_30 cores, replaced by NHL481 |
|
189-Eur |
US Biomax |
tissue |
| BS20011 |
Lymphoma tissue array, 30 cases_30 cores, replaced by NHL481; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| BS26011 |
Osteosarcoma tissue array, 32 cases_63 cores, replaced by OS804 |
|
231-Eur |
US Biomax |
tissue |
| BS26011 |
Osteosarcoma tissue array, 32 cases_63 cores, replaced by OS804; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| BS36011 |
Cartilages sarcoma (Chondrosarcoma) tissue array, 25 cases_75 cores, replaced by OS803 |
|
266-Eur |
US Biomax |
tissue |
| BS36011 |
Cartilages sarcoma (Chondrosarcoma) tissue array, 25 cases_75 cores, replaced by OS803; ihc Anti-PCNA confirmed |
|
267-Eur |
US Biomax |
tissue |
| CIN481 |
Cervical intraepithelial neoplasia tissue array with cervical disease spectrum, 48 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| CIN481 |
Cervical intraepithelial neoplasia tissue array with cervical disease spectrum, 48 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| CKIT061 |
Ckit molecule IHC control array, 3 cases_6 cores |
|
77-Eur |
US Biomax |
assays |
| CKIT061 |
Ckit molecule IHC control array, 3 cases_6 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
85-Eur |
US Biomax |
assays |
| CLC601 |
Colon cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases_60 cores |
|
266-Eur |
US Biomax |
tissue |
| CLC601 |
Colon cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases_60 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CM241 |
Common 4 types of cancer tissue array, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| CM241 |
Common 4 types of cancer tissue array, 12 cases_24 cores; ihc Anti-Vimentin (Vim) confirmed |
|
105-Eur |
US Biomax |
tissue |
| CM481 |
Common 4 types of cancer tissue array, 48 cases_54 cores, with stage and grade data |
|
231-Eur |
US Biomax |
tissue |
| CM481 |
Common 4 types of cancer tissue array, 48 cases_54 cores, with stage and grade data; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| CMA241 |
Human tumor cell array, 12 cell lines_24 cores |
|
278-Eur |
US Biomax |
human |
| CMA241 |
Human tumor cell array, 12 cell lines_24 cores, replaced by CMA241a; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
human |
| CMA241a |
Human tumor cell array, 12 cell lines_24 cores, replacing CMA241; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
human |
| CNS2081 |
Central nerve disease spectrum (central nerve tumor progression) tissue array, 104 cases_208 cores |
|
516-Eur |
US Biomax |
tissue |
| CNS2081 |
Central nerve disease spectrum (central nerve tumor progression) tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CNS801 |
Brain disease spectrum (brain cancer progression) tissue array, with stage, TNM and grade info, 79 cases_80 cores |
|
314-Eur |
US Biomax |
tissue |
| CNS801 |
Brain disease spectrum (brain cancer progression) tissue array, with stage, TNM and grade info, 79 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO1002 |
Colon and rectum carcinoma and normal tissue array, 73 cases_100 cores, replaced by CO1002b |
|
278-Eur |
US Biomax |
recombinant |
| CO1002 |
Colon and rectum carcinoma and normal tissue array, 73 cases_100 cores, replaced by CO1002b; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
recombinant |
| CO1002b |
Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002 |
|
321-Eur |
US Biomax |
recombinant |
| CO1002b |
Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002 |
|
266-Eur |
US Biomax |
recombinant |
| CO1002b |
Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
recombinant |
| CO1003 |
Colon carcinoma antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
|
| CO1003 |
Colon carcinoma antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
|
| CO1004 |
Colon carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| CO1004 |
Colon carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO1021 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 102 cases_102 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO1501 |
Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| CO1501 |
Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| CO1501 |
Colon adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| CO1502 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| CO1503 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| CO1921 |
High-density colon cancer tissue array with normal tissues, 192 cases_192 cores |
|
456-Eur |
US Biomax |
tissue |
| CO1921 |
High-density colon cancer tissue array with normal tissues, 192 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO1922 |
Advanced colon tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| CO1922 |
Advanced colon tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
elisa |
| CO2001 |
Colon cancer high-density tissue array, including TNM and pathology grade, 196 cases_200 core |
|
397-Eur |
US Biomax |
elisa |
| CO2001 |
Colon cancer high-density tissue array, including TNM and pathology grade, 196 cases_200 core; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
429-Eur |
US Biomax |
elisa |
| CO208 |
High-density, multiple colon cancer (1-4 grade) and normal colon tissue array, 70 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO208 |
High-density, multiple colon cancer (1-4 grade) and normal colon tissue array, 70 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO2081 |
Colon disease spectrum (colon cancer progression) tissue array, including TNM and pathology grade, 103 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2081 |
Colon disease spectrum (colon cancer progression) tissue array, including TNM and pathology grade, 103 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO20810 |
Colon cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO20810 |
Colon cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO20811 |
Colon tumor survey tissue array (1 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO20811 |
Colon tumor survey tissue array (1 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO20812 |
Colon tumor survey tissue array (2 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO20812 |
Colon tumor survey tissue array (2 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO20813 |
Colon tumor survey tissue array (3 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO20813 |
Colon tumor survey tissue array (3 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO20814 |
Colon tumor survey tissue array (4 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO20814 |
Colon tumor survey tissue array (4 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO2083 |
High-density colon cancer tissue array with normal tissue, stage and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2083 |
High-density colon cancer tissue array with normal tissue, stage and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO2085a |
High-density (208 cases_208 cores), multiple type colon adenocarcinoma (I-4 grade) tissue array with normal colon from autopsy and cancer adjacent tissue |
|
456-Eur |
US Biomax |
tissue |
| CO2085a |
High-density (208 cases_208 cores), multiple type colon adenocarcinoma (I-4 grade) tissue array with normal colon from autopsy and cancer adjacent tissue; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| CO2085b |
TMA BLOCK of high-density (208 cases_208 cores), multiple type colon adenocarcinoma (I-4 grade) with normal colon from autopsy and cancer adjacent tissue |
|
40981-Eur |
US Biomax |
tissue |
| CO2085b |
TMA BLOCK of high-density (208 cases_208 cores), multiple type colon adenocarcinoma (I-4 grade) with normal colon from autopsy and cancer adjacent tissue; ihc Anti-Cytokeratin (CK) confirmed |
|
33112-Eur |
US Biomax |
tissue |
| CO2086 |
Colon tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2086 |
Colon tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO2087 |
Colon cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2087 |
Colon cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO2088 |
Colon cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2088 |
Colon cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO2089 |
Colon cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2089 |
Colon cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO208b |
TMA Block of high-density (70 cases_208 cores), multiple colon cancer (1-4 grade) and normal colon tissue array block |
|
40981-Eur |
US Biomax |
tissue |
| CO208b |
TMA Block of high-density (70 cases_208 cores), multiple colon cancer (1-4 grade) and normal colon tissue array block; ihc Anti-Cytokeratin (CK) confirmed |
|
33112-Eur |
US Biomax |
tissue |
| CO2161 |
Colon cancer and normal colon tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
456-Eur |
US Biomax |
tissue |
| CO2161 |
Colon cancer and normal colon tissue array, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CO241 |
Colon cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| CO241 |
Colon cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores, replaced by CO241a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| CO241a |
Colon cancer tissue array with adjacent normal colon tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing CO241; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| CO242 |
Multiple colon cancer test tissue array with self-matching normal adjacent tissue, 10 cases_24 cores. |
|
88-Eur |
US Biomax |
assays |
| CO242 |
Multiple colon cancer test tissue array with self-matching normal adjacent tissue, 10 cases_24 cores, replaced by CO242a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| CO242a |
Colon carcinoma tissue array with adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing CO242; ihc Anti-Actin confirmed |
|
81-Eur |
US Biomax |
tissue |
| CO243 |
Colon cancer tissue array with normal tissue controls, 9 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| CO243 |
Colon cancer tissue array with normal tissue controls, 9 cases_24 cores, replaced by CO243a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| CO243a |
Colon carcinoma tissue array with matched adjacent normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing CO243; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| CO244 |
Colon cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| CO244 |
Colon cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO481 |
Colonic adenocarcinoma and matched adjacent tissue array, with TNM data, 12 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| CO481 |
Colonic adenocarcinoma and matched adjacent tissue array, with TNM data, 12 cases_48 cores; ihc Anti-actin confirmed Certified pathologist code Certified pathologist code |
|
210-Eur |
US Biomax |
tissue |
| CO482 |
Tissue array of colonic carcinoma with TNM data and normal colon tissue, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| CO482 |
Tissue array of colonic carcinoma with TNM data and normal colon tissue, 24 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
210-Eur |
US Biomax |
tissue |
| CO483 |
Multiple colon cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade information |
|
160-Eur |
US Biomax |
tissue |
| CO483 |
Multiple colon cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade information; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| CO484 |
Colon cancer tissue array with normal tissues with TNM and grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| CO484 |
Colon cancer tissue array with normal tissues with TNM and grade, 48 cases_48 cores, replaced by CO484a; ihc Anti-Cytokeratin (CK) confirmed |
|
210-Eur |
US Biomax |
tissue |
| CO484a |
Colon cancer tissue array with adjacent normal tissues, including TNM, clinical stage and pathology grade, 48 cases_48 cores, replacing CO484; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| CO485 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| CO485 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO486 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases_96 cores |
|
397-Eur |
US Biomax |
elisa |
| CO486 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases_96 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
382-Eur |
US Biomax |
elisa |
| CO487 |
Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| CO487 |
Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| CO487 |
Colon adenocarcinoma with matched adjacent colon tissue array, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| CO488 |
Colon adenocarcinoma with matched adjacent colon tissue array, including TNM, clinical stage and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| CO601 |
Colon cancer tissue array, with matched normal tissues, 29 cases_60 cores, with TNM data |
|
----Eur |
US Biomax |
tissue |
| CO6161 |
High-density colon cancer array, with stage, grade and normal colon tissue, 322 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| CO6161 |
High-density colon cancer array, with stage, grade and normal colon tissue, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| CO641 |
Colon cancer tissue array, 64 cases_66 cores, with TNM data |
|
----Eur |
US Biomax |
tissue |
| CO701 |
Colon cancer tissue array, with grade 1-4 and normal colon tissue, 70 cases_70 cores, with stage and grade information |
|
231-Eur |
US Biomax |
tissue |
| CO701 |
Colon cancer tissue array, with grade 1-4 and normal colon tissue, 70 cases_70 cores, with stage and grade information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO702 |
Colon cancer tissue array, with metastasis tissue and adjacent normal tissue, including TNM and pathology grade, 69 cases_69 cores, repalcing BC05115 |
|
266-Eur |
US Biomax |
tissue |
| CO702 |
Colon cancer tissue array, with metastasis tissue and adjacent normal tissue, including TNM and pathology grade, 69 cases_69 cores, repalcing BC05115; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| CO721 |
Colon cancer tissue array with stage and grade info, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| CO721 |
Colon cancer tissue array with stage and grade info, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO722 |
Colon adenocarcinoma tissue array with matched tumor adjacent and adjacent normal tissue control, with stage and grade info, 24 cases_72 cores, replacing BC05021 |
|
231-Eur |
US Biomax |
tissue |
| CO722 |
Colon adenocarcinoma tissue array with matched tumor adjacent and adjacent normal tissue control, with stage and grade info, 24 cases_72 cores, replacing BC05021; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO723 |
Colon well differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases_72 cores, replacing BS05021 |
|
231-Eur |
US Biomax |
tissue |
| CO723 |
Colon well differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases_72 cores, replacing BS05021; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO724 |
Colon moderately differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases_72 cores, replacing BS05031 |
|
278-Eur |
US Biomax |
tissue |
| CO724 |
Colon moderately differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases_72 cores, replacing BS05031; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO725 |
Colon poorly differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases_72 cores, replacing BS05041 |
|
231-Eur |
US Biomax |
tissue |
| CO725 |
Colon poorly differentiated adenocarcinoma and adjacent normal tissue array, with stage and grade info, 24 cases_72 cores, replacing BS05041; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO726 |
Metastatic colon carcinoma tissue array, 24 cases_72 cores, replacing BC050112 |
|
266-Eur |
US Biomax |
tissue |
| CO726 |
Metastatic colon carcinoma tissue array, 24 cases_72 cores, replacing BC050112; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO801 |
Colon cancer tissue array, with matched or unmatched adjacent normal tissue, 40 cases_80 cores, no overlaps with CO802 |
|
231-Eur |
US Biomax |
tissue |
| CO801 |
Colon cancer tissue array, with matched or unmatched adjacent normal tissue, 40 cases_80 cores, no overlaps with CO802; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO802 |
Colon carcinoma (multi-tissue combined panel) tissue array, 80 cases_80 cores, no overlaps with CO801 |
|
189-Eur |
US Biomax |
tissue |
| CO802 |
Colon carcinoma (multi-tissue combined panel) tissue array, 80 cases_80 cores, no overlaps with CO801, replaced by CO802b; ihc Anti-Cytokeratin (CK) confirmed |
|
258-Eur |
US Biomax |
tissue |
| CO802a |
Colon cancer tissue array with adjacent normal colon tissue, including TNM and clinical stage, 80 cases_80 cores, replacing CO802; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| CO802b |
Colon cancer tissue array with adjacent normal colon tissue, including pathology grade and clinical stage, 80 cases_80 cores, replacing CO802; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| CO803 |
Colon cancer tissue array, with matched tumor and adjacent normal tissue, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CO803 |
Colon cancer tissue array, with matched tumor and adjacent normal tissue, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO804 |
Multiple types of colon carcinoma tissue array (replacing BC05011), 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CO804 |
Multiple types of colon carcinoma tissue array (replacing BC05011), 80 cases_80 cores, replaced by CO804a; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO804a |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replcing CO804; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO805 |
Colon adenocarcinoma and normal tissue array with stage and grade information, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CO805 |
Colon adenocarcinoma and normal tissue array with stage and grade information, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO806 |
Colon normal adjacent tissue array, replacing BN05012, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CO806 |
Colon normal adjacent tissue array, replacing BN05012, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO807 |
Advanced colon cancer tissue array, with stage and grade info, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| CO807 |
Advanced colon cancer tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO808 |
Colon disease spectrum (colon cancer progression) tissue array, 76 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| CO808 |
Colon disease spectrum (colon cancer progression) tissue array, 76 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO809 |
Colon polyp and colitis tissue array, including colon adenoma and normal tissue, 80 cases_80 cores |
|
263-Eur |
US Biomax |
recombinant |
| CO809 |
Colon polyp and colitis tissue array, including colon adenoma and normal tissue, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
263-Eur |
US Biomax |
recombinant |
| CO811 |
Colon cancer tissue array with normal tissues from autopsy, with TNM data, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CO811 |
Colon cancer tissue array with normal tissues from autopsy, with TNM data, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CO812 |
Colon carcinoma and normal tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CO812 |
Colon carcinoma and normal tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CO951 |
Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores |
|
456-Eur |
US Biomax |
tissue |
| CO951 |
Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores, to be replaced by CO952; ihc Anti-Cytokeratin (C |
|
429-Eur |
US Biomax |
tissue |
| CO952 |
Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores, replacing CO951; ihc Anti-Cytokeratin (CK) confi |
|
429-Eur |
US Biomax |
tissue |
| CO961 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| CO962 |
Colon cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| CO991 |
Colorectal (colon and rectum) cancer with matched lymph node metastasis tissue array, 44 cases_99 cores. |
|
266-Eur |
US Biomax |
recombinant |
| CO991 |
Colorectal (colon and rectum) cancer with matched lymph node metastasis tissue array, 44 cases_99 cores, replaced by CO992.; ihc Anti-Cytokeratin (High MW) confirmed |
|
258-Eur |
US Biomax |
recombinant |
| CO992 |
Colorectal (colon and rectum) cancer with matched lymph node metastasis and normal adjacent tissue array, 43 cases_99 cores |
|
266-Eur |
US Biomax |
recombinant |
| CO992 |
Colorectal (colon and rectum) cancer with matched lymph node metastasis and normal adjacent tissue array, 43 cases_99 cores, replacing CO991; ihc Anti-Cytokeratin (CK) confirmed |
|
258-Eur |
US Biomax |
recombinant |
| COC1021 |
Colon cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| COC1021 |
Colon cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| COC1501 |
Colon cancer mid-density tissue array, non-overlapping with either COC1502 or COC1503, 75 cases_150 cores |
|
----Eur |
US Biomax |
tissue |
| COC1501 |
Colon cancer mid-density tissue array, non-overlapping with either COC1502 or COC1503, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| COC1502 |
Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1503 75 cases_150 cores |
|
----Eur |
US Biomax |
tissue |
| COC1502 |
Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1503 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| COC1503 |
Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| COC1503 |
Colon cancer mid-density tissue array, non-overlapping with either COC1501 or COC1502, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| COC2281 |
High density colon cancer tissue array, 228 cases_ 228 cores |
|
----Eur |
US Biomax |
tissue |
| COC2281 |
High density colon cancer tissue array, 228 cases_ 228 cores; ihc H&E, IHC anti- Cytokeratin |
|
434-Eur |
US Biomax |
tissue |
| COC481 |
Colon cancer and normal tissue array, non-overlapping with COC482???16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| COC481 |
Colon cancer and normal tissue array, non-overlapping with COC482???16 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| COC482 |
Colon cancer and normal tissue array, non-overlapping with COC481???16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| COC482 |
Colon cancer and normal tissue array, non-overlapping with COC481???16 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| COC961 |
Colon cancer and normal tissue array, non-overlapping with COC962???48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| COC961 |
Colon cancer and normal tissue array, non-overlapping with COC962???48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| COC962 |
Colon cancer and normal tissue array, non-overlapping with COC961, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| COC962 |
Colon cancer and normal tissue array, non-overlapping with COC961, 48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| CR1001 |
Multiple uterine carcinoma tissue array with normal tissue, 49 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| CR1001 |
Multiple uterine carcinoma tissue array with normal tissue, 49 cases_100 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| CR1002 |
Cervix carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
|
| CR1002 |
Cervix carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
|
| CR1003 |
Cervix cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| CR1003 |
Cervix cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR1501 |
Cervical cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| CR1921 |
Middle-advanced stage uterine cervix cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| CR1921 |
Middle-advanced stage uterine cervix cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
elisa |
| CR208 |
Cervical cancer high density tissue array, with normal cervix tissue as control, 69 cases_208 cores, with grade and stage |
|
456-Eur |
US Biomax |
tissue |
| CR208 |
Cervical cancer high density tissue array, with normal cervix tissue as control, 69 cases_208 cores, with grade and stage; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CR2081 |
High-density cervix cancer tissue array with normal tissues, with stage and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2081 |
High-density cervix cancer tissue array with normal tissues, with stage and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CR2082 |
High-density cervical cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2082 |
High-density cervical cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CR2083 |
Uterine cervical cancer and cancer adjacent normal tissue survey tissue array (1 of 5), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2083 |
Uterine cervical cancer and cancer adjacent normal tissue survey tissue array (1 of 5), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CR2084 |
Cervical cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2084 |
Cervical cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CR2085 |
Cervix cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2085 |
Cervix cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CR2086 |
Cervix tumor tissue array (4 of 5), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2086 |
Cervix tumor tissue array (4 of 5), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CR2087 |
Uterine cervical cancer tissue survey tissue array (5 of 5), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2087 |
Uterine cervical cancer tissue survey tissue array (5 of 5), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| CR2088 |
Cervix cancer survey tissue array (1 of 2), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2088 |
Cervix cancer survey tissue array (1 of 2), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CR2089 |
Cervix cancer survey tissue array (2 of 2), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| CR2089 |
Cervix cancer survey tissue array (2 of 2), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| CR241 |
Cervix cancer test tissue array with self-matching or unmatched normal adjacent tissue, 11 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| CR241 |
Cervix cancer test tissue array with self-matching or unmatched normal adjacent tissue, 11 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| CR242 |
Multiple cervix cancer test tissue array with self-matching or unmatched normal adjacent tissues, 22 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| CR242 |
Multiple cervix cancer test tissue array with self-matching or unmatched normal adjacent tissues, 22 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| CR243 |
Uterine cervix cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores, 2 sections_slide |
|
160-Eur |
US Biomax |
tissue |
| CR243 |
Uterine cervix cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores, 2 sections_slide; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| CR244 |
Uterine cervix cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases_24 cores, replacing CR241 |
|
189-Eur |
US Biomax |
tissue |
| CR244 |
Uterine cervix cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases_24 cores, replacing CR241; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| CR245 |
Cervical cancer tissue array with matched adjacent cervical tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| CR481 |
Cervical cancer tissue array with normal adjacent tissues, 24 cases_48 cores, with grade and stage data |
|
160-Eur |
US Biomax |
tissue |
| CR481 |
Cervical cancer tissue array with normal adjacent tissues, 24 cases_48 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| CR482 |
Multiple cervix cancer tissue array with 4 normal tissues control from autopsy, 24 cases_48 cores, with grade and stage data |
|
160-Eur |
US Biomax |
tissue |
| CR482 |
Multiple cervix cancer tissue array with 4 normal tissues control from autopsy, 24 cases_48 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| CR483 |
Multiple cervix cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with TNM data |
|
160-Eur |
US Biomax |
tissue |
| CR483 |
Multiple cervix cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with TNM data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| CR484 |
Cervix squamous cell carcinoma tissue array with matched adjacent cervix tissue, including TNM and pathology grade, 16 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| CR484 |
Cervix squamous cell carcinoma tissue array with matched adjacent cervix tissue, including TNM and pathology grade, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| CR484 |
Cervix squamous cell carcinoma tissue array with matched adjacent cervix tissue, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| CR485 |
Cervix cancer and adjacent normal tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| CR485 |
Cervix cancer and adjacent normal tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR501 |
Cervical cancer and normal tissue array with TNM and grade, 50 cases_50 cores |
|
160-Eur |
US Biomax |
tissue |
| CR501 |
Cervical cancer and normal tissue array with TNM and grade, 50 cases_50 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| CR601 |
Cervical carcinoma tissue array with cervical disease spectrum (normal, inflammation, CIN, malignant I-III), 59 cases_60 cores, replaced by CR602 |
|
231-Eur |
US Biomax |
tissue |
| CR601 |
Cervical carcinoma tissue array with cervical disease spectrum (normal, inflammation, CIN, malignant I-III), 59 cases_60 cores, replaced by CR602; ihc Anti-Cytokeratin (CK) |
|
267-Eur |
US Biomax |
tissue |
| CR602 |
Tissue array of uterine cervical disease spectrum (cervical cancer, CIN, inflammation and adjacent normal tissue), 60 cases_60 cores, replacing CR601 |
|
231-Eur |
US Biomax |
tissue |
| CR602 |
Tissue array of uterine cervical disease spectrum (cervical cancer, CIN, inflammation and adjacent normal tissue), 60 cases_60 cores, replacing CR601; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CR6161 |
High-density uterine cervix cancer array, with stage, grade and normal cervical tissue, 322 cases_616 cores |
|
872-Eur |
US Biomax |
tissue |
| CR6161 |
High-density uterine cervix cancer array, with stage, grade and normal cervical tissue, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| CR701 |
Cervical carcinoma, adjacent tissue and adjacent normal tissue array, including TNM and pathology grade, 70 cases_70 cores |
|
266-Eur |
US Biomax |
tissue |
| CR701 |
Cervical carcinoma, adjacent tissue and adjacent normal tissue array, including TNM and pathology grade, 70 cases_70 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR721 |
Uterine cervix cancer and normal tissue array, with grade and stage data, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| CR721 |
Uterine cervix cancer and normal tissue array, with grade and stage data, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR802 |
Cervical cancer tissue array, matched or unmatched tumor and adjacent normal tissue, 74 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CR802 |
Cervical cancer tissue array, matched or unmatched tumor and adjacent normal tissue, 74 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CR803 |
Multiple (uterine cervix) cervical squamous cancer tissue array, 80 cases_80 cores, replacing BS10011 |
|
231-Eur |
US Biomax |
tissue |
| CR803 |
Multiple (uterine cervix) cervical squamous cancer tissue array, 80 cases_80 cores, replacing BS10011; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| CR804 |
Cervical cancer and normal tissue array with TNM and grade, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CR804 |
Cervical cancer and normal tissue array with TNM and grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR805 |
Cervix cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| CR805 |
Cervix cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR806 |
Mid-advanced stage uterine cervix cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| CR806 |
Mid-advanced stage uterine cervix cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CR811 |
Cervical cancer tissue array with normal tissues from autopsy, 40 cases_80 cores, with grade and TNM data |
|
231-Eur |
US Biomax |
tissue |
| CR811 |
Cervical cancer tissue array with normal tissues from autopsy, 40 cases_80 cores, with grade and TNM data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CVD231 |
Cardiovascular disease tissue array, non-overlapping with CVD481, 23 cases_23 cores |
|
166-Eur |
US Biomax |
tissue |
| CVD231 |
Cardiovascular disease tissue array, non-overlapping with CVD481, 23 cases_23 cores; ihc H&E, IHC anti-CD34 |
|
178-Eur |
US Biomax |
tissue |
| CVD481 |
Cardiovascular disease tissue array, no overlapping with CVD231, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| CVD481 |
Cardiovascular disease tissue array, no overlapping with CVD231, 24 cases_48 cores; ihc H&E, IHC anti-CD34 |
|
205-Eur |
US Biomax |
tissue |
| CXC1021 |
Cervix cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| CXC1021 |
Cervix cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| CXC1501 |
Cervical cancer mid-density tissue array, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| CXC1501 |
Cervical cancer mid-density tissue array, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| CXC241 |
Cervical cancer tissue array, 12 cases_24 cores |
|
189-Eur |
US Biomax |
tissue |
| CXC241 |
Cervical cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| CXC481 |
Cervix cancer and normal tissue array, 16 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| CXC481 |
Cervix cancer and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| CXC961 |
Cervical cancer and normal tissue array, non-overlapping with CXC962, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| CXC961 |
Cervical cancer and normal tissue array, non-overlapping with CXC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| CXC962 |
Cervical cancer and normal tissue array, non-overlapping with CXC961, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| CXC962 |
Cervical cancer and normal tissue array, non-overlapping with CXC961, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| CyFDA |
FDA normal organ tissue array of cynomolgus monkey, 99 cases_99 cores |
|
314-Eur |
US Biomax |
tissue |
| CyFDA |
FDA normal organ tissue array of cynomolgus monkey, 99 cases_99 cores, replaced by CyFDA1; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| CyFDA1 |
FDA multiple organ normal tissue array of cynomolgus monkey, 34 organs_99 cores, replacing CyFDA; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| DGS2081 |
Digestive system tissue array, including TNM, stage and grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| DGS2081 |
Digestive system tissue array, including TNM, stage and grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| DID381 |
Digestive system disease tissue array, 38 cases_38 cores |
|
166-Eur |
US Biomax |
tissue |
| DID381 |
Digestive system disease tissue array, 38 cases_38 cores; ihc H&E, IHC anti- Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| DOG1061 |
GIST DOG1 molecule IHC control array, 3 cases_6 cores |
|
77-Eur |
US Biomax |
dog |
| DOG1061 |
GIST DOG1 molecule IHC control array, 3 cases_6 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
85-Eur |
US Biomax |
dog |
| EM1021 |
Endometrium cancer and normal tissue array, including TNM and pathology grade, 102 cases_102 cores |
|
314-Eur |
US Biomax |
tissue |
| EM1021 |
Endometrium cancer and normal tissue array, including TNM and pathology grade, 102 cases_102 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| EMC1021 |
Endometrial cancer tissue array, 102 caese_102 cores |
|
225-Eur |
US Biomax |
tissue |
| EMC1021 |
Endometrial cancer tissue array, 102 caese_102 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| EMC1501 |
Endometrial cancer mid-density tissue array, non-overlapping with EMC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| EMC1501 |
Endometrial cancer mid-density tissue array, non-overlapping with EMC1502, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| EMC1502 |
Endometrial cancer mid-density tissue array, non-overlapping with EMC1501, 75 caese_150 cores |
|
225-Eur |
US Biomax |
tissue |
| EMC1502 |
Endometrial cancer mid-density tissue array, non-overlapping with EMC1501, 75 caese_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| EMC241 |
Endometrium cancer tissue array, 12 cases_24 cores |
|
189-Eur |
US Biomax |
tissue |
| EMC241 |
Endometrium cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| EMC961 |
Endometrial cancer and normal tissue array, non-overlapping with EMC962, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| EMC961 |
Endometrial cancer and normal tissue array, non-overlapping with EMC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| EMC962 |
Endometrial cancer and normal tissue array, non-overlapping with EMC961???48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| EMC962 |
Endometrial cancer and normal tissue array, non-overlapping with EMC961???48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| EN801 |
Endocrine tumor tissue array, 40 cases_80 cores. |
|
266-Eur |
US Biomax |
tissue |
| EN801 |
Endocrine tumor tissue array, 40 cases_80 cores, replaced by EN801a; ihc IHC confirmed |
|
296-Eur |
US Biomax |
tissue |
| EN801a |
Endocrine cancer tissue array, including TNM and clinical stage, 40 cases_80 cores, replacing EN801; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ENS2081 |
Endocrine system benign, alignant tumor and normal tissue array, including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ENS2081 |
Endocrine system benign, alignant tumor and normal tissue array, including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| ERC031 |
Estrogen receptor IHC control array, 3 cases_3 cores |
|
77-Eur |
US Biomax |
recombinant |
| ERC031 |
Estrogen receptor (ER) IHC control array, 3 cases_3 cores; ihc H&E, IHC anti-ER |
|
85-Eur |
US Biomax |
recombinant |
| ES1001 |
Esophagus cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| ES1001 |
Esophagus cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES1002 |
Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| ES1002 |
Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES1201 |
Tissue array of esophageal squamous carcinoma and matched adjacent tissue, 60 cases_120 cores, replaced by ES1202 |
|
278-Eur |
US Biomax |
tissue |
| ES1201 |
Tissue array of esophageal squamous carcinoma and matched adjacent tissue, 60 cases_120 cores, replaced by ES1202; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES1202 |
Esophageal tumor tissue array, with stage, grade and matched adjacent tissue, 60 cases_120 cores, replacing ES1201 |
|
278-Eur |
US Biomax |
tissue |
| ES1202 |
Esophageal tumor tissue array, with stage, grade and matched adjacent tissue, 60 cases_120 cores, replacing ES1201; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES1501 |
Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| ES1501 |
Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| ES1501 |
Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| ES1502 |
Esophageal cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| ES1921 |
Middle-advanced stage esophagus cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| ES1921 |
Middle-advanced stage esophagus cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
elisa |
| ES2001 |
Esophagus squamous cell carcinoma and metastatic carcinoma tissue array, with adjacent tissue and adjacent normal tissue, including TNM and pathology grade, 120 cases_200 cores |
|
516-Eur |
US Biomax |
tissue |
| ES2001 |
Esophagus squamous cell carcinoma and metastatic carcinoma tissue array, with adjacent tissue and adjacent normal tissue, including TNM and pathology grade, 120 cases_200 cores; ihc Anti-Cytokeratin |
|
429-Eur |
US Biomax |
tissue |
| ES208 |
High density esophageal cancer tissue array, with normal tissue, grade and TNM, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ES208 |
High density esophageal cancer tissue array, with normal tissue, grade and TNM, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ES2081 |
Esophageal disease (progression) spectrum tissue array, 103 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ES2081 |
Esophageal disease (progression) spectrum tissue array, 103 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ES2082 |
High-density esophageal cancer and normal tissue array, with TNM and grade info, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ES2082 |
High-density esophageal cancer and normal tissue array, with TNM and grade info, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ES241 |
Esophagus cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| ES241 |
Esophagus cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| ES242 |
Multiple esophagus cancer test tissue array with matched or unmatched normal adjacent tissue, 11 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| ES242 |
Multiple esophagus cancer test tissue array with matched or unmatched normal adjacent tissue, 11 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| ES243 |
Esophagus cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| ES243 |
Esophagus cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ES244 |
Esophageal squamous cell carcinoma tissue array with matched adjacent esophageal tissue, including TNM and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| ES481 |
Esophageal cancer tissue array with matched or unmatched normal adjacent tissues (18 cases_48 cores) with stage and grade info |
|
160-Eur |
US Biomax |
tissue |
| ES481 |
Esophageal cancer tissue array with matched or unmatched normal adjacent tissues (18 cases_48 cores) with stage and grade info; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| ES482 |
Multiple esophagus cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with grade and stage data |
|
160-Eur |
US Biomax |
tissue |
| ES482 |
Multiple esophagus cancer tissue array with unmatched normal tissues, 48 cases_48 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| ES483 |
Esophagus cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| ES483 |
Esophagus cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES721 |
Esophagus cancer and normal tissue array with TNM and grade info, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| ES721 |
Esophagus cancer and normal tissue array with TNM and grade info, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES722 |
Esophageal cancer and adjacent tissue array, with stage and grade info, 30 cases_72 cores, replacing BC02023 |
|
231-Eur |
US Biomax |
tissue |
| ES722 |
Esophageal cancer and adjacent tissue array, with stage and grade info, 30 cases_72 cores, replacing BC02023; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ES723 |
Esophageal squamous cell carcinoma tissue array, with stage, grade and normal tissue, 23 cases_72 cores, replacing BS02031 |
|
231-Eur |
US Biomax |
tissue |
| ES723 |
Esophageal squamous cell carcinoma tissue array, with stage, grade and normal tissue, 23 cases_72 cores, replacing BS02031; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES781 |
Esophagus cancer tissue array, including TNM and pathology grade, 26 cases_78 cores, replacing BC02111 |
|
266-Eur |
US Biomax |
tissue |
| ES781 |
Esophagus cancer tissue array, including TNM and pathology grade, 26 cases_78 cores, replacing BC02111; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES801 |
Esophagus cancer, with matched normal adjacent tissue array, 40 cases_80 cores, replaced by ES8010 |
|
231-Eur |
US Biomax |
tissue |
| ES801 |
Esophagus cancer, with matched normal adjacent tissue array, 40 cases_80 cores, replaced by ES8010; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES8010 |
Esophageal cancer and adjacent normal tissue array, with TNM and grade info, 40 cases_80 cores, replacing ES801 |
|
231-Eur |
US Biomax |
tissue |
| ES8010 |
Esophageal cancer and adjacent normal tissue array, with TNM and grade info, 40 cases_80 cores, replacing ES801; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES8011 |
Esophageal cancer tissue array, with normal tissue, TNM and grade info, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES8011 |
Esophageal cancer tissue array, with normal tissue, TNM and grade info, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES8012 |
Middle-advanced stage esophageal cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| ES8012 |
Middle-advanced stage esophageal cancer tissue array, with metastasis tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ES802 |
Esophageal squamous cell carcinoma tissue array, grade I-III, 40 cases_80 cores, no overlaps with ES801 |
|
231-Eur |
US Biomax |
tissue |
| ES802 |
Esophageal squamous cell carcinoma tissue array, grade I-III, 40 cases_80 cores, no overlaps with ES801; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ES803 |
Esophageal inflammation, hyperplasia and atypical hyperplasia tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES803 |
Esophageal inflammation, hyperplasia and atypical hyperplasia tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ES804 |
Esophageal cancer progression tissue array, 76 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES804 |
Esophageal cancer progression tissue array, 76 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ES805 |
Esophagus cancer and normal tissue array, with grade and stage data, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES805 |
Esophagus cancer and normal tissue array, with grade and stage data, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES806 |
Metastatic esophageal cancer tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES806 |
Metastatic esophageal cancer tissue array, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES807 |
Esophageal cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES807 |
Esophageal cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES808 |
Esophagus cancer and normal tissue array, with TNM and grade info, 78 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES808 |
Esophagus cancer and normal tissue array, with TNM and grade info, 78 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES809 |
Esophageal disease spectrum (esophageal cancer progression) tissue array, 78 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES809 |
Esophageal disease spectrum (esophageal cancer progression) tissue array, 78 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES810 |
Esophagus cancer with matched lymph node metastasis tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ES810 |
Esophagus cancer with matched lymph node metastasis tissue array, 40 cases_80 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES811 |
Esophageal cancer tissue array with normal tissues from autopsy, 40 cases_80 cores, plus grade and stage information |
|
231-Eur |
US Biomax |
tissue |
| ES811 |
Esophageal cancer tissue array with normal tissues from autopsy, 40 cases_80 cores, plus grade and stage information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ES961 |
Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
336-Eur |
US Biomax |
elisa |
| ES961 |
Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
278-Eur |
US Biomax |
elisa |
| ES961 |
Esophagus squamous cell carcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| ES962 |
Esophageal squamous cell carcinoma tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| ESC1021 |
Esophagus cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| ESC1021 |
Esophagus cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| ESC1501 |
Esophageal cancer mid-density tissue array, non-overlapping with ESC1502???75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| ESC1501 |
Esophageal cancer mid-density tissue array, non-overlapping with ESC1502???75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| ESC1502 |
Esophagus cancer mid-density tissue array, non-overlapping with ESC1501, 75 cases_150 cores |
|
----Eur |
US Biomax |
tissue |
| ESC241 |
Esophagus cancer tissue array, 12 cases_24 cores |
|
166-Eur |
US Biomax |
tissue |
| ESC241 |
Esophagus cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| ESC242 |
Esophagus cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| ESC481 |
Esophagus cancer and normal tissue array, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| ESC481 |
Esophagus cancer and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| ESC961 |
Esophageal cancer tissue array, non-overlapping with ESC962, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| ESC961 |
Esophageal cancer tissue array, non-overlapping with ESC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| ESC962 |
Esophagus cancer tissue array, non-overlapping with ESC961, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| ESC962 |
Esophagus cancer tissue array, non-overlapping with ESC961, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| FBN401 |
Normal human multiple organ frozen tissue array (20 organs in duplicate), 20 cases_40 cores; ihc Anti-Actin confirmed |
|
278-Eur |
US Biomax |
tissue |
| FBN404 |
Multiple organ normal frozen tissue array, 20 cases_40 cores |
|
167-Eur |
US Biomax |
tissue |
| FBN404 |
Multiple organ normal frozen tissue array, 20 cases_40 cores; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FBN406 |
Multiple organ normal frozen tissue array, 20 cases_40 cores, replacing FBN404 |
|
167-Eur |
US Biomax |
tissue |
| FBN406 |
Multiple organ normal frozen tissue array, 20 cases_40 cores, replacing FBN404; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FBN406a |
Multiple organ normal frozen tissue array, 20 organs_40 cores; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FBN407 |
Multiple organ normal frozen tissue array, 20 cases_40 cores, replacing FBN404 |
|
281-Eur |
US Biomax |
tissue |
| FBN407 |
Multiple organ normal frozen tissue array, 20 cases_40 cores, replaced by FBN407a; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FBN407a |
Multiple organ normal frozen tissue array, 20 cases_40 cores, replaing FBN407; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FCO401 |
Colorectal organ carcinoma frozen tissue array, including TNM, clinical stage, 40 cases_40 cores, replaced by FCO401a |
|
293-Eur |
US Biomax |
recombinant |
| FCO401 |
Colorectal organ carcinoma frozen tissue array, including TNM, clinical stage, 40 cases_40 cores, replaced by FCO401a; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
recombinant |
| FCO401a |
Frozen colorectal adenocarcinoma tissue array, including TNM and clinical stage, 40 cases_40 cores, replacing FCO401 |
|
781-Eur |
US Biomax |
recombinant |
| FCO401a |
Frozen colorectal adenocarcinoma tissue array, including TNM and clinical stage, 40 cases_40 cores, replacing FCO401 |
|
331-Eur |
US Biomax |
recombinant |
| FCO401a |
Frozen colorectal adenocarcinoma tissue array, including TNM and clinical stage, 40 cases_40 cores, replacing FCO401; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
recombinant |
| FDA800 |
Multiple organ tumor tissue array, 72 cases of variety of cancers_72 cores, replacing FDA802-2 or FDA803-2 |
|
266-Eur |
US Biomax |
tissue |
| FDA800 |
Multiple organ tumor tissue array, 72 cases of variety of cancers_72 cores, replacing FDA802-2 or FDA803-2; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA801 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA802, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies. |
|
278-Eur |
US Biomax |
assays |
| FDA801 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA802, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies.; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA802 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA803, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies. |
|
278-Eur |
US Biomax |
assays |
| FDA802 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA803, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies.; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA803 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA804, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies. |
|
278-Eur |
US Biomax |
assays |
| FDA803 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA804, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies.; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA804 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA805, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies |
|
278-Eur |
US Biomax |
assays |
| FDA804 |
FDA normal and tumor organ tissue array of human (2 slide set), replaced by FDA805, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA804-2 |
Multiple tumor and 6 types of normal organ tissue array (slide 2 of 2 slide set), replacing FDA803-2, recommended by FDA to test tissue specificity, 72 cases_72 cores, replaced by FDA807-2 |
|
278-Eur |
US Biomax |
recombinant |
| FDA804-2 |
Multiple tumor and 6 types of normal organ tissue array (slide 2 of 2 slide set), replacing FDA803-2, recommended by FDA to test tissue specificity, 72 cases_72 cores, replaced by FDA807-2; ihc Anti- |
|
267-Eur |
US Biomax |
recombinant |
| FDA805 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA804, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies |
|
314-Eur |
US Biomax |
assays |
| FDA805 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA804, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA805-2 |
Multiple organ cancer and 6 types of normal organ tissue array, including TNM and pathology grade, 72 cases_72 cores, replaced by FDA808-2 |
|
278-Eur |
US Biomax |
tissue |
| FDA805-2 |
Multiple organ cancer and 6 types of normal organ tissue array, including TNM and pathology grade, 72 cases_72 cores, replaced by FDA808-2; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA806 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA805, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies |
|
380-Eur |
US Biomax |
assays |
| FDA806 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA805, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies |
|
314-Eur |
US Biomax |
assays |
| FDA806 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA805, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA807 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA806, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA807-1 |
Multiple organ normal tissue array, tissue 72 cores, replaced by FDA808-1; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA807-2 |
Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases_72 cores, replacing FDA806-2 |
|
336-Eur |
US Biomax |
tissue |
| FDA807-2 |
Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases_72 cores, replacing FDA806-2 |
|
278-Eur |
US Biomax |
tissue |
| FDA807-2 |
Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases_72 cores, replacing FDA806-2; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA808 |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA807, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA808-1 |
Multiple organ normal tissue array, tissue 72 cores, replaced by FDA808a-1; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA808-2 |
Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases_72 cores, replacing FDA805-2 |
|
277-Eur |
US Biomax |
tissue |
| FDA808-2 |
Multiple organ tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases_72 cores, replacing FDA805-2 |
|
231-Eur |
US Biomax |
tissue |
| FDA808-2 |
Multiple normal organ and tumor tissue array with adjacent normal human organs, including TNM and pathology grade, 72 cases_72 cores, replaced by FDA808a-2; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA808a |
FDA normal and tumor organ tissue array of human (2 slide set), replacing FDA808, 144 cases_144 cores, for FDA guidelines to test tissue specificity of antibodies; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA808a-1 |
Multiple organ normal tissue array, 72 cases_72 cores, replacing FDA808-1; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA808a-2 |
Multiple organ tumor tissue array with adjacent normal human organs, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replacing FDA808-2; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| FDA901 |
FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ, spanning two frozen tissue microarray slides.; ih |
|
1438-Eur |
US Biomax |
tissue |
| FDA901-1 |
FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ. (slide one); ihc Anti-Actin confirmed |
|
858-Eur |
US Biomax |
tissue |
| FDA901-2 |
FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ. (slide two); ihc Anti-Actin confirmed |
|
858-Eur |
US Biomax |
tissue |
| FDA902 |
FDA Standard Frozen Tissue Array (2 slide set), for therapeutic and diagnostic monoclonal antibody validation recommanded by FDA, 90 tissue cores of 30 organs, 3 individual donors per organ |
|
199-Eur |
US Biomax |
recombinant |
| FDA902 |
FDA Standard Frozen Tissue Array (2 slide set), for therapeutic and diagnostic monoclonal antibody validation recommanded by FDA, 90 tissue cores of 30 organs, 3 individual donors per organ, replaced |
|
1206-Eur |
US Biomax |
recombinant |
| FDA902-2 |
FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, 15 cases_45 cores, replaced by FDA902b-2; ihc Anti-Actin confirmed |
|
858-Eur |
US Biomax |
tissue |
| FDA902a |
FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, total 30 organs, 3 individual donors per organ, spanning two frozen tissue microarray slides, rep |
|
1206-Eur |
US Biomax |
tissue |
| FDA902b |
FDA Standard Frozen Tissue Array (2 slide set), for therapeutic and diagnostic monoclonal antibody validation recommanded by FDA, 90 tissue cores of 30 organs, 3 individual donors per organ, replacing |
|
1206-Eur |
US Biomax |
recombinant |
| FDA902b-2 |
FDA Standard Frozen Tissue Array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FDA902-2; ihc Anti-Actin confirmed |
|
1206-Eur |
US Biomax |
tissue |
| FDA992 |
FDA normal organ tissue array of human tissue, 67cases_100 cores |
|
278-Eur |
US Biomax |
tissue |
| FDA992 |
FDA normal organ tissue array of human tissue, 67cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA993 |
FDA normal human organ tissue array, 67cases_100 cores, replaced by FDA995 |
|
278-Eur |
US Biomax |
tissue |
| FDA993 |
FDA normal human organ tissue array, 67cases_100 cores, replaced by FDA995; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA994 |
FDA normal human organ tissue array, 99 cores_33 sites_75 cases, replacing FDA993, replaced by FDA995 |
|
314-Eur |
US Biomax |
tissue |
| FDA994 |
FDA normal human organ tissue array, 99 cores_33 sites_75 cases, replacing FDA993, replaced by FDA995; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA995 |
FDA normal human organ tissue array, 99 cores_33 sites_75 cases, replaced by FDA997 |
|
278-Eur |
US Biomax |
tissue |
| FDA995 |
FDA normal human organ tissue array, 99 cores_33 sites_75 cases, replaced by FDA997; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA997 |
FDA normal organ tissue array of human, 47 cases_99 cores, for FDA guidelines to test tissue specificity of antibodies, replaced by FDA998 |
|
314-Eur |
US Biomax |
assays |
| FDA997 |
FDA normal organ tissue array of human, 47 cases_99 cores, for FDA guidelines to test tissue specificity of antibodies, replaced by FDA998; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| FDA998 |
FDA normal organ tissue array of human, 47 cases_99 cores, replaced by FDA999 |
|
314-Eur |
US Biomax |
tissue |
| FDA998 |
FDA normal organ tissue array of human, 47 cases_99 cores, replaced by FDA999; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA999 |
Multiple organ normal tissue array, 47 cases_99 cores, replacing FDA998 |
|
314-Eur |
US Biomax |
tissue |
| FDA999 |
Multiple organ normal tissue array, 47 cases_99 cores, replaced by FDA999a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDA999a |
Multiple organ normal tissue array, 47 cases_99 cores, replacing FDA999; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| FDG281f |
Normal dog multiple organ frozen tissue array, 28 cases_28 cores |
|
199-Eur |
US Biomax |
tissue |
| FDG281f |
Normal dog multiple organ frozen tissue array, 28 cases_28 cores; ihc Anti-Actin confirmed |
|
278-Eur |
US Biomax |
tissue |
| FDG281m |
Normal male dog multiple organ frozen tissue array, 28 cases_28 cores |
|
199-Eur |
US Biomax |
tissue |
| FDG281m |
Normal male dog multiple organ frozen tissue array, 24 organs_24 cores; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FFE301 |
Human normal fetal frozen tissue array, total of 15 major organs from one case, 15 organs_30 cores, replaced by FFE302 |
|
199-Eur |
US Biomax |
tissue |
| FFE301 |
Human normal fetal frozen tissue array, total of 15 major organs from one case, 15 organs_30 cores, replaced by FFE302; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FFE302 |
Multiple organ normal frozen tissue array, 15 cases_30 cores, replacing FFE301 |
|
199-Eur |
US Biomax |
tissue |
| FFE302 |
Multiple organ normal frozen tissue array, 15 cases_30 cores, replacing FFE301; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FFE302a |
Multiple organ normal frozen tissue array, 15 organs_30 cores; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FMC281 |
Multiple tumor and corresponding normal frozen tissue (14 types) array, 14 cases_28 cores, previously named FMC401 |
|
91-Eur |
US Biomax |
tissue |
| FMC281 |
Multiple tumor and corresponding normal frozen tissue (14 types) array, 14 cases_28 cores, previously named FMC401; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FMC282 |
Multiple organ cancer frozen tissue array, including TNM and clinical stage, 28 cases_28 cores,replaced by FMC282a; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FMC282a |
Multiple organ cancer frozen tissue array, including pathology grade, 28 cases_28 cores, replacing FMC282; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
tissue |
| FMC401 |
Multiple organ cancer frozen tissue array, 20 cases_40 cores; ihc Anti-Actin confirmed |
|
510-Eur |
US Biomax |
tissue |
| FMC402 |
Multiple organ cancer frozen tissue array, with normal tissue 40 cases_40 cores |
|
91-Eur |
US Biomax |
tissue |
| FMC402 |
Multiple organ cancer frozen tissue array, with normal tissue 40 cases_40 cores, replaced by FMC402a; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC402a |
Multiple organ cancer frozen tissue array, with normal tissue, including pathology grade, 40 cases_40 cores, replaced by FMC402b; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC402b |
Multiple organ cancer frozen tissue array, with normal tissue, including pathology grade, 40 cases_40 cores, replacing FMC402a; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC405 |
Multiple organ carcinoma frozen tissue array, including TNM and clinical stage, 40 cases_40 cores |
|
167-Eur |
US Biomax |
tissue |
| FMC405 |
Multiple organ carcinoma frozen tissue array, including TNM and clinical stage, 40 cases_40 cores, replaced by FMC405a; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC405a |
Multiple organ cancer frozen tissue array, including pathology grade, 40 cases_40 cores, replacing FMC405; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC406 |
Digestive system carcinoma frozen tissue array, including TNM and clinical stage information, 40 cases_40 cores |
|
167-Eur |
US Biomax |
tissue |
| FMC406 |
Digestive system carcinoma frozen tissue array, including TNM and clinical stage information, 40 cases_40 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC406c |
Frozen multiple human organ cancer tissue array, including TNM and clinical stage, 40 cases_40 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC407 |
Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases_40 cores |
|
331-Eur |
US Biomax |
tissue |
| FMC407 |
Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases_40 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC407b |
Multiple organ cancer frozen tissue array, including TNM information, 40 cases_40 cores, replacing FMC407; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC408 |
Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases_40 cores |
|
167-Eur |
US Biomax |
tissue |
| FMC408 |
Multiple organ cancer frozen tissue array, including TNM and clinical stage, 40 cases_40 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC409 |
Multiple organ cancer frozen tissue array, 20 cases_40 cores???replacing FMC401 |
|
281-Eur |
US Biomax |
tissue |
| FMC409 |
Multiple organ cancer frozen tissue array, 20 cases_40 cores???replacing FMC401; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMC409a |
Frozen multiple organ cancer tissue array, 20 cases_40 cores, replacing FMC409; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMO721 |
FDA standard normal mouse multiple organ frozen tissue array, two slides, 24 cases_72 cores |
|
293-Eur |
US Biomax |
tissue |
| FMO721 |
FDA standard normal mouse multiple organ frozen tissue array, two slides, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
742-Eur |
US Biomax |
tissue |
| FMO901 |
FDA standard normal mouse multiple organ frozen tissue array, slide one, 15 organs_45 cores |
|
293-Eur |
US Biomax |
tissue |
| FMO901 |
FDA standard normal mouse multiple organ frozen tissue array, slide one, 15 organs_45 cores; ihc Anti-Actin confirmed |
|
858-Eur |
US Biomax |
tissue |
| FMO901-1 |
Normal mouse multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation, 15 organs_45 cores, slide 1 of 2 tissue arrays; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMO901-2 |
Normal mouse multiple organ frozen tissue array, for therapeutic and diagnostic antibody, 15 organs_45 cores, slide 2 of 2 tissue arrays; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FMS151 |
Brains of multiple species frozen tissue array, 14 cases_15 cores |
|
293-Eur |
US Biomax |
tissue |
| FMS151 |
Brains of multiple species frozen tissue array, 14 cases_15 cores; ihc Anti-Actin confirmed |
|
220-Eur |
US Biomax |
tissue |
| FMS152 |
Liver of multiple species frozen tissue array, 14 cases_15 cores |
|
293-Eur |
US Biomax |
tissue |
| FMS152 |
Liver of multiple species frozen tissue array, 14 cases_15 cores; ihc Anti-Actin confirmed |
|
220-Eur |
US Biomax |
tissue |
| FRA781 |
FDA standard normal rat multiple organ frozen tissue array, two slides, 26 cases_78 cores |
|
331-Eur |
US Biomax |
tissue |
| FRA781 |
Standard normal rat multiple organ frozen tissue array, two slides, 26 cases_78 cores; ihc Anti-Actin confirmed |
|
742-Eur |
US Biomax |
tissue |
| FRA781-1 |
FDA standard normal rat multiple organ frozen tissue array, slide one, 26 cases_78 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FRA781-2 |
FDA standard normal rat multiple organ frozen tissue array, slide two, 26 cases_78 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FRA901 |
Normal rat multiple organ (recommended by FDA) frozen tissue array, slide one, 15 cases_45 cores |
|
331-Eur |
US Biomax |
recombinant |
| FRA901 |
Normal rat multiple organ (recommended by FDA) frozen tissue array, slide one, 15 cases_45 cores; ihc Anti-Actin confirmed |
|
858-Eur |
US Biomax |
recombinant |
| FRA901-1 |
FDA standard normal rat multiple organ frozen tissue array, slide one, 15 cases_45 cores, replaced by FRA901a-1; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
tissue |
| FRA901-2 |
Normal rat multiple organ (recommended by FDA) frozen tissue array, slide two, 15 cases_45 cores, replaced by FRA901a-2; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
recombinant |
| FRA901a |
Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation, 45 cases_45 cores, 2 slides set, replacing FRA901; ihc Anti-Actin confirmed |
|
858-Eur |
US Biomax |
tissue |
| FRA901a-1 |
Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FRA901-1; ihc Anti-Actin c |
|
626-Eur |
US Biomax |
tissue |
| FRA901a-2 |
Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FRA901-2; ihc Anti-Actin c |
|
626-Eur |
US Biomax |
tissue |
| FRB281f |
Normal female rabbit multiple organ frozen tissue array, 28 cases_28 cores |
|
293-Eur |
US Biomax |
polyclonal |
| FRB281f |
Normal female rabbit multiple organ frozen tissue array, 28 organs_28 cores; ihc Anti-Actin confirmed |
|
278-Eur |
US Biomax |
polyclonal |
| FRB281m |
Normal male rabbit multiple organ frozen tissue array, 28 cases_28 cores |
|
293-Eur |
US Biomax |
polyclonal |
| FRB281m |
Normal male rabbit multiple organ frozen tissue array, 25 organs_25 cores; ihc Anti-Actin confirmed |
|
394-Eur |
US Biomax |
polyclonal |
| FRB901 |
FDA standard normal rabbit multiple organ frozen tissue array, slide one, 15 organs_45 cores |
|
331-Eur |
US Biomax |
polyclonal |
| FRB901 |
FDA standard normal rabbit multiple organ frozen tissue array, slide one, 15 organs_45 cores; ihc Anti-Actin confirmed |
|
626-Eur |
US Biomax |
polyclonal |
| FRS801 |
Female reproductive system tissue array, with stage and grade info, 80 cases_80 cores |
|
314-Eur |
US Biomax |
tissue |
| FRS801 |
Female reproductive system tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| GA2081 |
Gallbladder disease spectrum (cholecystic cancer progression) tissue array, 103 cases_208 cores |
|
236-Eur |
US Biomax |
tissue |
| GA2081 |
Gallbladder disease spectrum (cholecystic cancer progression) tissue array, 103 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| GA801 |
Gallbladder disease spectrum (gallbladder cancer progression) tissue array, 80 cases_80 cores |
|
123-Eur |
US Biomax |
tissue |
| GA801 |
Gallbladder disease spectrum (gallbladder cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| GI101 |
Multiple organ gastrointestinal (GI) tract cancer metastasis tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
assays |
| GI101 |
Multiple organ gastrointestinal (GI) tract cancer metastasis tissue array, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| GI481 |
GI cancer (gastric, colon and rectal carcinoma) tissue array, 24 cases_48 cores |
|
160-Eur |
US Biomax |
recombinant |
| GI481 |
GI cancer (gastric, colon and rectal carcinoma) tissue array, 24 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
162-Eur |
US Biomax |
recombinant |
| GI961 |
GI cancer (esophageal, gastric, liver, gall bladder, large intestine and small intestine carcinoma) tissue array, 48 cases_96 cores |
|
231-Eur |
US Biomax |
elisa |
| GI961 |
GI cancer (esophageal, gastric, liver, gall bladder, large intestine and small intestine carcinoma) tissue array, 48 cases_96 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
228-Eur |
US Biomax |
elisa |
| GIP541 |
Visceral peritoneum tissue array, 27 cases_54 cores |
|
173-Eur |
US Biomax |
tissue |
| GIP541 |
Visceral peritoneum tissue array, 27 cases_54 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| GIST481 |
Gastrointestinal stromal tumor tissue array, 24 cases_48 cores |
|
225-Eur |
US Biomax |
assays |
| GIST481 |
Gastrointestinal stromal tumor tissue array, 24 cases_48 cores; ihc H&E, IHC anti- CD117, CD34, S100 |
|
238-Eur |
US Biomax |
assays |
| GIST801 |
Gastrointestinal stromal tumor (GIST) tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
assays |
| GIST801 |
Gastrointestinal stromal tumor (GIST) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| GIST802 |
Multiple organ stromal tumor tissue array (containing stomach, colon, rectum, small intestine, cardia, pancreas, retroperitoneum stroma and pelvic cavity), 80 cases_80 cores, no overlapping with GIST8 |
|
296-Eur |
US Biomax |
recombinant |
| GL1001 |
Multiple brain cancer and normal adjacent tissue array, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| GL1001 |
Multiple brain cancer and normal adjacent tissue array, 100 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL1002 |
Brain tumor and normal tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| GL1002 |
Brain tumor and normal tissue array, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL1003 |
Brain tumor tissue array for antibody screening, 25 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| GL1003 |
Brain tumor tissue array for antibody screening, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL1921 |
Mid-advanced stage brain tumor tissue array, including pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| GL1921 |
Mid-advanced stage brain tumor tissue array, including pathology grade, 96 cases_192 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
elisa |
| GL208 |
Brain primary tumor high density (69 cases_208 cores) tissue microarray of astrocytoma, glioblastoma, glioblastoma multiforme (GBM) and normal tissue |
|
456-Eur |
US Biomax |
tissue |
| GL208 |
Brain primary tumor high density (69 cases_208 cores) tissue microarray of astrocytoma, glioblastoma, glioblastoma multiforme (GBM) and normal tissue; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| GL2082 |
Brain tumor (meningioma, astrocytoma and glioblastoma) tissue array, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| GL2082 |
Brain tumor (meningioma, astrocytoma and glioblastoma) tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| GL2083 |
Brain tumor and normal tissue array with pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| GL2083 |
Brain tumor and normal tissue array with pathology grade, 208 cases_208 cores, replaced by GL2083a; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| GL2083a |
Brain tumor tissue array, including TNM, clinical stage and pathology grade, 208 cases_208 cores, replacing GL2083; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| GL241 |
Multiple brain cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| GL241 |
Multiple brain cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores, replaced by GL241a; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed |
|
90-Eur |
US Biomax |
tissue |
| GL241a |
Brain tumor tissue array with adjacent normal brain tissue, including pathology grade, 10 cases_24 cores, replacing GL241; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| GL242 |
Brain tumor tissue array, with normal tissue, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| GL242 |
Brain tumor tissue array, with normal tissue, 2 serial sections, 24 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| GL481 |
Multiple brain cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| GL481 |
Astrocytoma and glioblastoma tissue array with unmatched normal adjacent tissues, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| GL482 |
Brain tumor tissue array, with normal tissue, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| GL482 |
Brain tumor tissue array, with normal tissue, 48 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| GL721 |
Brain tumor and normal tissue array with TNM and grade info, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| GL721 |
Brain tumor and normal tissue array with TNM and grade info, 24 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL722 |
Brain glioma (astrocytoma) tissue array, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| GL722 |
Brain glioma (astrocytoma) tissue array, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| GL801 |
Brain glioma tissue array, with matched or unmatched adjacent normal tissue, 76 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| GL801 |
Brain glioma tissue array, with matched or unmatched adjacent normal tissue, 76 cases_80 cores; ihc Anti-Glial Fibrillary acid protein antibody confirmed |
|
267-Eur |
US Biomax |
tissue |
| GL802 |
Glioblastoma (grade IV) tissue array, 40 cases_80 cores, replaced by GL805 |
|
231-Eur |
US Biomax |
tissue |
| GL802 |
Glioblastoma (grade IV) tissue array, 40 cases_80 cores, replaced by GL805; ihc Anti-Glial Fibrillary Acid Protein (GFAP) confirmed |
|
267-Eur |
US Biomax |
tissue |
| GL803 |
Brain tumor tissue array of glioblastoma, astrocytoma, ependymoma, oligo astrocytoma, medulloblastoma and oligodendroglioma, 78 cases_80 cores, replacing BS17015 |
|
266-Eur |
US Biomax |
tissue |
| GL803 |
Brain tumor tissue array of glioblastoma, astrocytoma, ependymoma, oligo astrocytoma, medulloblastoma and oligodendroglioma, 78 cases_80 cores, replaced by GL803a; ihc Anti-Glial Fibrillary Acid Prot |
|
296-Eur |
US Biomax |
tissue |
| GL803a |
Brain tumor and adjacent normal tissue array, including pathology grade, 80 cases_80 cores, replacing GL803; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL804 |
Brain tumor and normal tissue array with grade and TNM data, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| GL804 |
Brain tumor and normal tissue array with grade and TNM data, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL805 |
Glioblastoma multiforme (GBM) tissue array, 40 cases_80 cores, replaced by GL806 |
|
266-Eur |
US Biomax |
tissue |
| GL805 |
Glioblastoma multiforme (GBM) tissue array, 40 cases_80 cores, replaced by GL806; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| GL806 |
Brain glioblastoma and normal tissue array, 40 cases_80 cores, replacing GL805 |
|
266-Eur |
US Biomax |
tissue |
| GL806 |
Brain glioblastoma multiforme(GBM) tissue array, 40 cases_80 cores, replaced by GL806a; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| GL806a |
Brain glioblastoma multiforme(GBM) tissue array, 40 cases_80 cores, replacing GL806; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| GL807 |
Brain glioma and normal tissue array, including pathology grade, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| GL807 |
Brain glioma and normal tissue array, including pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| GL808 |
Brain tumor tissue array, with matched adjacent normal tissue, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| GL808 |
Brain tumor tissue array, with matched adjacent normal tissue, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| GL811 |
Brain tumor and normal tissue array, with pathology grade, 27 cases_81 cores, replacing BS17011 |
|
266-Eur |
US Biomax |
tissue |
| GL811 |
Brain tumor and normal tissue array, with pathology grade, 27 cases_81 cores, replacing BS17011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| HE1001 |
Heart disease spectrum (heart tumor progression) tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| HE1001 |
Heart disease spectrum (heart tumor progression) tissue array, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| HER2 |
Her-2 IHC Bio-marker control TMA, for CAP proficiency test survey, with breast invasive ductal carcinoma, 10 cases_10 cores; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
assays |
| HL481 |
Hodgkin's lymphoma tumor tissue array, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| HL481 |
Hodgkin's lymphoma tumor tissue array, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| HL801 |
Hodgkin's lymphoma tissue array, 45 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| HL801 |
Hodgkin's lymphoma tissue array, 45 cases_80 cores; ihc Anti-Leukocyte Common Antigen antibody confirmed |
|
267-Eur |
US Biomax |
tissue |
| HN241 |
Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| HN241 |
Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores, replaced by HN241a; ihc Anti-Cytokeratin (CK) confirmed |
|
90-Eur |
US Biomax |
assays |
| HN241a |
Head and neck cancer tissue array with adjacent normal head and neck tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing HN241; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| HN242 |
Multiple Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| HN242 |
Multiple Head & Neck cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores, replaced by HN242a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| HN242a |
Head and neck cancer tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing HN242; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| HN481 |
Head & Neck cancer tissue array with unmatched normal adjacent tissues, 24 cases_48 cores with stage and grade data |
|
160-Eur |
US Biomax |
tissue |
| HN481 |
Head & Neck cancer tissue array with unmatched normal adjacent tissues, 24 cases_48 cores with stage and grade data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| HN482 |
Multiple Head & Neck cancer tissue array with normal tissue from autopsy, 48 cases_48 cores with stage and grade data, replaced by HN483 |
|
160-Eur |
US Biomax |
tissue |
| HN482 |
Multiple Head & Neck cancer tissue array with normal tissue from autopsy, 48 cases_48 cores with stage and grade data, replaced by HN483; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| HN483 |
Multiple head and neck cancer with normal tissue array, including TNM and pathology grade, 48 cases_48 cores, replacing HN482 |
|
160-Eur |
US Biomax |
tissue |
| HN483 |
Multiple head and neck cancer with normal tissue array, including TNM and pathology grade, 48 cases_48 cores, replacing HN482; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| HN801 |
Multiple head and neck tumor tissue array with normal tissue, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| HN801 |
Multiple head and neck tumor tissue array with normal tissue, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| HN802 |
Multiple head and neck tumor with normal tissue array, with stage and grade info, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| HN802 |
Multiple head and neck tumor with normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| HN803 |
Head and neck squamous cancer tissue array, including TNM and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| HN803 |
Head and neck squamous cancer tissue array, including TNM and pathology grade, 80 cases_80 cores, replaced by HN803a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| HN803a |
Multiple head and neck cancer tissue array with normal tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing HN803; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| HN811 |
Head and Neck tumor and normal tissue array, including TNM, clinical stage and pathology grade, 27 cases_81 cores, replacing BC34111 |
|
266-Eur |
US Biomax |
tissue |
| HN811 |
Head and Neck tumor and normal tissue array, including TNM, clinical stage and pathology grade, 27 cases_81 cores, replacing BC34111; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| HND181 |
Head and neck disease tissue array, 18 cases_18 cores |
|
166-Eur |
US Biomax |
tissue |
| HND181 |
Head and neck disease tissue array, 18 cases_18 cores; ihc H&E, IHC anti-Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| HNT961 |
Head and neck disease tissue array, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| HNT961 |
Head and neck disease tissue array, 48 cases_96 cores; ihc H&E, IHC anti-Vimentin_cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| HRC041 |
HER2 IHC control array, 4 cases_4 cores |
|
77-Eur |
US Biomax |
|
| HRC041 |
HER2 IHC control array, 4 cases_4 cores; ihc H&E, IHC anti-HER2 |
|
85-Eur |
US Biomax |
|
| IC00011 |
Tissue array of gastritis with intestinal metaplasia and gastric carcinoma, 80 cases _80 cores, replaced by IC00011b |
|
231-Eur |
US Biomax |
assays |
| IC00011 |
Tissue array of gastritis with intestinal metaplasia and gastric carcinoma, 80 cases _80 cores, replaced by IC00011b; ihc Anti-Cytokeratin (Low MW) confirmed |
|
267-Eur |
US Biomax |
assays |
| IC00011b |
Gastric carcinoma, gastritis with intestinal metaplasia tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing IC00011 |
|
321-Eur |
US Biomax |
assays |
| IC00011b |
Gastric carcinoma, gastritis with intestinal metaplasia tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing IC00011 |
|
266-Eur |
US Biomax |
assays |
| IC00011b |
Gastric carcinoma, gastritis with intestinal metaplasia tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing IC00011; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
assays |
| IC03001 |
Liver tissue, type B hepatitis and hepatic cirrhosis tissue array, 80 cases_ 80 cores, replaced by LV805 |
|
231-Eur |
US Biomax |
tissue |
| IC03001 |
Liver tissue, type B hepatitis and hepatic cirrhosis tissue array, 80 cases_ 80 cores, replaced by LV805; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| KD1001 |
Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| KD1001 |
Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| KD1002 |
Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| KD1002 |
Kidney cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| KD1501 |
Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| KD1502 |
Kidney cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| KD1921 |
Mid-advanced stage kidney cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| KD1921 |
Mid-advanced stage kidney cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
elisa |
| KD208 |
High density tissue array (70 cases_208 cores) of kidney cancer and normal tissue |
|
456-Eur |
US Biomax |
tissue |
| KD208 |
High density tissue array (70 cases_208 cores) of kidney cancer and normal tissue; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| KD20810 |
Kidney cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD20810 |
Kidney cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| KD20811 |
Kidney cancer survey tissue array (2 of 3), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD20811 |
Kidney cancer survey tissue array (2 of 3), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| KD20812 |
Kidney cancer survey tissue array (3 of 3), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD20812 |
Kidney cancer survey tissue array (3 of 3), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| KD2082 |
High density kidney cancer tissue array with normal tissues, with TNM and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2082 |
High density kidney cancer tissue array with normal tissues, with TNM and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD2083 |
Kidney cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2083 |
Kidney cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| KD2084 |
Renal disease spectrum tissue array, with stage and TNM info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2084 |
Renal disease spectrum tissue array, with stage and TNM info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD2085 |
Kidney cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2085 |
Kidney cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD2086 |
Kidney cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2086 |
Kidney cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD2087 |
Kidney cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2087 |
Kidney cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD2088 |
Kidney cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2088 |
Kidney cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD2089 |
Kidney cancer survey tissue array (5 of 5), including TNM and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| KD2089 |
Kidney cancer survey tissue array (5 of 5), including TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| KD241 |
Kidney cancer test tissue array with matched cancer adjacent normal tissue, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| KD241 |
Kidney cancer test tissue array with matched cancer adjacent normal tissue, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| KD242 |
Multiple Kidney cancer test tissue array with unmatched normal adjacent tissue, 10 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| KD242 |
Multiple Kidney cancer test tissue array with unmatched normal adjacent tissue, 10 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| KD243 |
Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| KD243 |
Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| KD244 |
Kidney clear cell carcinoma tissue array with matched kidney adjacent tissue, including TNM and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| KD481 |
Tissue array of kidney clear cell carcinoma and matched adjacent tissue, with stage and grade data, 12 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| KD481 |
Tissue array of kidney clear cell carcinoma and matched adjacent tissue, with stage and grade data, 12 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| KD482 |
Tissue array of kidney carcinoma and matched adjacent tissue, with stage and grade data, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| KD482 |
Tissue array of kidney carcinoma and matched adjacent tissue, with stage and grade data, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| KD483 |
Multiple Kidney cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade data |
|
160-Eur |
US Biomax |
tissue |
| KD483 |
Multiple Kidney cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| KD484 |
Kidney cancer tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| KD484 |
Kidney cancer tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| KD485 |
Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| KD485 |
Kidney cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| KD486 |
Kidney clear cell carcinoma with matched adjacent kidney tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| KD486 |
Kidney clear cell carcinoma with matched adjacent kidney tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| KD486 |
Kidney clear cell carcinoma with matched adjacent kidney tissue array, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| KD6161 |
High-density renal cancer array, with stage, grade and normal renal tissue, 322 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| KD6161 |
High-density renal cancer array, with stage, grade and normal renal tissue, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| KD801 |
Kidney cancer tissue array, with matched adjacent normal tissue, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD801 |
Kidney cancer tissue array, with matched adjacent normal tissue, 40 cases_80 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
228-Eur |
US Biomax |
tissue |
| KD802 |
Kidney multiple cancer tissue array (clear, granular and transitional cell carcinoma, etc), 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD802 |
Kidney multiple cancer tissue array (clear, granular and transitional cell carcinoma, etc), 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| KD803 |
Normal kidney tissue array, replacing BN07012, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD803 |
Normal kidney tissue array, replacing BN07012, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| KD804 |
Multiple types of kidney cancer and normal, adjacent normal tissue array, 80 cases_80 cores, with stage and grade information |
|
231-Eur |
US Biomax |
tissue |
| KD804 |
Multiple types of kidney cancer and normal, adjacent normal tissue array, 80 cases_80 cores, with stage and grade information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| KD806 |
Advanced kidney cancer tissue array, with stage and grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD806 |
Advanced kidney cancer tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| KD807 |
Kidney disease spectrum (renal cancer progression) tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD807 |
Kidney disease spectrum (renal cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| KD808 |
Mid-advanced stage kidney cancer and metastatic carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD808 |
Mid-advanced stage kidney cancer and metastatic carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| KD811 |
Renal carcinoma and normal tissue array, with TNM, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| KD811 |
Kidney carcinoma and normal tissue array, with TNM, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| KD951 |
Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases_95 cores |
|
456-Eur |
US Biomax |
tissue |
| KD951 |
Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases_95 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| KD961 |
Kidney tumor tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| KD962 |
Kidney cancer tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| KD991 |
Kidney cancer tissue array with matched cancer adjacent and cancer adjacent normal tissue, 33 cases_99 cores |
|
231-Eur |
US Biomax |
tissue |
| KD991 |
Kidney cancer tissue array with matched cancer adjacent and cancer adjacent normal tissue, 33 cases_99 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| KIC1501 |
Kidney cancer mid-density tissue array, non-overlapping with KIC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| KIC1501 |
Kidney cancer mid-density tissue array, non-overlapping with KIC1502, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| KIC1502 |
Kidney cancer mid-density tissue array, non-overlapping with KIC1501, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| KIC1502 |
Kidney cancer mid-density tissue array, non-overlapping with KIC1501, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| KIC241 |
Kidney cancer tissue array, 12 cases_24 cores |
|
166-Eur |
US Biomax |
tissue |
| KIC241 |
Kidney cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| KIC481 |
Kidney cancer and normal tissue array, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| KIC481 |
Kidney cancer and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| KIC961 |
Kidney cancer and normal tissue array, non-overlapping with KIC962, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| KIC961 |
Kidney cancer and normal tissue array, non-overlapping with KIC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| KIC962 |
Kidney cancer and normal tissue array, non-overlapping with KIC961, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| KIC962 |
Kidney cancer and normal tissue array, non-overlapping with KIC961, 48 cases_96 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| LC10010 |
Small cell lung carcinoma tissue array, for antibody screening, including TNM and clinical stage, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| LC10010 |
Small cell lung carcinoma tissue array, for antibody screening, including TNM and clinical stage, 50 cases_100 cores, replaced by LC10010a; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC10010a |
Lung carcinoma tissue array with normal lung tissue as control, including TNM and clinical stage, 50 cases_100 cores, replacing LC10010; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC10011 |
Non-small cell lung carcinoma (NSCLC) tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| LC10011 |
Non-small cell lung carcinoma (NSCLC) tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC10012 |
Lung non-small cell cancer tissue array, with adjacent tissue and normal tissue, including TNM and pathology grade, 50 cases_100 cores, replacing LC1006 |
|
266-Eur |
US Biomax |
tissue |
| LC10012 |
Lung non-small cell cancer tissue array, with adjacent tissue and normal tissue, including TNM and pathology grade, 50 cases_100 cores, replacing LC1006; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC10013 |
Lung adenocarcinoma tissue array with adjacent normal lung tissue, including TNM and pathology grade, 50 cases_100 cores, replacing LC1002 |
|
266-Eur |
US Biomax |
tissue |
| LC10013 |
Lung adenocarcinoma tissue array with adjacent normal lung tissue, including TNM and pathology grade, 50 cases_100 cores, replacing LC1002; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LC1002 |
Lung adenocarcinoma (grade II-III) tissue array with self-matched adjacent normal tissue, and 4 non-cancer normal lung tissue, 52 cases_100 cores, replaced by LC10013 |
|
231-Eur |
US Biomax |
tissue |
| LC1002 |
Lung adenocarcinoma (grade II-III) tissue array with self-matched adjacent normal tissue, and 4 non-cancer normal lung tissue, with TNM info, 52 cases_100 cores, replaced by LC10013; ihc Anti-Cytoker |
|
296-Eur |
US Biomax |
tissue |
| LC1004 |
Lung carcinoma (multi-tissue combined panel) tissue array, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| LC1004 |
Lung carcinoma (multi-tissue combined panel) tissue array, 50 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC1005 |
Lung carcinoma progression tissue array, 77 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| LC1005 |
Lung carcinoma progression tissue array, 77 cases_100 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC1006 |
Non-small cell lung carcinoma (NSCLC) tissue array with matched adjacent normal tissue as control, 56 cases_100 cores, with stage and grade data, replacing LC1001 |
|
231-Eur |
US Biomax |
tissue |
| LC1006 |
Non-small cell lung carcinoma (NSCLC) tissue array with matched adjacent normal tissue as control, 56 cases_100 cores, with stage and grade data, replacing LC1001; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC1007 |
Lung tuberculosis tissue array with normal tissue, 48 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| LC1007 |
Lung tuberculosis tissue array with normal tissue, 48 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC1008 |
Non-small cell lung carcinoma array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
|
| LC1008 |
Non-small cell lung carcinoma array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
|
| LC1009 |
Lung small cell carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| LC1009 |
Lung small cell carcinoma tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC1201 |
Lung disease spectrum tissue array, 116 cases_120 cores, with grade and stage information |
|
278-Eur |
US Biomax |
tissue |
| LC1201 |
Lung disease spectrum tissue array, 116 cases_120 cores, with grade and stage information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC1501 |
Lung adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| LC1501 |
Lung adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| LC1501 |
Lung adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LC1502 |
Lung cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LC1503 |
Lung cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LC1921 |
High density non-small cell lung carcinoma (NSCLC) tissue array, with stage and grade info, 192 cases_192 cores |
|
456-Eur |
US Biomax |
tissue |
| LC1921 |
High density non-small cell lung carcinoma (NSCLC) tissue array, with stage and grade info, 192 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC1922 |
Middle-advanced stage lung non-small cell carcinoma tissue array, including TNM and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| LC1922 |
Middle-advanced stage lung non-small cell carcinoma tissue array, including TNM and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
elisa |
| LC2001 |
Lung cancer high-density (192 cases_200 cores) tissue array |
|
397-Eur |
US Biomax |
tissue |
| LC2001 |
Lung cancer high-density (192 cases_200 cores) tissue array; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
382-Eur |
US Biomax |
tissue |
| LC2081 |
Multiple lung carcinoma (Non-small cell lung carcinoma, NSCLC) and normal tissue form necroscopy tissue array, 70 cases_208 cores, with stage and grade information |
|
456-Eur |
US Biomax |
tissue |
| LC2081 |
Multiple lung carcinoma (Non-small cell lung carcinoma, NSCLC) and normal tissue form necroscopy tissue array, 70 cases_208 cores, with stage and grade information; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC20810 |
Lung cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20810 |
Lung cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC20811 |
Lung cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20811 |
Lung cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC20812 |
Lung cancer tissue array (1 of 5), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20812 |
Lung cancer tissue array (1 of 5), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC20813 |
Lung cancer tissue array (2 of 5), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20813 |
Lung cancer tissue array (2 of 5), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC20814 |
Lung cancer tissue array (3 of 5), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20814 |
Lung cancer tissue array (3 of 5), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC20815 |
Lung cancer tissue array (4 of 5), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20815 |
Lung cancer tissue array (4 of 5), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC20816 |
Lung cancer tissue array (5 of 5), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC20816 |
Lung cancer tissue array (5 of 5), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC2082 |
Multiple lung carcinoma and normal tissue array, 70 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2082 |
Multiple lung carcinoma and normal tissue array, 70 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC2083 |
Lung disease spectrum (pulmonary cancer progression) tissue array, 193 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2083 |
Lung disease spectrum (pulmonary cancer progression) tissue array, 193 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC2084 |
High-density Lung cancer tissue array with normal tissues, with stage and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2084 |
High-density Lung cancer tissue array with normal tissues, with stage and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC2085a |
High-density (188 cases_208 cores), multiple types of lung cancer (I-3 grade) tissue array with normal lung from autopsy and cancer adjacent tissue |
|
456-Eur |
US Biomax |
tissue |
| LC2085a |
High-density (188 cases_208 cores), multiple types of lung cancer (I-3 grade) tissue array with normal lung from autopsy and cancer adjacent tissue; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC2085b |
High-density (208 cores), multiple types of lung cancer (grade 1-3) tissue array with normal lung and cancer adjacent tissue, and staging info, 188 cases_208 cores (duplicate of LC2085a) |
|
456-Eur |
US Biomax |
tissue |
| LC2085b |
High-density (208 cores), multiple types of lung cancer (grade 1-3) tissue array with normal lung and cancer adjacent tissue, and staging info, 188 cases_208 cores (duplicate of LC2085a); ihc Anti-Cy |
|
487-Eur |
US Biomax |
tissue |
| LC2086 |
Normal lung tissue array, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2086 |
Normal lung tissue array, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC2087 |
Lung tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2087 |
Lung tumor survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC2088 |
Lung cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2088 |
Lung cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC2089 |
Lung cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2089 |
Lung cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LC2161 |
Lung cancer tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
456-Eur |
US Biomax |
tissue |
| LC2161 |
Lung cancer tissue array, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC241 |
Non-small cell lung carcinoma (NSCLC) test tissue array, with self-matching normal adjacent tissue, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| LC241 |
Non-small cell lung carcinoma (NSCLC) test tissue array, with self-matching normal adjacent tissue, 6 cases_24 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
90-Eur |
US Biomax |
assays |
| LC242 |
Non-small cell lung carcinoma (NSCLC) test tissue array, with unmatched normal adjacent tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| LC242 |
Non-small cell lung carcinoma (NSCLC) test tissue array, with unmatched normal adjacent tissue, 12 cases_24 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
90-Eur |
US Biomax |
assays |
| LC243 |
Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| LC243 |
Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LC481 |
Tissue array of lung carcinoma and matched adjacent tissue, 12 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LC481 |
Tissue array of lung carcinoma and matched adjacent tissue, 12 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC482 |
Non-small cell lung carcinoma (NSCLC) tissue array, with 4 normal tissue control from autopsy, 24 cases_48 cores, with grade and stage status |
|
160-Eur |
US Biomax |
tissue |
| LC482 |
Non-small cell lung carcinoma (NSCLC) tissue array, with 4 normal tissue control from autopsy, 24 cases_48 cores, with grade and stage status; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LC483 |
Multiple lung cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LC483 |
Multiple lung cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC484 |
Lung cancer tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| LC484 |
Lung cancer tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC485 |
Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| LC485 |
Lung cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LC486 |
Lung cancer and matched adjacent lung tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
188-Eur |
US Biomax |
tissue |
| LC486 |
Lung cancer and matched adjacent lung tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LC486 |
Lung cancer and matched adjacent lung tissue array, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC487 |
Lung disease spectrum tissue array, including TNM and pathology grade, 24 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| LC487 |
Lung disease spectrum tissue array, including TNM and pathology grade, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| LC487 |
Lung disease spectrum tissue array, including TNM and pathology grade, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC488 |
Lung cancer tissue array with matched adjacent lung tissue, including TNM, clinical stage and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC501 |
Tissue array of multi-type lung cancer and normal tissue with TNM and grade, 50 cases_50 cores |
|
160-Eur |
US Biomax |
tissue |
| LC501 |
Tissue array of multi-type lung cancer and normal tissue with TNM and grade, 50 cases_50 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
210-Eur |
US Biomax |
tissue |
| LC601 |
Non-small cell lung carcinoma (NSCLC) and normal tissue array, 25 cases plus normal tissues, with TNM data |
|
----Eur |
US Biomax |
tissue |
| LC6161 |
High-density lung cancer array, with stage, grade and normal lung tissue, 322 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| LC6161 |
High-density lung cancer array, with stage, grade and normal lung tissue, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| LC641 |
Non-small cell lung carcinoma (NSCLC) tissue array, 64 cases_66 cores, with TNM data |
|
----Eur |
US Biomax |
tissue |
| LC721 |
Non-small cell lung carcinoma (NSCLC) tissue array, 24 cases_72 cores, replacing BC04011 |
|
231-Eur |
US Biomax |
tissue |
| LC721 |
Non-small cell lung carcinoma (NSCLC) tissue array, 24 cases_72 cores, replacing BC04011; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC722 |
Lung cancer and normal tissue array, with TNM and grade data, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| LC722 |
Lung cancer and normal tissue array, with TNM and grade data, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC723 |
Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases_72 cores, replacing BS04071 |
|
231-Eur |
US Biomax |
tissue |
| LC723 |
Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases_72 cores, replacing BS04071; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC724 |
Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases_72 cores, replacing BS04031 |
|
231-Eur |
US Biomax |
tissue |
| LC724 |
Lung cancer and adjacent normal tissue array, with TNM and grade info, 24 cases_72 cores, replacing BS04031; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC725 |
Normal lung tissue array, 24 cases_72 cores, replacing BN04011 |
|
278-Eur |
US Biomax |
tissue |
| LC725 |
Normal lung tissue array, 24 cases_72 cores, replacing BN04011; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC726 |
Lung carcinoma tissue array, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replacing BC04016 |
|
231-Eur |
US Biomax |
tissue |
| LC726 |
Lung carcinoma tissue array, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replaced by LC726a; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| LC726a |
Lung cancer tissue array, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replacing LC726; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| LC727 |
Lung large cell carcinoma tissue array, including TNM and clinical stage, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| LC727 |
Lung large cell carcinoma tissue array, including TNM and clinical stage, 24 cases_72 cores; ihc Anti-Epithelial Membrane Antigen (EMA) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC801 |
Lung carcinoma (multi-tissue combined panel) tissue array, 79 cases_80 cores |
|
189-Eur |
US Biomax |
tissue |
| LC801 |
Lung carcinoma (multi-tissue combined panel) tissue array, 79 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| LC802 |
Lung small cell carcinoma tissue array (40 cases_80 cores) |
|
266-Eur |
US Biomax |
tissue |
| LC802 |
Lung small cell carcinoma tissue array, with normal lung tissue, 40 cases_80 cores; ihc Anti-Chromogranin A (CgA) confirmed |
|
228-Eur |
US Biomax |
tissue |
| LC803 |
Lung carcinoma (multi-tissue combined panel, 80 cases_80 cores) tissue array |
|
231-Eur |
US Biomax |
tissue |
| LC803 |
Lung carcinoma (multi-tissue combined panel, 80 cases_80 cores) tissue array; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC805 |
Lung large cell carcinoma and bronchioloalveolar carcinoma tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC805 |
Lung large cell carcinoma and bronchioloalveolar carcinoma tissue array, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
228-Eur |
US Biomax |
tissue |
| LC806 |
Multiple types of lung carcinoma tissue array, 80 cases_80 cores, replacing BC04013 |
|
231-Eur |
US Biomax |
tissue |
| LC806 |
Multiple types of lung carcinoma tissue array, 80 cases_80 cores, replacing BC04013; ihc Anti-Cytokeratin (CK) confirmed |
|
228-Eur |
US Biomax |
tissue |
| LC807 |
Lung cancer and normal tissue array, with TNM and grade info, 77 cases_80 cores, replacing BC04014 |
|
231-Eur |
US Biomax |
tissue |
| LC807 |
Lung cancer and normal tissue array, with TNM and grade info, 77 cases_80 cores, replacing BC04014; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC808 |
Lung squamous cell carcinoma tissue array, with TNM, stage and grade, 80 cases_80 cores, replacing BS04011 |
|
231-Eur |
US Biomax |
tissue |
| LC808 |
Lung squamous cell carcinoma tissue array, with TNM, stage and grade, 80 cases_80 cores, replacing BS04011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC809 |
Lung disease spectrum (pulmonary cancer progression) tissue array, 78 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC809 |
Lung disease spectrum (pulmonary cancer progression) tissue array, 78 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC810 |
Lung cancer with matched lymph node metastasis tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC810 |
Lung cancer with matched lymph node metastasis tissue array, 40 cases_80 cores, replaced by LC814; ihc Anti-Cytokeratin (High MW) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC811 |
Lung cancer tissue array with normal tissues, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| LC811 |
Lung cancer tissue array with normal tissues, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC812 |
Lung cancer tissue array with normal tissues from autopsy, with TNM data, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC812 |
Lung cancer tissue array with normal tissues from autopsy, with TNM data, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC813 |
Multiple non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma tissue array with normal lung tissue, 77 cases_80 cores, replacing BC04014 |
|
231-Eur |
US Biomax |
tissue |
| LC813 |
Multiple non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma tissue array with normal lung tissue, 77 cases_80 cores, replacing BC04014; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC814 |
Lung cancer with matched lymph node metastasis tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC814 |
Lung cancer with matched lymph node metastasis tissue array, 40 cases_80 cores, replacing LC810; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC815 |
Lung cancer and normal tissue array with stage and grade info, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC815 |
Lung cancer and normal tissue array with stage and grade info, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC816 |
Advanced lung cancer and normal tissue array, with stage TNM and grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LC816 |
Advanced lung cancer and normal tissue array, with stage TNM and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LC817 |
Lung cancer tissue array with matched lymph node metastatic tissue, including TNM, clinical stage and pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LC951 |
Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases_95 cores |
|
456-Eur |
US Biomax |
tissue |
| LC951 |
Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases_95 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| LC961 |
Lung cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| LC962 |
Lung cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| LC991 |
Lung squamous cell carcinoma (grade I-III) tissue array with matched tumor adjacent and normal control, 33 cases_99 cores |
|
231-Eur |
US Biomax |
tissue |
| LC991 |
Lung squamous cell carcinoma (grade I-III) tissue array with matched tumor adjacent and normal control, 33 cases_99 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LC992 |
Lung adenocarcinoma (grade I-III, 33 cases) tissue array with matched tumor adjacent and normal control, 33 cases_99 cores |
|
231-Eur |
US Biomax |
tissue |
| LC992 |
Lung adenocarcinoma (grade I-III, 33 cases) tissue array with matched tumor adjacent and normal control, 33 cases_99 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LM208 |
High density tissue microarray of Hodgkin's Disease, Non-Hodgkin's lymphoma and normal lymph node tissues, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LM208 |
High density tissue microarray of Hodgkin's Disease, Non-Hodgkin's lymphoma and normal lymph node tissues, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LM241 |
Multiple lymphoma tissue array with normal tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| LM241 |
Multiple lymphoma tissue array with normal tissues, 12 cases_24 cores; ihc Anti-CD20 confirmed |
|
105-Eur |
US Biomax |
tissue |
| LM481 |
Multiple lymphoma tissue array with normal tissues, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LM481 |
Multiple lymphoma tissue array with normal tissues, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LM482 |
Myeloma, lymphoma and normal tissue array, 48 cases_48 cores |
|
266-Eur |
US Biomax |
tissue |
| LM482 |
Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed |
|
320-Eur |
US Biomax |
tissue |
| LM482a |
Lymphoma tissue array with normal lymph node tissue as control, 48 cases_48 cores, replacing LM482; ihc Anti-Actin confirmed |
|
320-Eur |
US Biomax |
tissue |
| LM721 |
Lymphoma and normal lymph node tissue array, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| LM721 |
Lymphoma and normal lymph node tissue array, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LM801 |
Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| LM801 |
Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases_80 cores, replaced by LM801a; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LM801a |
Lymphoma tissue array with adjacent normal lymph node and spleen tissue as control, 80 cases_80 cores, replacing LM801; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LM802 |
Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases_80 cores, replaced by NHL803 |
|
266-Eur |
US Biomax |
tissue |
| LM802 |
Lymphoma (Hodgkin's and non-Hodgkin's disease) tissue array, 80 cases_80 cores, replaced by NHL803; ihc Anti-Leukocyte Common Antigen (LCA) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LM803 |
Lymphoma and normal lymph node tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LM803 |
Lymphoma and normal lymph node tissue array, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LN801 |
Normal lymphatic (lymph node, thymus, spleen, tonsil and appendix) tissue array, 80 cases_80 cores, replaced by LN802 |
|
231-Eur |
US Biomax |
tissue |
| LN801 |
Normal lymphatic (lymph node, thymus, spleen, tonsil and appendix) tissue array, 80 cases_80 cores, replaced by LN802; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| LN802 |
Multiple organ lymph tissue array, 80 cases_80 cores, replacing LN801 |
|
231-Eur |
US Biomax |
tissue |
| LN802 |
Multiple organ lymph tissue array, 80 cases_80 cores, replacing LN801; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| LP208 |
High density larynx and pharynx cancer tissue array with normal tissue (69 cases_208 core) including stage and grade data |
|
456-Eur |
US Biomax |
tissue |
| LP208 |
High density larynx and pharynx cancer tissue array with normal tissue (69 cases_208 core) including stage and grade data; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LP241 |
Larynx and pharynx cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| LP241 |
Larynx and pharynx cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| LP481 |
Larynx and pharynx cancer tissue array with unmatched normal tissues, 48 cases_48, cores with stage and grade data |
|
160-Eur |
US Biomax |
tissue |
| LP481 |
Larynx and pharynx cancer tissue array with unmatched normal tissues, 48 cases_48, cores with stage and grade data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LP721 |
Laryngeal cancer and normal tissue array, with grade and TNM information, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| LP721 |
Laryngeal cancer and normal tissue array, with grade and TNM information, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LP801 |
Larynx and pharynx cancer tissue array, with matched adjacent normal tissue, 70 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LP801 |
Larynx and pharynx cancer tissue array, with matched adjacent normal tissue, 70 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LP802 |
Laryngeal disease spectrum (progression) tissue array, 78 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| LP802 |
Laryngeal disease spectrum (progression) tissue array, 78 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| LP803 |
Laryngeal squamous cell carcinoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| LP803 |
Laryngeal squamous cell carcinoma tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LP804 |
Laryngeal cancerous, cancer adjacent and normal tissue array, with grade and stage info, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| LP804 |
Laryngeal cancerous, cancer adjacent and normal tissue array, with grade and stage info, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LUC1021 |
Lung cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| LUC1021 |
Lung cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LUC1501 |
Lung cancer mid-density tissue array, non-overlapping with LUC1502 or LUC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LUC1501 |
Lung cancer mid-density tissue array, non-overlapping with LUC1502 or LUC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LUC1502 |
Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LUC1502 |
Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LUC1503 |
Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LUC1503 |
Lung cancer mid-density tissue array, non-overlapping with LUC1501 or LUC1502, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LUC2281 |
High density lung cancer tissue array, 228 cases_228 cores |
|
403-Eur |
US Biomax |
tissue |
| LUC2281 |
High density lung cancer tissue array, 228 cases_228 cores; ihc H&E, IHC anti-Cytokeratin |
|
434-Eur |
US Biomax |
tissue |
| LUC481 |
Lung cancer and normal tissue array, non-overlapping with LUC482 , 16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| LUC481 |
Lung cancer and normal tissue array, non-overlapping with LUC482 , 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| LUC482 |
Lung cancer and normal tissue array, non-overlapping with LUC481, 16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| LUC482 |
Lung cancer and normal tissue array, non-overlapping with LUC481, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| LUC961 |
Lung cancer and normal tissue array, without overlapping with LUC962, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| LUC961 |
Lung cancer and normal tissue array, without overlapping with LUC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| LUC962 |
Lung cancer and normal tissue array, without overlapping with LUC961, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| LUC962 |
Lung cancer and normal tissue array, without overlapping with LUC961, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| LUD151 |
Lung disease tissue array, 15 cases_15 cores |
|
166-Eur |
US Biomax |
tissue |
| LUD151 |
Lung disease tissue array, 15 cases_15 cores; ihc H&E, IHC anti-Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| LUD481 |
Lung disease and normal tissue array, 16 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| LUD481 |
Lung disease and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LUP541 |
Visceral pleura tissue array, 27 cases_54 cores |
|
225-Eur |
US Biomax |
tissue |
| LUP541 |
Visceral pleura tissue array, 27 cases_54 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LV1001 |
Liver cancer antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
|
| LV1001 |
Liver cancer antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
rat |
| LV1002 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| LV1002 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV1003 |
Liver cancer tissue array, with HBV infection information, including TNM and pathology grade, 50 cases_100 cores |
|
314-Eur |
US Biomax |
tissue |
| LV1003 |
Liver cancer tissue array, with HBV infection information, including TNM and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV1201 |
Multiple diseases of liver tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores |
|
397-Eur |
US Biomax |
tissue |
| LV1201 |
Multiple diseases of liver tissue array, including TNM, clinical stage and pathology grade, 120 cases_120 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
320-Eur |
US Biomax |
tissue |
| LV1501 |
Liver hepatocellular carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| LV1501 |
Liver hepatocellular carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| LV1501 |
Liver hepatocellular carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LV1502 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LV1503 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LV1921 |
Liver late stage tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| LV1921 |
Liver late stage tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
elisa |
| LV2001 |
High-density liver cancer tissue array, paraffin section, 200 cases_200 cores |
|
397-Eur |
US Biomax |
tissue |
| LV2001 |
High-density liver cancer tissue array, paraffin section, 200 cases_200 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
382-Eur |
US Biomax |
tissue |
| LV208 |
Liver cancer (hepatocellular carcinoma) and normal tissue high density (69 cases_208 cores) tissue microarray, with stage and grade info |
|
456-Eur |
US Biomax |
tissue |
| LV208 |
Liver cancer (hepatocellular carcinoma) and normal tissue high density (69 cases_208 cores) tissue microarray, with stage and grade info; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| LV2081 |
Hepatic disease spectrum (liver cancer progression) tissue array, 103 cases_208 cores |
|
516-Eur |
US Biomax |
tissue |
| LV2081 |
Hepatic disease spectrum (liver cancer progression) tissue array, 103 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
592-Eur |
US Biomax |
tissue |
| LV20810 |
Liver cancer survey tissue array (2 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV20810 |
Liver cancer survey tissue array (2 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LV20811 |
Liver cancer survey tissue array (3 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV20811 |
Liver cancer survey tissue array (3 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LV20812 |
Liver tissue cancer tissue array, containing HBV infection, TNM and pathology grade information, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV20812 |
Liver disease tissue array, including HBV infection, TNM and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2082 |
Liver cancer tissue array with normal tissues, with TNM and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2082 |
Liver cancer tissue array with normal tissues, with TNM and grade info, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2083 |
High-density liver cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2083 |
High-density liver cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LV2084 |
Liver cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
516-Eur |
US Biomax |
tissue |
| LV2084 |
Liver cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2085 |
Liver cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2085 |
Liver cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2086 |
Liver cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2086 |
Liver cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2087 |
Liver cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2087 |
Liver cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2088 |
Liver cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2088 |
Liver cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2089 |
Liver cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2089 |
Liver cancer survey tissue array (1 of 3), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LV2091 |
Liver cancer tissue array with normal liver tissue as control, including TNM, clinical stage and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LV2161 |
Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 216 cases_216 cores |
|
456-Eur |
US Biomax |
tissue |
| LV2161 |
Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LV241 |
Liver cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| LV241 |
Liver cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| LV242 |
Multiple Liver cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| LV242 |
Multiple Liver cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| LV243 |
Liver cancer tissue array with normal tissues from autopsy, 12 cases_24 cores, with grade and stage |
|
88-Eur |
US Biomax |
tissue |
| LV243 |
Liver cancer tissue array with normal tissues from autopsy, 12 cases_24 cores, with grade and stage; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| LV244 |
Liver cancer tissue array, with stage and grade info, 8 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| LV244 |
Liver cancer tissue array, with stage and grade info, 8 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| LV245 |
Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| LV245 |
Liver cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LV481 |
Liver cancer tissue array with normal adjacent tissues, 23 cases_48 cores, with grade and stage data |
|
160-Eur |
US Biomax |
tissue |
| LV481 |
Liver cancer tissue array with normal adjacent tissues, 23 cases_48 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LV482 |
Multiple liver cancer tissue array with 4 normal tissues control from autopsy, with TNM, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LV482 |
Multiple liver cancer tissue array with 4 normal tissues control from autopsy, with TNM, 24 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| LV483 |
Multiple liver cancer tissue array with normal tissue control from autopsy, with TNM data, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LV483 |
Multiple liver cancer tissue array with normal tissue control from autopsy, with TNM data, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| LV484 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| LV484 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV485 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases_96 cores |
|
397-Eur |
US Biomax |
elisa |
| LV485 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases_96 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
382-Eur |
US Biomax |
elisa |
| LV486 |
Liver cancer tissue array with matched adjacent tumor tissue, including TNM and pathology grade, 16 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| LV486 |
Liver cancer tissue array with matched adjacent tumor tissue, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| LV487 |
Hepatocellular carcinoma tissue array with matched liver adjacent tissue, including TNM and pathology grade, 16 cases_48 cores,; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LV6161 |
High-density liver cancer array, with clinical stage, pathology grade and normal hepatic tissue, 322 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| LV6161 |
High-density liver cancer array, with clinical stage, pathology grade and normal hepatic tissue, 322 cases_616 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
811-Eur |
US Biomax |
tissue |
| LV631 |
Hepatocellular carcinoma tissue array with matched normal cancer adjacent tissue, 55 cases_63 cores |
|
231-Eur |
US Biomax |
tissue |
| LV631 |
Hepatocellular carcinoma tissue array with matched normal cancer adjacent tissue, 55 cases_63 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV721 |
Hepatocellular carcinoma and normal tissue array with stage and grade information, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| LV721 |
Hepatocellular carcinoma and normal tissue array with stage and grade information, 24 cases_72 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV723 |
Liver cancer and adjacent normal tissue array, including TNM and pathology grade, 72 cases_72 cores, replacing BC03013 |
|
231-Eur |
US Biomax |
tissue |
| LV723 |
Liver cancer and adjacent normal tissue array, including TNM and pathology grade, 72 cases_72 cores, replacing BC03013; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV801 |
Liver cancer tissue array, with matched or unmatched adjacent normal tissue, 75 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LV801 |
Liver cancer tissue array, with matched or unmatched adjacent normal tissue, 75 cases_80 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV8010 |
Liver cancer and normal tissue array, with stage and grade info, 80 cases_80 cores, replacing BC03011 |
|
231-Eur |
US Biomax |
tissue |
| LV8010 |
Liver cancer and normal tissue array, with stage and grade info, 80 cases_80 cores, replacing BC03011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV8011 |
Liver disease spectrum (hepatic cancer progression) tissue array, 76 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LV8011 |
Liver disease spectrum (hepatic cancer progression) tissue array, 76 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV8012 |
Mid-advanced stage liver cancer tissue array, including TNM and pathology grade, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LV8012 |
Mid-advanced stage liver cancer tissue array, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV8013 |
Hepatocellular carcinoma tissue array, including TNM, pathology grade, HBV and HCV infection information, 40 cases_80 cores |
|
321-Eur |
US Biomax |
tissue |
| LV8013 |
Hepatocellular carcinoma tissue array, including TNM, pathology grade, HBV and HCV infection information, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| LV8013 |
Hepatocellular carcinoma tissue array, including TNM, pathology grade, HBV and HCV infection information, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV802 |
Liver carcinoma (multi-tissue combined panel) tissue array, 80 cases_80 cores, no overlaps with LV801 |
|
189-Eur |
US Biomax |
tissue |
| LV802 |
Liver carcinoma (multi-tissue combined panel) tissue array, 80 cases_80 cores, no overlaps with LV801; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
185-Eur |
US Biomax |
tissue |
| LV803 |
Liver carcinoma (combination of cancer, cancer adjacent and normal tissue), 53 cases_72 cores, replacing BC03021 |
|
231-Eur |
US Biomax |
tissue |
| LV803 |
Liver carcinoma (combination of cancer, cancer adjacent and normal tissue), 53 cases_72 cores, replacing BC03021; ihc Anti-Alpha Fetoprotein (AFP) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV804 |
Liver cancer tissue array with normal tissue from autopsy, 38 cases_80 cores, replacing BS03011 |
|
231-Eur |
US Biomax |
tissue |
| LV804 |
Liver cancer tissue array with normal tissue from autopsy, 38 cases_80 cores, replacing BS03011; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV805 |
Liver cirrhosis and hepatitis tissue array, 80 cases_80 cores, replacing IC03001 |
|
231-Eur |
US Biomax |
tissue |
| LV805 |
Liver cirrhosis and hepatitis tissue array, 80 cases_80 cores, replacing IC03001; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV806 |
Liver hemangiomas tissue array with normal tissue control from autopsy, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LV806 |
Liver hemangiomas tissue array with normal tissue control from autopsy, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LV807 |
Liver cancer and normal tissue array with TNM and grade, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LV807 |
Liver cancer and normal tissue array with TNM and grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV808 |
Liver cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| LV808 |
Liver cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV809 |
Hepatocellular carcinoma and normal tissue array, with stage, TNM and grade, 80 cases_80 cores, replacing BS03014 |
|
231-Eur |
US Biomax |
tissue |
| LV809 |
Hepatocellular carcinoma and normal tissue array, with stage, TNM and grade, 80 cases_80 cores, replacing BS03014; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LV961 |
Hepatocellular carcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
228-Eur |
US Biomax |
elisa |
| LV962 |
Liver cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| LVC1021 |
Liver cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| LVC1021 |
Liver cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LVC1501 |
Liver cancer mid-density tissue array, non-overlapping with LVC1502 or LVC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LVC1501 |
Liver cancer mid-density tissue array, non-overlapping with LVC1502 or LVC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LVC1502 |
Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LVC1502 |
Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LVC1503 |
Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LVC1503 |
Liver cancer mid-density tissue array, non-overlapping with LVC1501 or LVC1502, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LVC2281 |
Liver cancer high density tissue array, 228 cases_228 cores, replaced by LV2161 |
|
403-Eur |
US Biomax |
tissue |
| LVC2281 |
Liver cancer high density tissue array, 228 cases_228 cores, replaced by LV2161; ihc H&E, IHC anti-Cytokeratin |
|
434-Eur |
US Biomax |
tissue |
| LVC481 |
Liver cancer and normal tissue array, non-overlapping with LVC482, 16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| LVC481 |
Liver cancer and normal tissue array, non-overlapping with LVC482, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| LVC482 |
Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC481, 16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| LVC482 |
Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC481, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| LVC961 |
Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC962, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| LVC961 |
Liver cancer and normal tissue array, with TNM and grade info, non-overlapping with LVC962, 48 cases_96 cores, replaced by LV961; ihc H&E, anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| LVC962 |
Liver cancer and normal tissue array, non-overlapping with LVC961, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| LVC962 |
Liver cancer and normal tissue array, non-overlapping with LVC961, 48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| LVN801 |
Normal liver and hepatocellular carcinoma tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores, replacing BN03011 |
|
231-Eur |
US Biomax |
tissue |
| LVN801 |
Normal liver and hepatocellular carcinoma tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores, replacing BN03011; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| LY1001 |
Diffuse large-B cell lymphoma tissue array, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| LY1001 |
Diffuse large-B cell lymphoma tissue array, 100 cases_100 cores, replaced by LY1001a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LY1001a |
Diffuse large-B cell lymphoma tissue array, 100 cases_100 cores, replacing LY1001; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| LY121 |
Diffuse large B-cell lymphoma tissue array, 12 cases_12 cores |
|
189-Eur |
US Biomax |
tissue |
| LY121 |
Diffuse large B-cell lymphoma tissue array, 12 cases_12 cores, replaced by LY121a; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LY121a |
Diffuse large B-cell lymphoma tissue array, 12 cases_12 cores, replacing LY121; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LY1501 |
Lymphoma tumor tissue array, 75 cases_150 cores |
|
380-Eur |
US Biomax |
tissue |
| LY1501 |
Lymphoma tumor tissue array, 75 cases_150 cores |
|
314-Eur |
US Biomax |
tissue |
| LY1501 |
Lymphoma tumor tissue array, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| LY2081 |
Lymphoma tumor survey tissue array (1 of 5), with normal tissue, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2081 |
Lymphoma tumor survey tissue array (1 of 5), with normal tissue, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LY2082 |
Lymphoma survey tissue array (2 of 5), 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2082 |
Lymphoma survey tissue array (2 of 5), 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LY2083 |
Lymphoma survey tissue array (3 of 5), 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2083 |
Lymphoma survey tissue array (3 of 5), 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LY2084 |
Lymphoma tumor survey tissue array (4 of 5), 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2084 |
Lymphoma tumor survey tissue array (4 of 5), 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LY2085 |
Lymphoma tumor survey tissue array (5 of 5), 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2085 |
Lymphoma tumor survey tissue array (5 of 5), 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LY2086 |
Lymphoma tumor tissue array, 208 cases_208 cores |
|
633-Eur |
US Biomax |
tissue |
| LY2086 |
Lymphoma tumor tissue array, 208 cases_208 cores |
|
516-Eur |
US Biomax |
tissue |
| LY2086 |
Lymphoma tumor tissue array, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| LY2087 |
Lymphoma tumor survey tissue array (2 of 3), 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2087 |
Lymphoma tumor survey tissue array (2 of 3), 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LY2088 |
Lymphoma tumor tissue array, 208 cases_208 cores |
|
558-Eur |
US Biomax |
tissue |
| LY2088 |
Lymphoma tumor tissue array, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| LY2088 |
Lymphoma tumor tissue array, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| LY241 |
Lymphatic tissue array, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| LY241 |
Lymphatic tissue array, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| LY481 |
Lymphatic tissue array, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| LY481 |
Lymphatic tissue array, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| LY6161 |
High-density lymphoma and normal lymph node tissue array, 322 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| LY6161 |
High-density lymphoma and normal lymph node tissue array, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| LY802 |
Lymph node metastatic squamous cell carcinoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| LY802 |
Lymph node metastatic squamous cell carcinoma tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LY803 |
Lymphatic metastatic adenocarcinoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| LY803 |
Lymphatic metastatic adenocarcinoma tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| LYM1501 |
Lymphoma mid-density tissue array, non-overlapping with LYM1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LYM1501 |
Lymphoma mid-density tissue array, non-overlapping with LYM1502, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| LYM1502 |
Lymphoma mid-density tissue array, non-overlapping with LYM1501, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| LYM1502 |
Lymphoma mid-density tissue array, non-overlapping with LYM1501, 75 cases_150 cores; ihc H&E, IHC anti-LCA |
|
238-Eur |
US Biomax |
tissue |
| LYM181 |
Lymphoma tissue array, 18 cases_18 cores |
|
166-Eur |
US Biomax |
tissue |
| LYM181 |
Lymphoma tissue array, 18 cases_18 cores; ihc H&E, IHC anti-LCA |
|
178-Eur |
US Biomax |
tissue |
| LYM401 |
Lymphoma array, together with LYM321, LYM761 and LYM771 forming the lymphoma array set, 39 cases_40 cores |
|
142-Eur |
US Biomax |
|
| LYM401 |
Lymphoma array, together with LYM321, LYM761 and LYM771 forming the lymphoma array set, 39 cases_40 cores; ihc H&E, IHC anti-LCA |
|
151-Eur |
US Biomax |
|
| MBN481 |
Multiple organ normal tissue array, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MC2081 |
Top 5 types of cancer (colon, rectum, breast, prostate and lung) 208 core high-density tissue array, 208 cases_208 cores |
|
397-Eur |
US Biomax |
recombinant |
| MC2081 |
Top 5 types of cancer (colon, rectum, breast, prostate and lung) 208 core high-density tissue array, 208 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
recombinant |
| MC2082 |
Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| MC2082 |
Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| MC241 |
Multiple cancer (12 type) tissue array, 12 cases_24 cores, replaced by MC244 |
|
88-Eur |
US Biomax |
tissue |
| MC241 |
Multiple cancer (12 type) tissue array, 12 cases_24 cores, replaced by MC244; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| MC242 |
Multiple cancer (12 type) tissue array, 16 cases_24 cores, replaced by MC245 |
|
88-Eur |
US Biomax |
tissue |
| MC242 |
Multiple cancer (12 type) tissue array, 16 cases_24 cores, replaced by MC245; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| MC243 |
Multiple cancer (3 types) tissue array, 24 cases_24 cores, with grade and stage data |
|
100-Eur |
US Biomax |
tissue |
| MC243 |
Multiple cancer (3 types) tissue array, 24 cases_24 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
123-Eur |
US Biomax |
tissue |
| MC244 |
Multiple organ cancer and normal adjacent tissue array, replacing MC241, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| MC244 |
Multiple organ cancer and normal adjacent tissue array, replacing MC241, 12 cases_24 cores, replaced by MC246; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| MC245 |
Multiple cancer (12 type) and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing MC242 |
|
88-Eur |
US Biomax |
tissue |
| MC245 |
Multiple cancer (12 type) and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing MC242; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| MC246 |
Multiple organ tumor with matched adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing MC244; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| MC2501 |
Multiple organs tumor and normal tissue array, with TNM, clinical stage and pathology grade, 250 cases_250 cores |
|
516-Eur |
US Biomax |
tissue |
| MC2501 |
Multiple organs tumor and normal tissue array, with TNM, clinical stage and pathology grade, 250 cases_250 cores; ihc Anti-Actin confirmed |
|
592-Eur |
US Biomax |
tissue |
| MC481 |
Multiple cancer (12 types) tissue microarray, 33 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| MC481 |
Multiple cancer (12 types) tissue microarray, 33 cases_48 cores; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| MC482 |
Multiple cancer (12 type) tissue microarray, 40 cases_48 cores, with stage and grade information |
|
160-Eur |
US Biomax |
tissue |
| MC482 |
Multiple cancer (12 type) tissue microarray, 40 cases_48 cores, with stage and grade information; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| MC483 |
Multiple types of cancer tissue array with normal control, replacing BC00119, 26 cases_48 cores, with stage and grade data |
|
160-Eur |
US Biomax |
tissue |
| MC483 |
Multiple types of cancer tissue array with normal control, replacing BC00119, 26 cases_48 cores, with stage and grade data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| MC484 |
Multiple organs tumor and normal adjacent tissue, replacing BC00113, 44 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| MC484 |
Multiple organs tumor and normal adjacent tissue, replacing BC00113, 44 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MC485 |
Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 24 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| MC485 |
Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| MC5001 |
High density (495 cases_500 cores) tissue array of multiple organ cancer and normal, with stage and grade information, replaced by MC5002 |
|
634-Eur |
US Biomax |
tissue |
| MC5001 |
High density (495 cases_500 cores) tissue array of multiple organ cancer and normal, with stage and grade information, replaced by MC5002; ihc Anti-Cytokeratin (CK) confirmed |
|
592-Eur |
US Biomax |
tissue |
| MC5002 |
High-density multiple organ tumor tissue array, with adjacent normal tissue, information of TNM, stage and grade, 500 cases_500 cores, replacing MC5001 |
|
634-Eur |
US Biomax |
tissue |
| MC5002 |
High-density multiple organ tumor tissue array, with adjacent normal tissue, information of TNM, stage and grade, 500 cases_500 cores, replacing MC5001; ihc Anti-Actin confirmed |
|
592-Eur |
US Biomax |
tissue |
| MC5003 |
High-density multiple organ tumor and normal tissue array, with TNM and pathology grade, 500 cases_500 cores, replacing MC5002 |
|
634-Eur |
US Biomax |
tissue |
| MC5003 |
High-density multiple organ tumor and normal tissue array, with TNM and pathology grade, 500 cases_500 cores, replacing MC5002; ihc Anti-Actin confirmed |
|
592-Eur |
US Biomax |
tissue |
| MC501 |
Multiple organs tumor and matched adjacent tissue array, 27 cases_50 cores |
|
160-Eur |
US Biomax |
tissue |
| MC501 |
Multiple organs tumor and matched adjacent tissue array, 27 cases_50 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MC541 |
Multiple organ, diseased tissue array (54 cases_54 cores, 18 types of cancers), replaced by MC542 |
|
160-Eur |
US Biomax |
tissue |
| MC541 |
Multiple organ, diseased tissue array (54 cases_54 cores, 18 types of cancers), replaced by MC542; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MC542 |
Multiple organ???diseased tissue array, including TNM and pathology grade, 54 cases_54 cores, replacing MC541 |
|
160-Eur |
US Biomax |
tissue |
| MC542 |
Multiple organ???diseased tissue array, including TNM and pathology grade, 54 cases_54 cores, replacing MC541; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MC601 |
Multi-organ cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| MC601 |
Multi-organ cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases_60 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| MC616 |
High-density lung, breast, brain and colon cancer array, with stage, grade and normal tissue array, 308 cases_616 cores |
|
753-Eur |
US Biomax |
tissue |
| MC616 |
High-density lung, breast, brain and colon cancer array, with stage, grade and normal tissue array, 308 cases_616 cores; ihc Anti-Actin confirmed |
|
1146-Eur |
US Biomax |
tissue |
| MC6162 |
High-density stomach, colonrectal cancer tissue array, with stage, grade and normal tissue, 616 cases_616 cores |
|
753-Eur |
US Biomax |
recombinant |
| MC6162 |
High-density stomach, colonrectal cancer tissue array, with stage, grade and normal tissue, 616 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
recombinant |
| MC6163 |
High-density tissue array of multiple organ tumor and normal tissue, with pathology grade, cllinical stage and TNM, 616 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
tissue |
| MC631 |
Multiple organ, diseased tissue array (63 cases_63 cores, 20 types of cancer and disease), replacing BC00014 |
|
160-Eur |
US Biomax |
tissue |
| MC631 |
Multiple organ, diseased tissue array (63 cases_63 cores, 20 types of cancer and disease), replacing BC00014; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MC641 |
Multiple organ cancer and adjacent normal tissue array, including TNM and pathology grade, 59 cases_64 cores, replacing BC00115 |
|
----Eur |
US Biomax |
tissue |
| MC642 |
Multiple cancer tissue array - I, 6 common types of cancer and some of matched normal tissues, with TNM data, 58 cases_66 cores |
|
----Eur |
US Biomax |
tissue |
| MC643 |
Multiple cancer tissue array - II, 6 common types of cancer and some of matched normal tissues, with TNM data, 58 cases_66 cores |
|
----Eur |
US Biomax |
tissue |
| MC644 |
Multiple cancer tissue array - III, 6 common types of cancer and some of matched normal tissues, with TNM data, 58 cases_66 cores |
|
----Eur |
US Biomax |
tissue |
| MC801 |
Multiple cancer tissue array, replacing BC00012, 80 cases_80 cores, with grade information |
|
266-Eur |
US Biomax |
tissue |
| MC801 |
Multiple cancer tissue array, replacing BC00012, 80 cases_80 cores, with grade information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MC8010 |
Multiple organ cancer tissue array, including TNM and pathology grade, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| MC8010 |
Multiple organ cancer tissue array, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| MC802 |
Multiple cancer tissue array with matched or unmatched normal control, replacing BC00115, 44 cases_80 cores, with grade information |
|
266-Eur |
US Biomax |
tissue |
| MC802 |
Multiple cancer tissue array with matched or unmatched normal control, replacing BC00115, 44 cases_80 cores, with grade information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MC803 |
Retinoblastoma, nephroblastoma, neuroblastoma and leukemia tissue array, 40 cases_80 cores |
|
314-Eur |
US Biomax |
tissue |
| MC803 |
Retinoblastoma, nephroblastoma, neuroblastoma and leukemia tissue array, 40 cases_80 cores, replaced by MC803a; ihc Anti-Actin confirmed |
|
320-Eur |
US Biomax |
tissue |
| MC803a |
Multiple organ tumor tissue array with adjacent normal tissue, including TNM and clinical stage, 40 cases_80 cores, replacing MC803; ihc Anti-Actin confirmed |
|
320-Eur |
US Biomax |
tissue |
| MC804 |
Adamantinoma and hamartoma tissue array, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| MC804 |
Adamantinoma and hamartoma tissue array, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MC805 |
Synovial sarcoma and cancer sarcomatodes tissue array, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| MC805 |
Synovial sarcoma and cancer sarcomatodes tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| MC806 |
Gangliocytoma and paraganglioma tissue array, 40 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| MC806 |
Gangliocytoma and paraganglioma tissue array, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| MC807 |
Multiple types of cancer tissue array, with stage and TNM information, 40 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| MC807 |
Multiple types of cancer tissue array, with stage and TNM information, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| MC808 |
Multiple tumor tissue array - 58 different tumors and their corresponding normal tissues with TNM data, 58 cases_96 cores |
|
266-Eur |
US Biomax |
elisa |
| MC808 |
Multiple tumor tissue array - 58 different tumors and their corresponding normal tissues with TNM data, 58 cases_96 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
elisa |
| MC809 |
Neuroblastoma and retinoblastoma tissue array, with TNM and grade info, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| MC809 |
Neuroblastoma and retinoblastoma tissue array, with TNM and grade info, 80 cases_80 cores, replaced by MC809a; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| MC809a |
Blastoma tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing MC809; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| MC961 |
Multiple organ cancer tissue array for testing tumor tissue specificity of therapeutic antibodies, 96 cases_96 cores, replaced by MC964 |
|
231-Eur |
US Biomax |
elisa |
| MC961 |
Multiple organ cancer tissue array for testing tumor tissue specificity of therapeutic antibodies, 96 cases_96 cores, replaced by MC964; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
elisa |
| MC962 |
Multiple carcinoma tissue array with matched normal organ tissue, 58 cases_96 cores |
|
----Eur |
US Biomax |
elisa |
| MC963 |
Multiple cancer tissue array with four 24 core array squares mounted on glass, 12 cases_96 cores |
|
266-Eur |
US Biomax |
elisa |
| MC963 |
Multiple cancer tissue array with four 24 core array squares mounted on glass, 12 cases_96 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
elisa |
| MC964 |
Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, for testing tumor tissue specificity of therapeutic antibodies, 96 cases_96 cores, replacing MC961 |
|
266-Eur |
US Biomax |
elisa |
| MC964 |
Multiple organ tumor tissue array, including TNM, clinical stage and pathology grade, for testing tumor tissue specificity of therapeutic antibodies, 96 cases_96 cores, replacing MC961; ihc Anti-Act |
|
296-Eur |
US Biomax |
elisa |
| MCN601 |
Multiple organ tumor and normal tissue array, 58 cases_60 cores, replaced by MCN602 |
|
231-Eur |
US Biomax |
tissue |
| MCN601 |
Multiple organ tumor and normal tissue array, 58 cases_60 cores, replaced by MCN602; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| MCN602 |
Multiple organ tumor and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 58 cases_60 cores, replacing MCN601 |
|
231-Eur |
US Biomax |
tissue |
| MCN602 |
Multiple organ tumor and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 58 cases_60 cores, replacing MCN601; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ME1001 |
Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| ME1001 |
Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases_100 cores; ihc Anti-HMB45 confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME1002 |
Malignant melanoma and normal tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| ME1002 |
Malignant melanoma and normal tissue array, 50 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME1003 |
Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases_100 cores, replaced by ME1004 |
|
266-Eur |
US Biomax |
tissue |
| ME1003 |
Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases_100 cores, replaced by ME1004; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME1004 |
Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases_100 cores, replacing ME1003 |
|
314-Eur |
US Biomax |
tissue |
| ME1004 |
Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases_100 cores, replaced by ME1004a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME1004a |
Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage, 100 cases_100 cores, replacing ME1004; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME207 |
High-density (69 cases_207 cores), multiple primary melanoma, metastatic and normal tissues array |
|
456-Eur |
US Biomax |
tissue |
| ME207 |
High-density (69 cases_207 cores), multiple primary melanoma, metastatic and normal tissues array; ihc S-100 confirmed |
|
487-Eur |
US Biomax |
tissue |
| ME207b |
High-density (69 cases_207 cores), multiple primary melanoma, metastatic and normal skin tissue array block |
|
40981-Eur |
US Biomax |
tissue |
| ME207b |
High-density (69 cases_207 cores), multiple primary melanoma, metastatic and normal skin tissue array block; ihc S-100 confirmed |
|
33112-Eur |
US Biomax |
tissue |
| ME2081 |
Mid-density malignant melanoma and normal tissue array, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ME2081 |
Mid-density malignant melanoma and normal tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| ME2082 |
Malignant melanoma tissue array, including TNM and clinical stage, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ME2082 |
Malignant melanoma tissue array, including TNM and clinical stage, 208 cases_208 cores, replaced by ME2082a; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| ME2082a |
Malignant melanoma tissue array, including TNM and clinical stage, 208 cases_208 cores, replacing ME2082; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| ME241 |
Multiple melanoma tissue array with normal tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| ME241 |
Multiple melanoma tissue array with normal tissues, 12 cases_24 cores, replaced by ME241a; ihc Anti-S-100 confirmed |
|
105-Eur |
US Biomax |
tissue |
| ME241a |
Multiple malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 12 cases_24 cores, replacing ME241; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| ME242 |
Low-density malignant melanoma array, with stage and grade info, 24 cases_24 cores |
|
88-Eur |
US Biomax |
|
| ME242 |
Low-density malignant melanoma array, with stage and grade info, 24 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
|
| ME481 |
Multiple melanoma tissue array with normal skin tissues, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| ME481 |
Multiple melanoma tissue array with normal skin tissues, 48 cases_48 cores, replaced by ME481a; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| ME481a |
Melanoma tissue array with normal skin tissues, including TNM and clinical stage, 48 cases_48 cores, replacing ME481; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| ME482 |
Malignant melanoma array with matched normal tissue control, stage and TNM, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| ME482 |
Malignant melanoma array with matched normal tissue control, stage and TNM, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| ME483 |
Melanoma tissue array, including TNM and clinical stage, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| ME483 |
Melanoma tissue array, including TNM and clinical stage, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ME801 |
Malignant melanoma tissue array, 80 cases_80 cores, replaced by ME804 |
|
231-Eur |
US Biomax |
tissue |
| ME801 |
Malignant melanoma tissue array, 80 cases_80 cores, replaced by ME804; ihc Anti-S-100 antibody confirmed |
|
258-Eur |
US Biomax |
tissue |
| ME802 |
Malignant melanoma with normal skin tissue array, 40 cases_80 cores, replacing BS38011 |
|
266-Eur |
US Biomax |
tissue |
| ME802 |
Malignant melanoma with normal skin tissue array, 40 cases_80 cores, replacing BS38011; ihc Anti-S100 confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME803 |
Malignant melanoma array with matched and unmatched normal skin tissue control, with stage and TNM, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| ME803 |
Malignant melanoma array with matched and unmatched normal skin tissue control, with stage and TNM, 80 cases_80 cores, replaced by ME803a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME803a |
Malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 80 cases_80 cores, replacing ME803; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ME804 |
Malignant melanoma tissue array, including TNM and clinical stage, 80 cases_80 cores, replacing ME801 |
|
266-Eur |
US Biomax |
tissue |
| ME804 |
Malignant melanoma tissue array, including TNM and clinical stage, 80 cases_80 cores, replacing ME801; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MET181 |
Metastatic cancer tissue array, 18 cases_18 cores |
|
166-Eur |
US Biomax |
tissue |
| MET181 |
Metastatic cancer tissue array, 18 cases_18 cores; ihc H&E, IHC anti- Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| MET961 |
Metastatic cancer tissue array, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| MET961 |
Metastatic cancer tissue array, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| MG801 |
Meningioma of central nerve tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| MG801 |
Meningioma of central nerve tissue array, 80 cases_80 cores; ihc Anti-Vimentin confirmed |
|
267-Eur |
US Biomax |
tissue |
| MGS801 |
Male genitourinary system tissue array with normal, inflammation, disease and cancer tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| MGS801 |
Male genitourinary system tissue array with normal, inflammation, disease and cancer tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MNO341 |
Antibody cross-reactivity testing tissue array, 33 cases_34 cores |
|
118-Eur |
US Biomax |
assays |
| MNO341 |
Antibody cross-reactivity testing tissue array, 33 cases_34 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
123-Eur |
US Biomax |
assays |
| MNO381 |
Tissue profiling tissue array with 19 types of normal human tissues, 19 cases_38 cores |
|
166-Eur |
US Biomax |
tissue |
| MNO381 |
Tissue profiling tissue array with 19 types of normal human tissues, 19 cases_38 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| MNO661 |
Normal organ tissue array of human, 66 cases_66 cores |
|
189-Eur |
US Biomax |
tissue |
| MNO661 |
Normal organ tissue array of human, 66 cases_66 cores; ihc H&E, IHC anti- Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| MNO961 |
35 types of normal human tissue array, 90 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| MNO961 |
35 types of normal human tissue array, 90 cases_96 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| MNT241 |
Multiple tumor and normal tissue array for IHC antibody and ISH probe optimization and initial screening, 12 cases_24 cores |
|
77-Eur |
US Biomax |
tissue |
| MNT241 |
Multiple tumor and normal tissue array for IHC antibody and ISH probe optimization and initial screening, 12 cases_24 cores; ihc H&E, IHC Vimentin_Cytokeratin |
|
85-Eur |
US Biomax |
tissue |
| MO01011 |
Mouse stomach tissue array, 100 cases_100 cores, 50 from different male, 50 from different female |
|
160-Eur |
US Biomax |
tissue |
| MO01011 |
Mouse stomach tissue array, 100 cases_100 cores, 50 from different male, 50 from different female; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO03011 |
Mouse liver tissue array, 100 cases_100 cores, 50 male and 50 female |
|
160-Eur |
US Biomax |
tissue |
| MO03011 |
Mouse liver tissue array, 100 cases_100 cores, 50 male and 50 female; ihc Anti-EMA confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO04011 |
Mouse lung tissue array, 100 cases_100 cores, 50 male and 50 female |
|
160-Eur |
US Biomax |
tissue |
| MO04011 |
Mouse lung tissue array, 100 cases_100 cores, 50 male and 50 female; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO07011 |
Mouse kidney tissue array, 100 cases_100 cores, 50 male and 50 female |
|
160-Eur |
US Biomax |
tissue |
| MO07011 |
Mouse kidney tissue array, 100 cases_100 cores, 50 male and 50 female; ihc Anti-EMA confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO1001 |
Mouse normal kidney tissue array, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| MO1001 |
Mouse normal kidney tissue array, 100 cases_100 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| MO1002 |
Mouse spleen tissue array, 100 cases_100 cores, 50 male and 50 female, replacing MO32011 |
|
189-Eur |
US Biomax |
tissue |
| MO1002 |
Mouse spleen tissue array, 100 cases_100 cores, 50 male and 50 female, replacing MO32011; ihc Anti-CD20 confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO1601 |
Mouse tissue array of liver, kidney, lung, muscle, brain, heart, stomach, spleen, 160 cases_160 cores, replacing BM01011 |
|
278-Eur |
US Biomax |
tissue |
| MO1601 |
Mouse tissue array of liver, kidney, lung, muscle, brain, heart, stomach, spleen, 160 cases_160 cores, replacing BM01011; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| MO17011 |
Mouse brain tissue array, 100 cases_100 cores, 50 male and 50 female |
|
160-Eur |
US Biomax |
tissue |
| MO17011 |
Mouse brain tissue array, 100 cases_100 cores, 50 male and 50 female; ihc Anti-GFAP confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO24011 |
Mouse muscle tissue array, 100 cases_100 cores, 50 male and 50 female |
|
160-Eur |
US Biomax |
tissue |
| MO24011 |
Mouse muscle tissue array, 100 cases_100 cores, 50 male and 50 female; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO30011 |
Mouse heart tissue array, 100 cases_100 cores, 50 male and 50 female |
|
160-Eur |
US Biomax |
tissue |
| MO30011 |
Mouse heart tissue array, 100 cases_100 cores, 50 male and 50 female; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO32011 |
Mouse spleen tissue array, 100 cases_100 cores, 50 male and 50 female, replaced by MO1002 |
|
189-Eur |
US Biomax |
tissue |
| MO32011 |
Mouse spleen tissue array, 100 cases_100 cores, 50 male and 50 female, replaced by MO1002; ihc Anti-CD20 confirmed |
|
185-Eur |
US Biomax |
tissue |
| MO541 |
Mouse multiple organ normal tissue array, 24 cases_54 cores; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| MS481 |
Human mesothelioma tissue array, 24 cases_48 cores |
|
314-Eur |
US Biomax |
tissue |
| MS481 |
Human mesothelioma tissue array, 24 cases_48 cores, replaced by MS481a; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| MS481a |
Mesothelioma tissue array with normal tissue as control, including TNM and clinical stage, 24 cases_48 cores, replacing MS481; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MS801 |
Mesothelioma tissue array with normal mesothelium, with stage and TNM data, 40 cases_80 cores |
|
397-Eur |
US Biomax |
tissue |
| MS801 |
Mesothelioma tissue array with normal mesothelium, with stage and TNM data, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| MT2081 |
Multiple organ metastatic cancer tissue array, 19 organ_104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| MT2081 |
Multiple organ metastatic cancer tissue array, 19 organ_104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| MT801 |
Multiple organ cancer metastasis tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| MT801 |
Multiple organ cancer metastasis tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| MTU241 |
Multiple tumor and normal tissue array, with 12 major types of cancer paired with matched NAT, 12 cases_24 cores |
|
166-Eur |
US Biomax |
tissue |
| MTU241 |
Multiple tumor and normal tissue array, with 12 major types of cancer paired with matched NAT, 12 cases_24 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| MTU391 |
Top 10 cancer tissue array (15 major types from Oriental and Western population), 20 cases_39 cores |
|
166-Eur |
US Biomax |
tissue |
| MTU391 |
Top 10 cancer tissue array (15 major types from Oriental and Western population), 20 cases_39 cores; ihc H&E, IHC anti-Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| MTU481 |
Multiple tumor tissue array, 48 cases_48 cores |
|
142-Eur |
US Biomax |
tissue |
| MTU481 |
Multiple tumor tissue array, 48 cases_48 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
151-Eur |
US Biomax |
tissue |
| MTU951 |
Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases_95 cores |
|
225-Eur |
US Biomax |
tissue |
| MTU951 |
Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases_95 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| NGL481 |
Nervous system glioma tissue array, 24 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| NGL481 |
Nervous system glioma tissue array, 24 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| NGL961 |
Nervous system glioma tissue array, 48 cases_96 cores |
|
261-Eur |
US Biomax |
elisa |
| NGL961 |
Nervous system glioma tissue array, 48 cases_96 cores; ihc H&E, IHC anti-Vimentin |
|
281-Eur |
US Biomax |
elisa |
| NH1001 |
Nasopharynx disease spectrum (nasopharynx cancer progression) tissue array, 49 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| NH1001 |
Nasopharynx disease spectrum (nasopharynx cancer progression) tissue array, 49 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| NHL401 |
Lymphoma, multiple myeloma and lymph node tissue array, 40 cases_40 cores |
|
266-Eur |
US Biomax |
tissue |
| NHL401 |
Lymphoma, multiple myeloma and lymph node tissue array, 40 cases_40 cores, replaced by NHL401a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| NHL401a |
Lymphoma, myeloma and lymph node tissue array, 40 cases_40 cores, replacing NHL401; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| NHL481 |
Lymphoma tissue array, 48 cases_48 cores, replaced by NHL482 |
|
189-Eur |
US Biomax |
tissue |
| NHL481 |
Lymphoma tissue array, 48 cases_48 cores, replaced by NHL482; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| NHL482 |
Lymphoma tissue array, 48 cases_48 cores, replacing NHL481 |
|
189-Eur |
US Biomax |
tissue |
| NHL482 |
Lymphoma tissue array, 48 cases_48 cores, replacing NHL481; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| NHL483 |
Non-Hodgkin's lymphoma tumor tissue array, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| NHL483 |
Non-Hodgkin's lymphoma tumor tissue array, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| NHL801 |
Non-Hodgkin's lymphoma tissue array, 42 cases_80 cores, no overlaps with NHL802 |
|
266-Eur |
US Biomax |
tissue |
| NHL801 |
Non-Hodgkin's lymphoma tissue array, 42 cases_80 cores, no overlaps with NHL802; ihc Anti-Leukocyte Common Antigen antibody confirmed |
|
267-Eur |
US Biomax |
tissue |
| NHL802 |
Non-Hodgkin's lymphoma tissue array, 42 cases_80 cores, no overlaps with NHL801, replaced by NHL803 |
|
266-Eur |
US Biomax |
tissue |
| NHL802 |
Non-Hodgkin's lymphoma tissue array, 42 cases_80 cores, no overlaps with NHL801, replaced by NHL803a; ihc Anti-Leukocyte Common Antigen antibody confirmed |
|
267-Eur |
US Biomax |
tissue |
| NHL802a |
Non-Hodgkin's lymphoma tissue array, 42 cases_80 cores, replacing NHL802; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| NHL803 |
Lymphoma tissue array, 80 cases_80 cores, replacing LM802 |
|
266-Eur |
US Biomax |
tissue |
| NHL803 |
Lymphoma tissue array, 80 cases_80 cores, replacing LM802; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| NHL803b |
Lymphoma tissue array, 80 cases_80 cores, replacing NHL803 |
|
321-Eur |
US Biomax |
tissue |
| NHL803b |
Lymphoma tissue array, 80 cases_80 cores, replacing NHL803 |
|
266-Eur |
US Biomax |
tissue |
| NHL803b |
Lymphoma tissue array, 80 cases_80 cores, replacing NHL803; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| NPC111 |
Nasopharyngeal carcinoma tissue array, 11 cases_11 cores |
|
106-Eur |
US Biomax |
tissue |
| NPC111 |
Nasopharyngeal carcinoma tissue array, 11 cases_11 cores; ihc H&E, IHC anti-Cytokeratin |
|
123-Eur |
US Biomax |
tissue |
| NPC481 |
Nasopharyngeal carcinoma tissue array, 48 cases_49 cores |
|
189-Eur |
US Biomax |
tissue |
| NPC481 |
Nasopharyngeal carcinoma tissue array, 48 cases_49 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| NPC961 |
Nasopharyngeal carcinoma tissue array, non-overlapping with NPC962, >50 cases_96 cores |
|
344-Eur |
US Biomax |
elisa |
| NPC961 |
Nasopharyngeal carcinoma tissue array, non-overlapping with NPC962, >50 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
358-Eur |
US Biomax |
elisa |
| NPC962 |
Nasopharyngeal carcinoma tissue array, non-overlapping with NPC961, 96 cases_96 cores |
|
308-Eur |
US Biomax |
elisa |
| NPC962 |
Nasopharyngeal carcinoma tissue array, non-overlapping with NPC961, 96 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
358-Eur |
US Biomax |
elisa |
| NST961 |
Nervous system tumor tissue array, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| NST961 |
Nervous system tumor tissue array, 48 cases_96 cores; ihc H&E, IHC anti-Vimentin_S100_GFAP |
|
238-Eur |
US Biomax |
elisa |
| OM601 |
Metastatic carcinoma of epiploon tissue array, 60 cases_60 cores |
|
266-Eur |
US Biomax |
tissue |
| OM601 |
Metastatic carcinoma of epiploon tissue array, 60 cases_60 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ON481 |
Oncocytoma tissue array, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| OR1001 |
Tonsil disease spectrum (tonsil tumor progression) tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| OR1001 |
Tonsil disease spectrum (tonsil tumor progression) tissue array, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OR208 |
Oral cavity squamous cell carcinoma and normal tissues high density (69 cases_208 cores) tissue microarray) with grade and stage info |
|
456-Eur |
US Biomax |
tissue |
| OR208 |
Oral cavity squamous cell carcinoma and normal tissues high density (69 cases_208 cores) tissue microarray) with grade and stage info; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OR2081 |
Oral cavity disease spectrum (oral cancer progression) tissue array, 98 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OR2081 |
Oral cavity disease spectrum (oral cancer progression) tissue array, 98 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OR481 |
Oral cavity (tongue and parotid) cancer tissue array, 48 cases_48 cores. |
|
160-Eur |
US Biomax |
tissue |
| OR481 |
Oral cavity (tongue and parotid) cancer tissue array, 48 cases_48 cores.; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| OR601 |
Oral squamous cancer tissue array with normal oral control tissue, 60 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| OR601 |
Oral squamous cancer tissue array with normal oral control tissue, 60 cases_60 cores, replaced by OR601a; ihc Anti-Cytokeratin (CK) confirmed |
|
258-Eur |
US Biomax |
tissue |
| OR601a |
Oral squamous cell cancer tissue array with adjacent normal tongue tissue, including TNM, clinical stage and pathology grade, 60 cases_60 cores, replacing OR601; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| OR801 |
Parotid gland disease spectrum (parotidean cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OR801 |
Parotid gland disease spectrum (parotidean cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OR802 |
Oral cavity disease spectrum (oral cavity cancer progression) tissue array, 79 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OR802 |
Oral cavity disease spectrum (oral cavity cancer progression) tissue array, 79 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OS208 |
High density (208 core) tissue microarray of osteosarcoma, chondrosarcoma, giant cell tumor of bone and normal tissue, with TNM data, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OS208 |
High density (208 core) tissue microarray of osteosarcoma, chondrosarcoma, giant cell tumor of bone and normal tissue, with TNM data, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OS801 |
Osteosarcoma and chondrosarcoma tissue array, with matched or unmatched adjacent normal tissue, 79 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OS801 |
Osteosarcoma and chondrosarcoma tissue array, with matched or unmatched adjacent normal tissue, 79 cases_80 cores, replaced by OS802; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
258-Eur |
US Biomax |
tissue |
| OS802 |
Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases_80 cores, replacing BC26111 |
|
266-Eur |
US Biomax |
tissue |
| OS802 |
Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases_80 cores, replacing OS801 and BC26111; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| OS803 |
Chondrosarcoma tissue tissue array, 27 cases_80 cores, replacing BS36011 |
|
266-Eur |
US Biomax |
tissue |
| OS803 |
Chondrosarcoma tissue tissue array, 27 cases_80 cores, replacing BS36011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OS804 |
Osteosarcoma tissue tissue array, with stage and grade, 40 cases_80 cores, replacing BS26011 |
|
266-Eur |
US Biomax |
tissue |
| OS804 |
Osteosarcoma tissue tissue array, with stage and grade, 40 cases_80 cores, replacing BS26011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV1001 |
Ovarian disease spectrum (ovarian cancer progression) tissue array, 100 cases_100 cores, replaced by OV1005 |
|
231-Eur |
US Biomax |
tissue |
| OV1001 |
Ovarian disease spectrum (ovarian cancer progression) tissue array, 100 cases_100 cores, replaced by OV1005; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV1002 |
Ovarian cancer (multiple types) tissue array, 100 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| OV1002 |
Ovarian cancer (multiple types) tissue array, 100 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV1003 |
Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| OV1003 |
Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV1004 |
Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| OV1004 |
Ovarian cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV1005 |
Ovarian disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replacing OV1001 |
|
266-Eur |
US Biomax |
tissue |
| OV1005 |
Ovarian disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replaced by OV1005a; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV1005a |
Ovary disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replacing OV1005; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV1501 |
Ovarian cancer tissue array, with TNM, clinical stage and pathology grade, 75 cases_150 cores |
|
231-Eur |
US Biomax |
tissue |
| OV1501 |
Ovarian cancer tissue array, with TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| OV1502 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| OV1502 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| OV1502 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| OV1921 |
Late stage ovarian tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| OV1921 |
Late stage ovarian tumor tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
elisa |
| OV2001 |
Ovarian cancer high-density (200 cases_200 cores) tissue array |
|
397-Eur |
US Biomax |
tissue |
| OV2001 |
Ovarian cancer high-density (200 cases_200 cores) tissue array; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
382-Eur |
US Biomax |
tissue |
| OV208 |
Ovarian cancer and normal tissue high density (69 cases_208 cores) tissue microarray, with grade and stage data |
|
456-Eur |
US Biomax |
tissue |
| OV208 |
Ovarian cancer and normal tissue high density (69 cases_208 cores) tissue microarray, with grade and stage data; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV20810 |
Ovary cancer survey tissue array (1 of 4), with normal tissue, including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV20810 |
Ovary cancer survey tissue array (1 of 4), with normal tissue, including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV20811 |
Ovary cancer tissue array (2 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV20811 |
Ovary cancer tissue array (2 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV20812 |
Ovary cancer tissue array (3 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV20812 |
Ovary cancer tissue array (3 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV20813 |
Ovary cancer tissue array (4 of 4), including TNM and pathology grade, 208 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV20813 |
Ovary cancer tissue array (4 of 4), including TNM and pathology grade, 208 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV20814 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 208 cases_208 cores, replacing OV2084 |
|
558-Eur |
US Biomax |
tissue |
| OV20814 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 208 cases_208 cores, replacing OV2084 |
|
456-Eur |
US Biomax |
tissue |
| OV20814 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 208 cases_208 cores, replacing OV2084; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV2082 |
Ovary cancer tissue array with normal tissues, with TNM and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2082 |
Ovary cancer tissue array with normal tissues, with TNM and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV2083 |
High-density ovarian cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2083 |
High-density ovarian cancer tissue array with normal tissues, with stage and grade info, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV2084 |
Ovarian cancer tissue array with normal adjacent ovary, TNM, clinical stage and pathology grade, 208 cases_208 cores, replaced by OV20814 |
|
456-Eur |
US Biomax |
tissue |
| OV2084 |
Ovarian cancer tissue array with normal adjacent ovary, TNM, clinical stage and pathology grade, 208 cases_208 cores, replaced by OV20814; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV2085 |
Ovary cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2085 |
Ovary cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV2086 |
Ovary cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2086 |
Ovary cancer survey tissue array (2 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV2087 |
Ovary cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2087 |
Ovary cancer survey tissue array (3 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV2088 |
Ovary cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2088 |
Ovary cancer survey tissue array (4 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV2089 |
Ovary cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| OV2089 |
Ovary cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV2161 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
633-Eur |
US Biomax |
tissue |
| OV2161 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
516-Eur |
US Biomax |
tissue |
| OV2161 |
Ovary adenocarcinoma tissue array, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| OV241 |
Ovarian cancer test tissue array with self-matching or unmatched normal adjacent tissues, 10 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| OV241 |
Ovarian cancer test tissue array with self-matching or unmatched normal adjacent tissues, 10 cases_24 cores, replaced by OV241a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| OV241a |
Ovary cancer and adjacent normal tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing OV241; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| OV242 |
Multiple ovarian cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| OV242 |
Multiple ovarian cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| OV243 |
Ovary cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| OV243 |
Ovary cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV481 |
Ovarian cancer tissue array with unmatched normal adjacent tissues, 24 cases_48 cores, with stage and grade data |
|
160-Eur |
US Biomax |
tissue |
| OV481 |
Ovarian cancer tissue array with unmatched normal adjacent tissues, 24 cases_48 cores, with stage and grade data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| OV482 |
Multiple ovarian cancer tissue array with 4 normal tissues control from autopsy, (24 cases_48 cores) with grade and stage info |
|
160-Eur |
US Biomax |
tissue |
| OV482 |
Multiple ovarian cancer tissue array with 4 normal tissues control from autopsy, (24 cases_48 cores) with grade and stage info; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| OV483 |
Multiple ovarian cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade info |
|
160-Eur |
US Biomax |
tissue |
| OV483 |
Multiple ovarian cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade info; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| OV484 |
Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores |
|
231-Eur |
US Biomax |
tissue |
| OV484 |
Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV485 |
Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases_96 cores |
|
397-Eur |
US Biomax |
elisa |
| OV485 |
Ovarian cancer tissue array, including TNM, clinical stage and pathology grade, 2 serial sections, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
elisa |
| OV602 |
Tissue array of ovarian granulosa-theca cell tumor (GTCT, malignant and benign) and cysts, 60 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| OV602 |
Tissue array of ovarian granulosa-theca cell tumor (GTCT, malignant and benign) and cysts, 60 cases_60 cores; ihc Anti-Vimtin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV603 |
Ovarian serous cystadenoma tissue array, 30 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| OV603 |
Ovarian serous cystadenoma tissue array, 30 cases_60 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV6161 |
High-density ovarian cancer array, with stage and grade information, 322 cases_616 cores |
|
753-Eur |
US Biomax |
|
| OV6161 |
High-density ovarian cancer array, with stage and grade information, 322 cases_616 cores; ihc Anti-Actin confirmed |
|
811-Eur |
US Biomax |
|
| OV641 |
Ovary cancer tissue array, 64 cases_66 cores, with TNM data |
|
----Eur |
US Biomax |
tissue |
| OV701 |
Ovary cancer tissue array, with adjacent normal tissue, including TNM, clinical stage and pathology grade, 70 cases_70 cores, replacing BC111110; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
tissue |
| OV721 |
Ovary cancer and normal tissue array, with grade and stage data, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| OV721 |
Ovary cancer and normal tissue array, with grade and stage data, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV801 |
Ovarian cancer tissue array, with matched or unmatched adjacent normal tissue, 70 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| OV801 |
Ovarian cancer tissue array, with matched or unmatched adjacent normal tissue, 70 cases_80 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV8010 |
Mid-advanced stage ovary cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OV8010 |
Mid-advanced stage ovary cancer tissue array, with metastasis tissue, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV802 |
Multiple ovarian carcinoma and normal tissue array, with stage and TNM info, 78 cases_80 cores, replacing BC11011 |
|
231-Eur |
US Biomax |
tissue |
| OV802 |
Multiple ovarian carcinoma and normal tissue array, with stage and TNM info, 78 cases_80 cores, replacing BC11011; ihc Anti-Cytokeratin (CK) confirmed |
|
228-Eur |
US Biomax |
tissue |
| OV803 |
Ovarian adenocarcinoma tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| OV803 |
Ovarian adenocarcinoma tissue array, 80 cases_80 cores, replaced by OV803a; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV803a |
Ovary cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing OV803; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| OV804 |
Ovarian metastatic carcinoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OV804 |
Ovarian metastatic carcinoma tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
258-Eur |
US Biomax |
tissue |
| OV805 |
Ovarian teratoma tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| OV805 |
Ovarian teratoma tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV806 |
Normal ovarian tissue array, 30 cases_60 cores |
|
231-Eur |
US Biomax |
tissue |
| OV806 |
Normal ovarian tissue array, 30 cases_60 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV807 |
Ovarian cancer tissue array with normal tissue, grade and TNM data, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| OV807 |
Ovarian cancer tissue array with normal tissue, grade and TNM data, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| OV808 |
Ovarian cancer metastasis tissue array, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OV808 |
Ovarian cancer metastasis tissue array, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV809 |
Ovary cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| OV809 |
Ovary cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV811 |
Ovarian cancer tissue array with normal tissues from autopsy, 35 cases_80 cores, with stage and grade data |
|
231-Eur |
US Biomax |
tissue |
| OV811 |
Ovarian cancer tissue array with normal tissues from autopsy, 35 cases_80 cores, with stage and grade data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| OV951 |
Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases_95 cores, |
|
456-Eur |
US Biomax |
tissue |
| OV951 |
Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases_95 cores,; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| OV961 |
Ovary tumor tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
elisa |
| OV962 |
Ovary tumor tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
elisa |
| OVC1021 |
Ovary cancer tissue array, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| OVC1021 |
Ovary cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| OVC1501 |
Ovarian cancer mid-density tissue array, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| OVC1501 |
Ovarian cancer mid-density tissue array, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| OVC2281 |
Hidensity ovarian cancer tissue array containing 8 cases of normal_benign conditions and 220 cases of cancers with grading and TNM staging data, 228 cases_228 cores |
|
403-Eur |
US Biomax |
tissue |
| OVC2281 |
Hidensity ovarian cancer tissue array containing 8 cases of normal_benign conditions and 220 cases of cancers with grading and TNM staging data, 228 cases_228 cores; ihc H&E, IHC anti-Cytokeratin |
|
434-Eur |
US Biomax |
tissue |
| OVC241 |
Ovary cancer tissue array, 12 cases_24 cores |
|
166-Eur |
US Biomax |
tissue |
| OVC241 |
Ovary cancer tissue array, 12 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| OVC961 |
Ovarian cancer and normal tissue array, non-overlapping with OVC962, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| OVC961 |
Ovarian cancer and normal tissue array, non-overlapping with OVC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| OVC962 |
Ovarian cancer and normal tissue array, non-overlapping with OVC961, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| OVC962 |
Ovarian cancer and normal tissue array, non-overlapping with OVC961, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| PA1001 |
Multiple pancreatic cancer tissue array with unmatched normal adjacent tissues, with TNM data, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| PA1001 |
Multiple pancreatic cancer tissue array with unmatched normal adjacent tissues, with TNM data, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA1002 |
Pancreas cancer tissue array for antibody screening, with normal tissue, including TNM and pathology grade, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| PA1002 |
Pancreas cancer tissue array for antibody screening, with normal tissue, including TNM and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| PA1003 |
Pancreas cancer tissue array for antibody screening, including TNM and pathology grade, 25 cases_100 cores |
|
314-Eur |
US Biomax |
tissue |
| PA1003 |
Pancreas cancer tissue array for antibody screening, including TNM and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA1921 |
Mid-advanced stage pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| PA1921 |
Mid-advanced stage pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
elisa |
| PA207 |
High-density (69 cases_207 cores), multiple pancreatic cancer (1-3 grade) and normal pancreatic tissue array, replaced by PA2072 |
|
456-Eur |
US Biomax |
tissue |
| PA207 |
High-density (69 cases_207 cores), multiple pancreatic cancer (1-3 grade) and normal pancreatic tissue array, replaced by PA2072; ihc Anti-Cytokeratin (CK) confirmed |
|
487-Eur |
US Biomax |
tissue |
| PA2072 |
Pancreas cancer tissue array, with normal tissue, including TNM and pathology grade, 69 cases_207 cores, replacing PA207 |
|
456-Eur |
US Biomax |
tissue |
| PA2072 |
Pancreatic cancer tissue array, with normal tissue, including TNM and pathology grade, 69 cases_207 cores, replacing PA207; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| PA207b |
High-density (69 cases_207 cores), multiple pancreatic cancer (I-4 grade) and normal pancreatic tissue array BLOCK |
|
40981-Eur |
US Biomax |
tissue |
| PA207b |
High-density (69 cases_207 cores), multiple pancreatic cancer (I-4 grade) and normal pancreatic tissue array block; ihc Anti-Cytokeratin (CK) confirmed |
|
19019-Eur |
US Biomax |
tissue |
| PA2081 |
Pancreatic disease spectrum (pancreatic cancer progression) tissue array with pathology grade and TNM information, 101 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| PA2081 |
Pancreatic disease spectrum (pancreatic cancer progression) tissue array with pathology grade and TNM information, 101 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| PA2082 |
High-density pancreatic cancer and normal tissue array, with stage and grade info, 101 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| PA2082 |
High-density pancreatic cancer and normal tissue array, with stage and grade info, 101 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| PA241 |
Pancreatic cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores, replaced by PA241b |
|
100-Eur |
US Biomax |
assays |
| PA241 |
Pancreatic cancer test tissue array with self-matching normal adjacent tissue, 6 cases_24 cores, replaced by PA241b; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| PA241b |
Pancreas adenocarcinoma tissue array with matched adjacent normal pancreas tissue, including TNM and pathology grade, 6 cases_24 cores, replacing PA241 |
|
99-Eur |
US Biomax |
tissue |
| PA241b |
Pancreas adenocarcinoma tissue array with matched adjacent normal pancreas tissue, including TNM and pathology grade, 6 cases_24 cores, replacing PA241 |
|
88-Eur |
US Biomax |
tissue |
| PA241b |
Pancreas adenocarcinoma tissue array with matched adjacent normal pancreas tissue, including TNM and pathology grade, 6 cases_24 cores, replacing PA241; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| PA242 |
Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| PA242 |
Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, 12 cases_24 cores, replaced by PA242a; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| PA242a |
Pancreas cancer tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing PA242; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| PA243 |
Pancreas cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| PA243 |
Pancreas cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| PA481 |
Multiple pancreatic cancer with 4 normal tissues control from autopsy, 24 cases_48 cores, with grade and stage |
|
160-Eur |
US Biomax |
tissue |
| PA481 |
Multiple pancreatic cancer with 4 normal tissues control from autopsy, 24 cases_48 cores, with grade and stage; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| PA482 |
Multiple pancreatic cancer tissue array with 4 normal tissue control from autopsy, 24 cases_48 cores, with TNM data |
|
160-Eur |
US Biomax |
tissue |
| PA482 |
Multiple pancreatic cancer tissue array with 4 normal tissue control from autopsy, 24 cases_48 cores, with TNM data; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| PA483 |
Multiple pancreatic cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with grade and stage data |
|
160-Eur |
US Biomax |
tissue |
| PA483 |
Multiple pancreatic cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with grade and stage data, replaced by PA483b; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| PA483a |
Pancreatic cancer tissue array, including TNM and pathology grade, 48 cases_48 cores, replacing PA483; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| PA483b |
Pancreas cancer tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 48 cases_48 cores, replacing PA483; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| PA484 |
Pancreas adenocarcinoma tissue array, including TNM and pathology grade, 24 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| PA484 |
Pancreas adenocarcinoma tissue array, including TNM and pathology grade, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| PA484 |
Pancreas adenocarcinoma tissue array, including TNM and pathology grade, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| PA721 |
Pancreatic carcinoma (multi-tissue combined panel), 24 cases_72 cores, replacing BC14012 |
|
231-Eur |
US Biomax |
tissue |
| PA721 |
Pancreatic cancer (multi-tissue combined panel), 24 cases_72 cores, replacing BC14012; ihc Anti-Cytokeration (CK) confirmed |
|
228-Eur |
US Biomax |
tissue |
| PA722 |
Pancreatic cancer and normal tissue array, with TNM and pathology grade, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| PA722 |
Pancreatic cancer and normal tissue array, with TNM and pathology grade, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA801 |
Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, with stage and grade info, 70 cases_80 cores, replaced by PA802 |
|
231-Eur |
US Biomax |
tissue |
| PA801 |
Multiple pancreatic cancer tissue array with unmatched normal adjacent tissue, with stage and grade info, 70 cases_80 cores, replaced by PA802; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| PA802 |
Multiple pancreatic cancer tissue array with unmatched normal tissues, with TNM data, 78 cases_80 cores, replacing PA801, to be replaced by PA805 |
|
266-Eur |
US Biomax |
tissue |
| PA802 |
Multiple pancreatic cancer tissue array with unmatched normal tissues, with TNM data, 78 cases_80 cores, replacing PA801, to be replaced by PA805; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA803 |
Pancreatic duct adenocarcinoma and normal tissue array with TNM and grade info, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| PA803 |
Pancreatic duct adenocarcinoma and normal tissue array with TNM and grade info, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA804 |
Pancreatic cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| PA804 |
Pancreatic cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA805 |
Pancreatic cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases_80 cores, replacing PA802 |
|
266-Eur |
US Biomax |
tissue |
| PA805 |
Pancreatic cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases_80 cores, replaced by PA805a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA805a |
Pancreas cancer tissue array with adjacent normal tissue as control, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing PA805; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PA961 |
Pancreatic cancer and normal tissue array, including TNM, clinical stage and pathology grade, 96 cases_96 cores |
|
278-Eur |
US Biomax |
elisa |
| PA961 |
Pancreatic cancer and normal tissue array, including TNM, clinical stage and pathology grade, 96 cases_96 cores; ihc Anti-Actin confirmed |
|
320-Eur |
US Biomax |
elisa |
| PA961a |
Pancreatic cancer tissue array with normal pancreatic tissue, including TNM, clinical stage and pathology grade, 96 cases_96 cores, replacing PA961; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| PAC481 |
Pancreatic cancer tissue array, 24 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| PAC481 |
Pancreatic cancer tissue array, 24 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| PE241 |
Penis cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| PE241 |
Penis cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| PE601 |
Penis disease spectrum (penis tumor progression) tissue array, 59 cases_60 cores |
|
266-Eur |
US Biomax |
tissue |
| PE601 |
Penis disease spectrum (penis tumor progression) tissue array, 59 cases_60 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PE801 |
Penile (penis) carcinoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| PE801 |
Penile (penis) carcinoma tissue array, 80 cases_80 cores; ihc IHC confirmed |
|
296-Eur |
US Biomax |
tissue |
| PIT501 |
Normal pituitary gland tissue array, 25 cases_50 cores |
|
261-Eur |
US Biomax |
tissue |
| PIT501 |
Normal pituitary gland tissue array, 25 cases_50 cores; ihc H&E, IHC anti-Vimentin |
|
281-Eur |
US Biomax |
tissue |
| PM2-ER |
ER Immunohistochemistry control tissue array, including TNM and pathology grade of breast cancer and IHC results of ER_Ki67_PR_Her-2, 10 cases_10 cores; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
tissue |
| PM2-PR |
PR Immunohistochemistry control tissue array, including TNM and pathology grade of breast cancer, 11 cases_11 cores; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
tissue |
| PR1001 |
Prostate cancer tissue array, including TNM and pathology grade, 25 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| PR1001 |
Prostate cancer tissue array, including TNM and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR207b |
High-density prostate cancer (1-4 grade) and normal prostate tissue array, 70 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| PR207b |
High-density prostate cancer (1-4 grade) and normal prostate tissue array, 70 cases_208 cores, replaced by PR208; ihc P504S confirmed |
|
487-Eur |
US Biomax |
tissue |
| PR208 |
High-density (70 cases_208 cores), multiple prostate cancer (1-4 grade), normal prostate and placenta tissue array |
|
456-Eur |
US Biomax |
tissue |
| PR208 |
High-density prostate cancer tissue array(1-4 grade), normal prostate and placenta (as control), 70 cases_208 cores, replacing PR207b; ihc P504S confirmed |
|
487-Eur |
US Biomax |
tissue |
| PR2085a |
High-density (114 cases_208 cores) prostate adenocarcinoma (I-4 grade) and normal prostate (from autopsy and cancer adjacent) tissue array |
|
456-Eur |
US Biomax |
tissue |
| PR2085a |
High-density (114 cases_208 cores) prostate adenocarcinoma (grade 1-4) and normal prostate (from autopsy and cancer adjacent) tissue array, replaced by PR2085b; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| PR2085b |
High-density (208 core) prostate adenocarcinoma (I-4 grade) and normal prostate (from autopsy and cancer adjacent) tissue BLOCK |
|
46914-Eur |
US Biomax |
tissue |
| PR2085b |
High-density prostate cancer tissue array, including TNM, pathology grade, Gleason grade and Gleason scores, 114 cases_208 cores, replacing PR2085a; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| PR241 |
Prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores, replaced by PR243 |
|
88-Eur |
US Biomax |
assays |
| PR241 |
Prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores, replaced by PR243; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| PR242 |
Multiple prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| PR242 |
Multiple prostate cancer test tissue array with unmatched normal adjacent tissue, 12 cases_24 cores, replaced by PR242a; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
105-Eur |
US Biomax |
assays |
| PR242a |
Prostate cancer tissue array with adjacent normal prostate tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing PR242; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| PR243 |
Prostate cancer and normal tissue array, with stage and grade info, 12 cases_24 cores, replacing PR241 |
|
88-Eur |
US Biomax |
tissue |
| PR243 |
Prostate cancer and normal tissue array, with stage and grade info, 12 cases_24 cores, replaced by PR243a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| PR243a |
Prostate cancer tissue array with adjacent normal prostate tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing PR243; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| PR481 |
Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases_48 cores, with grades, stages and Gleason scores |
|
160-Eur |
US Biomax |
tissue |
| PR481 |
Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases_48 cores, with grades, stages and Gleason scores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| PR482 |
Multiple prostate cancer tissue array with 4 normal tissue control from autopsy, with TNM and Gleason Scores, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| PR482 |
Multiple prostate cancer tissue array with 4 normal tissue control from autopsy, with TNM and Gleason Scores, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| PR483 |
Multiple prostate cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage, grade and Gleason score info |
|
160-Eur |
US Biomax |
tissue |
| PR483 |
Multiple prostate cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage, grade and Gleason score info, replaced by PR483a; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| PR483a |
Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores, replacing PR483; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| PR484 |
Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| PR631 |
Prostatic carcinoma tissue array with 3 cases of normal prostate tissue from autopsy, 33 cases_63 cores, with grade and Gleason scores |
|
266-Eur |
US Biomax |
tissue |
| PR631 |
Prostatic carcinoma tissue array with 3 cases of normal prostate tissue from autopsy, 33 cases_63 cores, with grade and Gleason scores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR632 |
Prostate cancer, hyperplasia with normal tissue array, with Gleason scores and stage information, 21cases_63 cores |
|
266-Eur |
US Biomax |
tissue |
| PR632 |
Prostate cancer, hyperplasia with normal tissue array, with Gleason scores and stage information, 21cases_63 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR633 |
Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 63 cases_63 cores, replacing PR8010; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR721 |
Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| PR721 |
Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR751 |
Prostate cancer, PIN (prostatic intraepithelial neoplasia) and hyperplasia tissue array, 75 cases_75 cores, with grade and Gleason's Score data |
|
266-Eur |
US Biomax |
tissue |
| PR751 |
Prostate cancer, PIN (prostatic intraepithelial neoplasia) and hyperplasia tissue array, 75 cases_75 cores, with grade and Gleason's Score data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR752 |
Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases_75 cores |
|
266-Eur |
US Biomax |
tissue |
| PR752 |
Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases_75 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR753 |
Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases_75 cores |
|
266-Eur |
US Biomax |
tissue |
| PR753 |
Prostate cancer and hyperplasia tissue array, including TNM and pathology grade, 75 cases_75 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR801 |
Prostate cancer tissue array with unmatched normal prostate tissue, 78 cases_80 cores, replaced by PR803 |
|
231-Eur |
US Biomax |
tissue |
| PR801 |
Prostate cancer tissue array with unmatched normal prostate tissue, 78 cases_80 cores, replaced by PR803; ihc Anti-Proliferating Cell Nuclear Antigen antibody confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR8010 |
Prostate cancer tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing PR802 |
|
266-Eur |
US Biomax |
tissue |
| PR8010 |
Prostate cancer tissue array, including TNM and pathology grade, 80 cases_80 cores, replaced by PR633; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR8011 |
Prostate disease spectrum tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing PR805 |
|
314-Eur |
US Biomax |
tissue |
| PR8011 |
Prostate disease spectrum tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing PR805; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR802 |
Prostate carcinoma tissue array, 80 cases_80 cores, no overlaps with PR801, replaced by PR8010 |
|
231-Eur |
US Biomax |
tissue |
| PR802 |
Prostate carcinoma tissue array, 80 cases_80 cores, no overlaps with PR801, replaced by PR8010; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR803 |
Prostate cancer tissue array with unmatched normal prostate tissue, 80 cases_80 cores, replacing PR801 |
|
231-Eur |
US Biomax |
tissue |
| PR803 |
Prostate cancer tissue array with unmatched normal prostate tissue, 80 cases_80 cores, replacing PR801, replaced by PR803a; ihc Anti-Proliferating Cell Nuclear Antigen (PCNA) confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR803a |
Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing PR803; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR804 |
Hyperplasia and carcinoma of prostate tissue array, 80 cases_80 cores, with grade and Gleason score information |
|
266-Eur |
US Biomax |
tissue |
| PR804 |
Hyperplasia and carcinoma of prostate tissue array, 80 cases_80 cores, with grade and Gleason score information; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR805 |
Prostate disease spectrum (prostatic cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| PR805 |
Prostate disease spectrum (prostatic cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR806 |
Prostate adenocarcinoma and normal tissue array with stage and Gleason Scores, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| PR806 |
Prostate adenocarcinoma and normal tissue array with stage and Gleason Scores, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR807 |
Prostate cancer, hyperplasia and normal tissue array, with stage (Gleason Scores) and grade info, 79 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| PR807 |
Prostate cancer, hyperplasia and normal tissue array, with stage (Gleason Scores) and grade info, 79 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR807a |
Prostate cancer, hyperplasia and normal tissue array, including TNM and pathology grade, 79 cases_80 cores, replacing PR807; ihc Anti-Prostate Specific Antigen (PSA) confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR808 |
Prostate cancer and normal tissue array, with TNM, stage, Gleason's score and grade info, 40 cases_80 cores, replacing BC19012 |
|
266-Eur |
US Biomax |
tissue |
| PR808 |
Prostate cancer and normal tissue array, with TNM, stage, Gleason's score and grade info, 40 cases_80 cores, replacing BC19012; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR809 |
Prostate cancer and hyperplasia tissue array, with stage and grade, 40 cases_80 cores, replacing BC19019 |
|
266-Eur |
US Biomax |
tissue |
| PR809 |
Prostate cancer and hyperplasia tissue array, with stage and grade, 40 cases_80 cores, replacing BC19019; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR951 |
Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases_95 cores, with TNM and Gleason scores, replaced by PR952; ihc Anti-PCNA confirmed |
|
487-Eur |
US Biomax |
tissue |
| PR952 |
Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases_95 cores, with TNM and Gleason scores, replaced by PR953 |
|
314-Eur |
US Biomax |
tissue |
| PR952 |
Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases_95 cores, with TNM and Gleason scores, replaced by PR953; ihc Anti-PCNA confirmed |
|
296-Eur |
US Biomax |
tissue |
| PR953 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replaced by PR954 |
|
456-Eur |
US Biomax |
tissue |
| PR953 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replaced by PR954; ihc Anti-Actin conf |
|
487-Eur |
US Biomax |
tissue |
| PR954 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replaced by PR955 |
|
456-Eur |
US Biomax |
tissue |
| PR954 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replaced by PR955; ihc Anti-Actin conf |
|
487-Eur |
US Biomax |
tissue |
| PR955 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replacing PR954 |
|
558-Eur |
US Biomax |
tissue |
| PR955 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replacing PR954 |
|
456-Eur |
US Biomax |
tissue |
| PR955 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replaced by PR956; ihc Anti-Actin conf |
|
487-Eur |
US Biomax |
tissue |
| PR956 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases_95 cores, replacing PR955; ihc Anti-Actin confir |
|
487-Eur |
US Biomax |
tissue |
| PRC481 |
Prostate cancer tissue array, 24 cases_48 cores |
|
225-Eur |
US Biomax |
tissue |
| PRC481 |
Prostate cancer tissue array, 24 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| PRC961 |
Prostate cancer tissue array, 48 cases_96 cores |
|
261-Eur |
US Biomax |
elisa |
| PRC961 |
Prostate cancer tissue array, 48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
281-Eur |
US Biomax |
elisa |
| PRF281 |
Prostate cancer frozen tissue array, with grade and Gleason scores and normal prostate tissue control, 28 cases_28 cores; ihc H&E and Anti-Actin confirmed |
|
742-Eur |
US Biomax |
tissue |
| RA161 |
Multiple organs normal tissue array of rat, 8 cases_16 cores |
|
189-Eur |
US Biomax |
tissue |
| RA161 |
Multiple organs normal tissue array of rat, 8 cases_16 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| RA162 |
Multiple organs normal tissue array of rat, 8 cases_16 cores |
|
189-Eur |
US Biomax |
tissue |
| RA162 |
Multiple organs normal tissue array of rat, 8 cases_16 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| RAT901 |
Rat multiple organs, normal tissue array, 22 cases_90 cores, replacing BR01013 |
|
231-Eur |
US Biomax |
tissue |
| RAT901 |
Rat multiple organs, normal tissue array, 22 cases_90 cores, replacing BR01013; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| RE1021 |
Rectum cancer tissue array, including TNM, clinical stage and pathology grade, 102 cases_102 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
recombinant |
| RE1501 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
recombinant |
| RE1501 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
recombinant |
| RE1501 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
recombinant |
| RE1502 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
recombinant |
| RE1502 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
recombinant |
| RE1502 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
recombinant |
| RE1503 |
Rectum cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
recombinant |
| RE2001 |
Rectum cancer high-density (200 core) tissue array, 192 cases_208 cores |
|
397-Eur |
US Biomax |
recombinant |
| RE2001 |
Rectum cancer high-density (200 core) tissue array, 192 cases_208 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
382-Eur |
US Biomax |
recombinant |
| RE2081 |
Rectum disease spectrum (rectal cancer progression) tissue array, 98 cases_208 cores |
|
456-Eur |
US Biomax |
recombinant |
| RE2081 |
Rectum disease spectrum (rectal cancer progression) tissue array, 98 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
recombinant |
| RE2161 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
558-Eur |
US Biomax |
recombinant |
| RE2161 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
456-Eur |
US Biomax |
recombinant |
| RE2161 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
recombinant |
| RE241 |
Rectal cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
recombinant |
| RE241 |
Rectal cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
recombinant |
| RE242 |
Multiple rectal cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
recombinant |
| RE242 |
Multiple rectal cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
recombinant |
| RE481 |
Tissue array of rectal adenocarcinoma and matched adjacent tissue, 12 cases_48 cores |
|
160-Eur |
US Biomax |
recombinant |
| RE481 |
Tissue array of rectal adenocarcinoma and matched adjacent tissue, 12 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
recombinant |
| RE482 |
Multiple rectal cancer tissue array with normal tissue, stage and grade data, 48 cases_48 cores |
|
160-Eur |
US Biomax |
recombinant |
| RE482 |
Multiple rectal cancer tissue array with normal tissue, stage and grade data, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
recombinant |
| RE483 |
Rectum adenocarcinoma tissue array with matched adjacent rectum tissue, including TNM and pathology grade, 16 cases_48 cores |
|
188-Eur |
US Biomax |
recombinant |
| RE483 |
Rectum adenocarcinoma tissue array with matched adjacent rectum tissue, including TNM and pathology grade, 16 cases_48 cores |
|
160-Eur |
US Biomax |
recombinant |
| RE483 |
Rectum adenocarcinoma tissue array with matched adjacent rectum tissue, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
recombinant |
| RE601 |
Colon and rectum cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases_60 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE601 |
Colon and rectum cancer tissue array, including TNM, clinical stage and pathology grade, 60 cases_60 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
recombinant |
| RE641 |
Rectum cancer tissue array, 64 cases_66 cores, with TNM data |
|
----Eur |
US Biomax |
recombinant |
| RE721 |
Normal rectum and cancer tissue array, 22 cases_72 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE721 |
Normal rectum and cancer tissue array, 22 cases_72 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
recombinant |
| RE722 |
Rectal cancer tissue array with matched adjacent normal tissue, including stage and grade info, 24 cases_72 cores, replacing BC06022 |
|
231-Eur |
US Biomax |
recombinant |
| RE722 |
Rectal cancer tissue array with matched adjacent normal tissue, including stage and grade info, 24 cases_72 cores, replacing BC06022; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
recombinant |
| RE723 |
Rectal adenocarcinoma (grade 2) tissue array, with stage, TNM and grade, 24 cases_72 cores, replacing BS06031 |
|
231-Eur |
US Biomax |
recombinant |
| RE723 |
Rectal adenocarcinoma (grade 2) tissue array, with stage, TNM and grade, 24 cases_72 cores, replacing BS06031; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
recombinant |
| RE724 |
Rectal adenocarcinoma (grade 3) tissue array, with stage, TNM and grade info, 24 cases_72 cores, replacing BS06041 |
|
231-Eur |
US Biomax |
recombinant |
| RE724 |
Rectal adenocarcinoma (grade 3) tissue array, with stage, TNM and grade info, 24 cases_72 cores, replacing BS06041; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
recombinant |
| RE801 |
Rectal cancer tissue array, with matched adjacent normal tissue, 40 cases_80 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE801 |
Rectal cancer tissue array, with matched adjacent normal tissue, 40 cases_80 cores; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
recombinant |
| RE802 |
Rectal normal adjacent tissue and cancer tissue array, 74 cases_80 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE802 |
Rectal normal adjacent tissue and cancer tissue array, 74 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
recombinant |
| RE803 |
Rectal cancer and normal tissue array, with TNM and grade info, 73 cases_80 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE803 |
Rectal cancer and normal tissue array, with TNM and grade info, 73 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
recombinant |
| RE804 |
Rectal disease spectrum (rectum cancer progression) tissue array, 75 cases_80 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE804 |
Rectal disease spectrum (rectum cancer progression) tissue array, 75 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
recombinant |
| RE811 |
Rectal cancer tissue array with normal tissues from autopsy, with TNM and grade data, 80 cases_80 cores |
|
231-Eur |
US Biomax |
recombinant |
| RE811 |
Rectal cancer tissue array with normal tissues from autopsy, with TNM and grade data, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
recombinant |
| RE812 |
Rectal cancer tissue array with normal tissue from autopsy, 40 cases_80 cores, with grade and stage data |
|
231-Eur |
US Biomax |
recombinant |
| RE812 |
Rectal cancer tissue array with normal tissue from autopsy, 40 cases_80 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
recombinant |
| RE961 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
321-Eur |
US Biomax |
elisa |
| RE961 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
266-Eur |
US Biomax |
elisa |
| RE961 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| RE962 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
321-Eur |
US Biomax |
elisa |
| RE962 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
266-Eur |
US Biomax |
elisa |
| RE962 |
Rectum adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| REC1021 |
Rectum cancer tissue array, 102 cases_102 cores |
|
----Eur |
US Biomax |
recombinant |
| REC1021 |
Rectum cancer tissue array, 102 cases_102 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
recombinant |
| REC1501 |
Rectal cancer mid-density tissue array, non-overlapping with REC1502 or REC1503, 75 cases_150 cores |
|
----Eur |
US Biomax |
recombinant |
| REC1501 |
Rectal cancer mid-density tissue array, non-overlapping with REC1502 or REC1503, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
recombinant |
| REC1502 |
Rectal cancer mid-density tissue array, non-overlapping with REC1501 or REC1503, 75 cases_150 cores |
|
----Eur |
US Biomax |
recombinant |
| REC1502 |
Rectal cancer mid-density tissue array, non-overlapping with REC1501 or REC1503, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
recombinant |
| REC1503 |
Rectum cancer mid-density tissue array, non-overlapping with REC1501 or REC1502, 75 cases_150 cores |
|
----Eur |
US Biomax |
recombinant |
| REC1503 |
Rectum cancer mid-density tissue array, non-overlapping with REC1501 or REC1502, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
recombinant |
| REC2281 |
Rectum cancer high density tissue array, 228 cases_228 cores |
|
----Eur |
US Biomax |
recombinant |
| REC481 |
Rectum cancer and normal tissue array, 16 cases_48 cores |
|
----Eur |
US Biomax |
recombinant |
| REC481 |
Rectum cancer and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
205-Eur |
US Biomax |
recombinant |
| REC961 |
Rectum cancer and normal tissue array, non-overlapping with REC962, 48 cases_96 cores |
|
----Eur |
US Biomax |
elisa |
| REC961 |
Rectum cancer and normal tissue array, non-overlapping with REC962, 48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| REC962 |
Rectal cancer and normal tissue array, non-overlapping with REC961,48 cases_96 cores |
|
----Eur |
US Biomax |
elisa |
| REC962 |
Rectal cancer and normal tissue array, non-overlapping with REC961,48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| RhFDA1 |
FDA normal organ tissue array of rhesus monkey, 99 cases_99 cores |
|
278-Eur |
US Biomax |
tissue |
| RhFDA1 |
FDA normal organ tissue array of rhesus monkey, 99 cases_99 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| RhFDA2 |
FDA normal organ tissue array (TMA) block of rhesus monkey, 99 cases_99 cores |
|
23184-Eur |
US Biomax |
tissue |
| RhFDA2 |
FDA normal organ tissue array (TMA) block of rhesus monkey, 99 cases_99 cores; ihc Anti-Actin confirmed |
|
18780-Eur |
US Biomax |
tissue |
| RS321 |
Tissue microarray of normal human respiratory tract, 32 cases_32 cores |
|
266-Eur |
US Biomax |
tissue |
| RS321 |
Tissue microarray of normal human respiratory tract, 32 cases_32 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
296-Eur |
US Biomax |
tissue |
| SF961 |
Soft tissue tumor tissue array, including TNM and clinical stage, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
elisa |
| SFD241 |
Human soft tissue disease tissue array, 24 cases_24 cores |
|
166-Eur |
US Biomax |
tissue |
| SFD241 |
Human soft tissue disease tissue array, 24 cases_24 cores; ihc H&E, IHC anti- Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| SFT961 |
Soft tissue tumor tissue array, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| SFT961 |
Soft tissue tumor tissue array, 48 cases_96 cores; ihc H&E, IHC anti-vimentin |
|
238-Eur |
US Biomax |
elisa |
| SK208 |
Skin cancer and normal tissue high density (69 cases_208 core) tissue microarray |
|
456-Eur |
US Biomax |
tissue |
| SK208 |
Skin cancer and normal tissue high density (69 cases_208 core) tissue microarray; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| SK2081 |
Skin disease spectrum (dermatic cancer progression) tissue array, 102 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| SK2081 |
Skin disease spectrum (dermatic cancer progression) tissue array, 102 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| SK241 |
Skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| SK241 |
Skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| SK242 |
Multiple skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| SK242 |
Multiple skin cancer test tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| SK243 |
Age grouped female skin tissue array, 12 cases_24 cores, replaced by SK244 |
|
231-Eur |
US Biomax |
tissue |
| SK243 |
Age grouped female skin tissue array, 12 cases_24 cores, replaced by SK244; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| SK244 |
Age grouped female skin tissue array, 12 cases_24 cores, replacing SK243 |
|
99-Eur |
US Biomax |
tissue |
| SK244 |
Age grouped female skin tissue array, 12 cases_24 cores, replacing SK243 |
|
88-Eur |
US Biomax |
tissue |
| SK244 |
Age grouped female skin tissue array, 12 cases_24 cores, replacing SK243; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| SK245 |
Skin disease tissue array, including TNM, clinical stage and pathology grade, 24 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| SK481 |
Skin cancer tissue array with corresponding (unmatched) normal adjacent tissues, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| SK481 |
Skin cancer tissue array with corresponding (unmatched) normal adjacent tissues, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| SK482 |
Multiple skin cancer tissue array with 4 normal tissue control from autopsy, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| SK482 |
Multiple skin cancer tissue array with 4 normal tissue control from autopsy, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| SK483 |
Multiple skin squamous cell carcinoma tissue array with normal tissues control from autopsy, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| SK483 |
Multiple skin squamous cell carcinoma tissue array with normal tissues control from autopsy, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| SK484 |
Skin basal cell cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| SK484 |
Skin basal cell cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| SK721 |
Skin cancer and normal tissue array, with stage and grade info, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| SK721 |
Skin cancer and normal tissue array, with stage and grade info, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| SK801 |
Skin cancer tissue array, with matched or unmatched adjacent normal tissue, 80 cases_73 cores, replaced by SK801b |
|
278-Eur |
US Biomax |
tissue |
| SK801 |
Skin cancer tissue array, with matched or unmatched adjacent normal tissue, 80 cases_73 cores, replaced by SK801b; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| SK801b |
Skin squamous cell carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing SK801 |
|
321-Eur |
US Biomax |
tissue |
| SK801b |
Skin squamous cell carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing SK801 |
|
266-Eur |
US Biomax |
tissue |
| SK801b |
Skin squamous cell carcinoma tissue array, including TNM and pathology grade, 80 cases_80 cores, replacing SK801; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| SK802 |
Skin squamous cell carcinoma (SCC) tissue array, 80 cases_80 cores, no overlaps with SK801 |
|
231-Eur |
US Biomax |
tissue |
| SK802 |
Skin squamous cell carcinoma (SCC) tissue array, with pathology grade and clinical stage, 80 cases_80 cores, no overlaps with SK801; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| SK803 |
Skin basal cell cancer (BCC) and benign nevus tissue array, 52 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| SK803 |
Skin basal cell cancer (BCC) and benign nevus tissue array, 52 cases_100 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| SK804 |
Skin cancerous and normal tissue array, with stage and grade info, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| SK804 |
Skin cancerous and normal tissue array, with stage and grade info, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| SK805 |
Skin disease spectrum (dermatic cancer progression) tissue array, 79 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| SK805 |
Skin disease spectrum (dermatic cancer progression) tissue array, 79 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| SK961 |
Skin tumor tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| SKD241 |
Skin disease tissue array, 24 cases_24 cores |
|
166-Eur |
US Biomax |
tissue |
| SKD241 |
Skin disease tissue array, 24 cases_24 cores; ihc H&E, IHC anti-Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| SKT1501 |
Skin cancer mid-density tissue array, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| SKT1501 |
Skin cancer mid-density tissue array, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| SKT961 |
Skin cancer and normal tissue array, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| SKT961 |
Skin cancer and normal tissue array, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| SLC601 |
Stomach cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases_60 cores |
|
266-Eur |
US Biomax |
tissue |
| SLC601 |
Stomach cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases_60 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| SM208 |
Small intestine cancer, metastatic lymph nodes and normal tissue high density tissue microarray, 69 cases_208 core, with stage and grade data |
|
456-Eur |
US Biomax |
assays |
| SM208 |
Small intestine cancer, metastatic lymph nodes and normal tissue high density tissue microarray, 69 cases_208 core, with stage and grade data; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
assays |
| SM2081 |
Small intestine disease (cancer progression) spectrum tissue array, 95 cases_208 cores |
|
456-Eur |
US Biomax |
assays |
| SM2081 |
Small intestine disease (cancer progression) spectrum tissue array, 95 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
assays |
| SM241 |
Small intestine adenocarcinoma tissue array (including normal adjacent tissue), 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| SM241 |
Small intestine adenocarcinoma tissue array (including normal adjacent tissue), 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| SM242 |
Small intestine adenocarcinoma with normal tissue array, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| SM242 |
Small intestine adenocarcinoma with normal tissue array, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| SM801 |
Small intestine carcinoma and normal tissue array, 77 cases_80 cores |
|
266-Eur |
US Biomax |
assays |
| SM801 |
Small intestine carcinoma and normal tissue array, 77 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| SM802 |
Small intestine disease spectrum (small intestine cancer progression) tissue array, with grade, stage and TNM data, 72 cases_80 cores |
|
266-Eur |
US Biomax |
assays |
| SM802 |
Small intestine disease spectrum (small intestine cancer progression) tissue array, with grade, stage and TNM data, 72 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| SO1001 |
Peripheral nerve disease spectrum (peripheroneural cancer progression) tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| SO1001 |
Peripheral nerve disease spectrum (peripheroneural cancer progression) tissue array, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| SO208 |
Soft tissue sarcoma high density tissue array with normal controls, 69 cases_208 cores, with grade and stage data |
|
456-Eur |
US Biomax |
tissue |
| SO208 |
Soft tissue sarcoma high density tissue array with normal controls, 69 cases_208 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| SO2081 |
Muscle disease spectrum (smooth muscle and striated muscle cancer progression) tissue array, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| SO2081 |
Muscle disease spectrum (smooth muscle and striated muscle cancer progression) tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| SO2083 |
Adipose tissue disease spectrum (adipose tumor progression) tissue array, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| SO2083 |
Adipose tissue disease spectrum (adipose tumor progression) tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| SO2084 |
Fibrous tissue disease spectrum (fibrous tissue cancer progression) tissue array, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| SO2084 |
Fibrous tissue disease spectrum (fibrous tissue cancer progression) tissue array, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| SO241 |
Soft tissue cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| SO241 |
Soft tissue cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Vimentin (Vim) confirmed |
|
105-Eur |
US Biomax |
tissue |
| SO481 |
Soft tissue cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with TNM information |
|
160-Eur |
US Biomax |
tissue |
| SO481 |
Soft tissue cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with TNM information; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| SO482 |
Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| SO482 |
Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO751 |
Leiomyosarcoma and rhabdomyosarcoma tissue array, including TNM and clinical stage, 39 cases_75 cores, replacing BC24021; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO801 |
Soft tissue cancer tissue array, with matched or unmatched adjacent normal tissue, 78 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| SO801 |
Soft tissue cancer tissue array, with matched or unmatched adjacent normal tissue, 78 cases_80 cores; ihc Anti-Vimentin (Vim) confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO8010 |
Blood vessel disease spectrum (blood vessel cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| SO8010 |
Blood vessel disease spectrum (blood vessel cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| SO8011 |
Smooth muscle and striated muscle disease spectrum (cancer progression) tissue array, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| SO8011 |
Smooth muscle and striated muscle disease spectrum (cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| SO8012 |
Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 40 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| SO8012 |
Soft tissue cancer tissue array, with normal tissue, including TNM and pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO802 |
Malignant fibrohistiocytoma tissue array, 80 cases_80 cores; ihc CD68 confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO803 |
Liparomphalus and liposarcoma tissue array, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| SO803 |
Liparomphalus and liposarcoma tissue array, 80 cases_80 cores; ihc Vim confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO804 |
Leiomyosarcoma tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| SO804 |
Leiomyosarcoma tissue array, 80 cases_80 cores; ihc SMA confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO805 |
Neurilemmoma of peripheral nerve tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| SO805 |
Neurilemmoma of peripheral nerve tissue array, 80 cases_80 cores; ihc Anti-S-100 confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO806 |
Leiomyoma of uterus tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| SO806 |
Leiomyoma of uterus tissue array, 80 cases_80 cores; ihc Smooth muscle actin (SMA) confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO807 |
Interstitialoma of gastrointestinal tract tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
assays |
| SO807 |
Interstitialoma of gastrointestinal tract tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
assays |
| SO808 |
Schwannoma (neurilemmoma or neurinoma) of central nerve tissue array, 30 cases_60 cores |
|
266-Eur |
US Biomax |
tissue |
| SO808 |
Schwannoma (neurilemmoma or neurinoma) of central nerve tissue array, 30 cases_60 cores; ihc Anti-S100 confirmed |
|
267-Eur |
US Biomax |
tissue |
| SO809 |
Sarcoma tissue array of soft tissue (adipose, fibrous tissue, smooth muscles and striated muscles), 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| SO809 |
Sarcoma tissue array of soft tissue (adipose, fibrous tissue, smooth muscle and skeletal muscle), 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| SP1001 |
Spleen disease spectrum (splenic cancer progression) tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| SP1001 |
Spleen disease spectrum (splenic cancer progression) tissue array, 50 cases_100 cores; ihc Anti-actin confirmed |
|
401-Eur |
US Biomax |
tissue |
| SP241 |
Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| SP241 |
Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Leukocyte Common Antigen (LCA) confirmed |
|
105-Eur |
US Biomax |
tissue |
| SP242 |
Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| SP242 |
Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Leukocyte Common Antigen (LCA) confirmed |
|
105-Eur |
US Biomax |
tissue |
| SP481 |
Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| SP481 |
Spleen cancer tissue array with unmatched normal adjacent tissues, 12 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| SP482 |
Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 28 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| SP482 |
Multiple spleen cancer tissue array with unmatched normal adjacent tissues, 28 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| ST1001 |
Stomach disease spectrum (stomach cancer progression) tissue array, 100 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| ST1001 |
Stomach disease spectrum (stomach cancer progression) tissue array, 100 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST1002 |
Stomach carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
231-Eur |
US Biomax |
|
| ST1002 |
Stomach carcinoma for antibody screening array, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
|
| ST1003 |
Stomach cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores |
|
231-Eur |
US Biomax |
tissue |
| ST1003 |
Stomach cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST1004 |
Stomach adenocarcinoma with matched adjacent tissue array, including TNM and pathology grade, 55 cases_100 cores, replacing BC01114; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| ST1501 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| ST1501 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| ST1501 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| ST1502 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
321-Eur |
US Biomax |
tissue |
| ST1502 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores |
|
266-Eur |
US Biomax |
tissue |
| ST1502 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| ST1503 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| ST1921 |
Middle-advanced stage stomach cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores |
|
456-Eur |
US Biomax |
elisa |
| ST1921 |
Middle-advanced stage stomach cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
elisa |
| ST2001 |
Stomach cancer high density (200 cases_200 cores) tissue array, including TNM and pathology grade |
|
397-Eur |
US Biomax |
tissue |
| ST2001 |
Stomach cancer high density (200 cases_200 cores) tissue array, including TNM and pathology grade, replaced by ST2091; ihc Anti-Cytokeratin (CK) confirmed |
|
429-Eur |
US Biomax |
tissue |
| ST208 |
Stomach cancer and normal tissue high density (70 cases_208 core) tissue microarray |
|
456-Eur |
US Biomax |
tissue |
| ST208 |
Stomach cancer and normal tissue high density (70 cases_208 core) tissue microarray; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ST2082 |
High-density stomach cancer tissue array with normal tissues, with stage and grade info, 104 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ST2082 |
High-density stomach cancer tissue array with normal tissues, with stage and grade info, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| ST2083 |
Stomach cancer and normal stomach tissue array with stage and grade, 69 cases_208 cores |
|
456-Eur |
US Biomax |
tissue |
| ST2083 |
Stomach cancer and normal stomach tissue array with stage and grade, 69 cases_208 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ST2091 |
Stomach cancer tissue array with adjacent normal stomach tissue, including TNM and clinical stage, 208 cases_208 cores, replacing ST2001; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ST2161 |
Stomach cancer tissue array, including TNM and pathology grade, 216 cases_216 cores |
|
456-Eur |
US Biomax |
tissue |
| ST2161 |
Stomach cancer tissue array, including TNM and pathology grade, 216 cases_216 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| ST241 |
Stomach cancer test tissue array with self-matching normal adjacent tissues, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| ST241 |
Stomach cancer test tissue array with self-matching normal adjacent tissues, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| ST242 |
Multiple stomach cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| ST242 |
Multiple stomach cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| ST481 |
Stomach cancer tissue array with corresponding (self-matching) normal adjacent tissues (12 cases_48 cores), with stage and grade info |
|
160-Eur |
US Biomax |
tissue |
| ST481 |
Stomach cancer tissue array with corresponding (self-matching) normal adjacent tissues (12 cases_48 cores), with stage and grade info; ihc Anti-Actin confirmed |
|
162-Eur |
US Biomax |
tissue |
| ST482 |
Multiple stomach cancer tissue array with 4 normal tissues control from autopsy (24 caeas_48 cores), with stage and grade info |
|
160-Eur |
US Biomax |
tissue |
| ST482 |
Multiple stomach cancer tissue array with 4 normal tissues control from autopsy (24 caeas_48 cores), with stage and grade info; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| ST483 |
Multiple stomach cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade info |
|
160-Eur |
US Biomax |
tissue |
| ST483 |
Multiple stomach cancer tissue array with normal tissue control from autopsy, 48 cases_48 cores, with stage and grade info, replaced by ST483b; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| ST483a |
Stomach cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores, replacing ST483; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
tissue |
| ST483b |
Stomach cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_48 cores, replacing ST483; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| ST484 |
Stomach cancer tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| ST484 |
Stomach cancer tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| ST485 |
Stomach cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| ST485 |
Stomach cancer and matched adjacent tissue array, including TNM and pathology grade, 16 cases_48 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST721 |
Stomach adenocarcinoma and normal tissue array with TNM and pathology grade data, 24 cases_72 cores, replacing BC01011 |
|
231-Eur |
US Biomax |
tissue |
| ST721 |
Stomach adenocarcinoma and normal tissue array with TNM and pathology grade data, 24 cases_72 cores, replacing BC01011; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST722 |
Stomach adenocarcinoma with self-matched adjacent and normal tissue array, with stage and grade info, 24 cases_72 cores |
|
231-Eur |
US Biomax |
tissue |
| ST722 |
Stomach adenocarcinoma with self-matched adjacent and normal tissue array, with stage and grade info, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST723 |
Stomach poorly differentiated adenocarcinoma tissue array with adjacent normal control, stage and grade info, 24 cases_72 cores, replacing BS01042 |
|
231-Eur |
US Biomax |
tissue |
| ST723 |
Stomach poorly differentiated adenocarcinoma tissue array with adjacent normal control, stage and grade info, 24 cases_72 cores, replacing BS01042; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST781 |
Stomach adenocarcinoma (grade I-III) tissue array with self-matched adjacent and normal tissues, 26 cases_78 cores |
|
231-Eur |
US Biomax |
tissue |
| ST781 |
Stomach adenocarcinoma (grade I-III) tissue array with self-matched adjacent and normal tissues, 26 cases_78 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST801 |
Stomach cancer tissue array, with matched adjacent normal tissue, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST801 |
Stomach cancer tissue array, with matched adjacent normal tissue, 40 cases_80 cores, replaced by ST801a; ihc Anti-Cytokeratin (High MW) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST8011 |
Gastric cardia disease spectrum (cardia cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| ST8011 |
Gastric cardia disease spectrum (cardia cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST8012 |
Stomach adenocarcinoma and normal tissue array, with stage and grade information, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST8012 |
Stomach adenocarcinoma and normal tissue array, with stage and grade information, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST8013 |
Stomach cancer metastatic tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST8013 |
Stomach cancer metastatic tissue array, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST8014 |
Stomach cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST8014 |
Stomach cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST8015 |
Stomach cancer and adjacent normal tissue array, including TNM and pathology grade, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST8015 |
Stomach cancer and adjacent normal tissue array, including TNM and pathology grade, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST801a |
Stomach cancer tissue array with matched adjacent normal stomach tissue, including TNM and clinical stage, 40 cases_80 cores, replacing ST801; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST802 |
Stomach carcinoma (multi-tissue combined panel) tissue array, 78 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST802 |
Stomach carcinoma (multi-tissue combined panel) tissue array, 78 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST803 |
Stomach adenocarcinoma tissue array, in various type, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST803 |
Stomach adenocarcinoma tissue array, in various type, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST804 |
Stomach adenocarcinoma tissue array, mucous type, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST804 |
Stomach adenocarcinoma tissue array, mucous type, 40 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST805 |
Stomach cancer progression tissue array (containing normal, inflammation, hyperplasia and adenocarcinoma), 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST805 |
Stomach cancer progression tissue array (containing normal, inflammation, hyperplasia and adenocarcinoma), 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST806 |
Gastritis, stomach hyperplasia and dysplasia, 80 cases_80 cores |
|
231-Eur |
US Biomax |
|
| ST806 |
Gastritis, stomach hyperplasia and dysplasia, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
rat |
| ST807 |
Stomach carcinoma (multi-tissue combined panel) tissue array (replacing BC01014), 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST807 |
Stomach carcinoma (multi-tissue combined panel) tissue array (replacing BC01014), 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| ST808 |
Stomach adenocarcinoma and normal tissue array, 80 cases_80 cores, replacing BS01032 |
|
231-Eur |
US Biomax |
tissue |
| ST808 |
Stomach adenocarcinoma and normal tissue array, 80 cases_80 cores, replacing BS01032; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST810 |
Stomach cancer with matched lymph node metastasis tissue array, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST810 |
Stomach cancer with matched lymph node metastasis tissue array, 40 cases_80 cores; ihc Anti-Cytokeratin (Low-MW) confirmed |
|
228-Eur |
US Biomax |
tissue |
| ST811 |
Stomach cancer tissue array with normal tissues from autopsy, 80 cases_80 cores, with grade and stage data |
|
231-Eur |
US Biomax |
tissue |
| ST811 |
Stomach cancer tissue array with normal tissues from autopsy, 80 cases_80 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST812 |
Stomach cancer tissue array with normal tissues from autopsy, with clinical stage (TNM) and pathology grade info, 40 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| ST812 |
Stomach cancer tissue array with normal tissues from autopsy, with clinical stage (TNM) and pathology grade info, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| ST961 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
321-Eur |
US Biomax |
elisa |
| ST961 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores |
|
266-Eur |
US Biomax |
elisa |
| ST961 |
Stomach adenocarcinoma tissue array, including TNM and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
elisa |
| ST962 |
Stomach cancer tissue array, including clinical stage, TNM and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
elisa |
| ST991 |
Stomach adenocarcinoma (combination of margin and normal tissue) tissue array, 33 cases_99 cores |
|
231-Eur |
US Biomax |
tissue |
| ST991 |
Stomach adenocarcinoma (combination of margin and normal tissue) tissue array, 33 cases_99 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| STC1021 |
Stomach cancer tissue array with normal and gastritis tissue control, having grade and stage info, 102 cases_102 cores |
|
225-Eur |
US Biomax |
tissue |
| STC1021 |
Stomach cancer tissue array with normal and gastritis tissue control, having grade and stage info, 102 cases_102 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| STC1501 |
Stomach cancer mid-density tissue array, non-overlapping with STC1502 or STC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| STC1501 |
Stomach cancer mid-density tissue array, non-overlapping with STC1502 or STC1503, 75 cases_150 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| STC1502 |
Human stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1503, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| STC1502 |
Human stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1503, 75 cases_150 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| STC1503 |
Stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1502, 75 cases_150 cores |
|
225-Eur |
US Biomax |
tissue |
| STC1503 |
Stomach cancer mid-density tissue array, non-overlapping with STC1501 or STC1502, 75 cases_150 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
238-Eur |
US Biomax |
tissue |
| STC2281 |
Stomach cancer high density tissue array, 228 cases_228 cores |
|
----Eur |
US Biomax |
tissue |
| STC481 |
Stomach cancer and normal tissue array, 16 cases_48 cores |
|
166-Eur |
US Biomax |
tissue |
| STC481 |
Stomach cancer and normal tissue array, 16 cases_48 cores; ihc H&E, IHC anti-Cytokeratin |
|
205-Eur |
US Biomax |
tissue |
| STC961 |
Stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| STC961 |
Stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| STC962 |
Human stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases_96 cores |
|
189-Eur |
US Biomax |
elisa |
| STC962 |
Human stomach cancer and normal tissue array, non-overlapping with STC962, 48 cases_96 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| T001 |
Embryonal tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T001 |
Embryonal tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases_24 cores, replaced by T001a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T0010 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T0010 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T0011 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T0011 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T0012 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T0012 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T0013 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T0013 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T0014 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T0014 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T001a |
Embryonal tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases_24 cores, replacing T001; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T002 |
Endocrine organ cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T002 |
Endocrine organ cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T003 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T003 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T004 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T004 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T005 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T005 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T006 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T006 |
Multiple organ cancer and normal tissue array, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T007 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T007 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T008 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T008 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T009 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T009 |
Multiple organ cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T011 |
Stomach cancer test tissue array, with TNM and grade info, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T011 |
Stomach cancer test tissue array, with TNM and grade info, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T012 |
Stomach cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T012 |
Stomach cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T013 |
Stomach cancer test tissue array, with normal stomach tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T013 |
Stomach cancer test tissue array, with normal stomach tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T014 |
Stomach cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T021 |
Esophageal cancer tissue array, with normal tissues, TNM and grade info, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T021 |
Esophageal cancer tissue array, with normal tissues, TNM and grade info, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
90-Eur |
US Biomax |
tissue |
| T022 |
Esophageal cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T022 |
Esophageal cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| T023 |
Esophagus carcer test tissue array, with normal esophagus tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T023 |
Esophagus carcer test tissue array, with normal esophagus tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T024 |
Esophageal cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T031 |
Liver cancer test tissue array with normal liver tissues, with TNM, stage and grade info, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T031 |
Liver cancer test tissue array with normal liver tissues, with TNM, stage and grade info, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
90-Eur |
US Biomax |
assays |
| T032 |
Liver cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T032 |
Liver cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T032a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T032a |
Liver tumor tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T032; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T033 |
Liver cancer test tissue array, with normal liver tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T033 |
Liver cancer test tissue array, with normal liver tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| T034 |
Liver cancer test tissue array (4x (2x3) array)???including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T041 |
Lung cancer test tissue array, with normal lung control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T041 |
Lung cancer test tissue array, with normal lung control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
90-Eur |
US Biomax |
assays |
| T042 |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T044 |
|
88-Eur |
US Biomax |
assays |
| T042 |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T044; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| T043 |
Lung cancer test tissue array, with normal lung tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T043 |
Lung cancer test tissue array, with normal lung tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| T044 |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T045 |
|
88-Eur |
US Biomax |
assays |
| T044 |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T045; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T045 |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T045b |
|
88-Eur |
US Biomax |
assays |
| T045 |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T045c; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T045b |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T045 |
|
99-Eur |
US Biomax |
assays |
| T045b |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T045 |
|
88-Eur |
US Biomax |
assays |
| T045b |
Lung cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T045; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T045c |
Lung cancer test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases_24 cores, replacing T045; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T046 |
Lung cancer test tissue array (4x (2x3)array)???including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T047 |
Non-small cell lung cancer test tissue array (4x (2x3)array)???including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T051 |
Colon cancer test tissue array, with normal colon tissues as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T051 |
Colon cancer test tissue array, with normal colon tissues as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
90-Eur |
US Biomax |
assays |
| T052 |
Colon cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T052 |
Colon cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| T053 |
Colon cancer test tissue array, with normal colon tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T053 |
Colon cancer test tissue array, with normal colon tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T054 |
Colon tumor test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases_24 cores, replacing T052 |
|
88-Eur |
US Biomax |
assays |
| T054 |
Colon tumor test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases_24 cores, replaced by T054a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T054a |
Colon cancer tissue array with normal colon tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T054; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T055 |
Colon cancer test tissue array (4x (2x3) array)???including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T061 |
Rectal cancer test tissue array, with normal rectal control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
recombinant |
| T061 |
Rectal cancer test tissue array, with normal rectal control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
recombinant |
| T063 |
Rectum cancer test tissue array, with normal rectum tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
recombinant |
| T063 |
Rectum cancer test tissue array, with normal rectum tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
recombinant |
| T071 |
Kidney cancer test tissue array, with normal renal tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T071 |
Kidney cancer test tissue array, with normal renal tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T072 |
Kidney cancer test tissue array, with normal tissue, TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T072 |
Kidney cancer test tissue array, with normal tissue, TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T073 |
Kidney cancer test tissue array, with normal kidney tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T073 |
Kidney cancer test tissue array, with normal kidney tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T074 |
Kidney cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T081 |
Breast cancer test tissue array, with normal breast tissues as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T085 |
|
88-Eur |
US Biomax |
assays |
| T081 |
Breast cancer test tissue array, with normal breast tissues as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T085; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T082 |
Breast cancer test tissue array, with normal tissue as control, including TNM, stage and grade, 12 cases_24 cores, replaced by T084 |
|
88-Eur |
US Biomax |
assays |
| T082 |
Breast cancer test tissue array, with normal tissue as control, including TNM, stage and grade, 12 cases_24 cores, replaced by T084; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T083 |
Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T083 |
Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores, replaced by T087; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T084 |
Breast cancer test tissue array, with normal control tissue, with TNM, Grade and Stage, 12 cases_24 cores, replacing T082 |
|
88-Eur |
US Biomax |
assays |
| T084 |
Breast cancer test tissue array, with normal control tissue, with TNM, Grade and Stage, 12 cases_24 cores, replaced by T086a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T085 |
Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T088 |
|
88-Eur |
US Biomax |
assays |
| T085 |
Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T088; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T086 |
Breast cancer test tissue array, with normal tissue, including TNM and pathology grade, 12 cases_24 cores, replacing T084 |
|
88-Eur |
US Biomax |
assays |
| T086 |
Breast cancer test tissue array, with normal tissue, including TNM and pathology grade, 12 cases_24 cores, replacing T084, replaced by T086a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T086a |
Breast invasive ductal carcinoma test tissue array, with normal tissue, including TNM and pathology grade, 12 cases_24 cores, replaced by T086b; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T086b |
Breast cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T086a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T087 |
Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores, replaced by T087a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T087a |
Breast cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores, replacing T087; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T088 |
Breast cancer tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases_24 cores, replacing T085 |
|
88-Eur |
US Biomax |
tissue |
| T088 |
Breast cancer tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases_24 cores, replacing T085; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T089 |
Breast cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T091 |
Endometrial cancer test tissue array, with normal endometriual tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T091 |
Endometrial cancer test tissue array, with normal endometriual tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T092 |
Endometrium cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T092 |
Endometrium cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T093 |
Uterus cancer test tissue array, with normal endometrial tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T093 |
Uterus cancer test tissue array, with normal endometrial tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T095 |
Endometrium cancer test tissue array (4x (2x3)array), including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T101 |
Cervix cancer test tissue array, with normal cervix control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T101 |
Cervix cancer test tissue array, with normal cervix control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T102 |
Cervix cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T102 |
Cervix cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T103 |
Cervical cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T103 |
Cervical cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T104 |
Cervical cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T111 |
Ovary cancer test tissue array, with normal ovary control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T111 |
Ovary cancer test tissue array, with normal ovary control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T112 |
Ovary cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T112 |
Ovary cancer test tissue array, with normal control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T112a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T112a |
Ovary cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T112; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T113 |
Ovarian cancer test tissue array, with normal ovary tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T113 |
Ovarian cancer test tissue array, with normal ovary tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T113a |
Ovary cancer test tissue array with normal ovary tissue, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores, replacing T113; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T114 |
Ovary cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T121 |
Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T121 |
Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T122 |
Bladder cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T122 |
Bladder cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T124; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T123 |
Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T123 |
Bladder cancer test tissue array, with normal bladder tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T124 |
Bladder cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T122; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T125 |
Bladder cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T141 |
Pancreatic cancer test tissue array, with normal pancreas control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T141 |
Pancreatic cancer test tissue array, with normal pancreas control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T141a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T141a |
Pancreas cancer test tissue array, including TNM and pathology grade, 6 cases_24 cores, replacing T141; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T142 |
Pancreatic cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T142 |
Pancreatic cancer test tissue array, with normal tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T142a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T142a |
Pancreas tumor test tissue array, including TNM and pathology grade, 12 cases_24 cores, replacing T142; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T143 |
Pancreatic cancer test tissue array, with normal pancreatic tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T143 |
Pancreatic cancer test tissue array, with normal pancreatic tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T144 |
Pancreas cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T151 |
Thyroid cancer test tissue array, with normal thyroid control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T151 |
Thyroid cancer test tissue array, with normal thyroid control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T153 |
Thyroid cancer test tissue array, with normal thyroid gland tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T153 |
Thyroid cancer test tissue array, with normal thyroid gland tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T161 |
Nasopharyngeal and laryngeal cancer test tissue array, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T161 |
Nasopharyngeal and laryngeal cancer test tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T163 |
Nose, pharyngeal and laryngeal cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T163 |
Nose, pharyngeal and laryngeal cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirme |
|
105-Eur |
US Biomax |
assays |
| T171 |
Brain glioma test tissue array, with normal brain tissues as control, including pathology grade, 6 cases_24 cores, replaced by T174 |
|
88-Eur |
US Biomax |
assays |
| T171 |
Brain glioma test tissue array, with normal brain tissues as control, including pathology grade, 6 cases_24 cores, replaced by T174a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T172 |
Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T172 |
Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T175; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T173 |
Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T173 |
Brain cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores, replaced by T173a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T173a |
Brain cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 2 serial sections, 6 cases_24 cores, replacing T173; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T174 |
Brain tumor test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores, replacing T171 |
|
88-Eur |
US Biomax |
assays |
| T174 |
Brain tumor test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores, replacing T171; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T174a |
Brain tumor tissue array with normal brain tissue as control, including pathology grade, 6 cases_24 cores, replacing T171; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T175 |
Brain tumor tissue array with normal brain tissue as control, including pathology grade, 12 cases_24 cores, replacing T172; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T176 |
Brain tumor tissue array, including pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T191 |
Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T191 |
Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T192 |
Prostate cancer test tissue array, with normal control tissue, including TNM, clinical stage, pathology grade, gleason grade and gleason score, 12 cases_24 cores, replaced by T195 |
|
88-Eur |
US Biomax |
assays |
| T192 |
Prostate cancer test tissue array, with normal control tissue, including TNM, clinical stage, pathology grade, gleason grade and gleason score, 12 cases_24 cores, replaced by T195; ihc Anti-Actin con |
|
105-Eur |
US Biomax |
assays |
| T193 |
Prostate cancer test tissue array, with normal prostate tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T193 |
Prostate cancer test tissue array, with normal prostate tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T194 |
Prostate cancer test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases_24 cores, replaced by T195 |
|
88-Eur |
US Biomax |
assays |
| T194 |
Prostate cancer test tissue array, with normal control tissue, including TNM and pathology grade, 12 cases_24 cores, replaced by T195; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T195 |
Prostate adenocarcinoma tissue array, including TNM and pathology grade, 12 cases_24 cores, 2 serial sections, replacing T192 |
|
113-Eur |
US Biomax |
tissue |
| T195 |
Prostate adenocarcinoma tissue array, including TNM and pathology grade, 12 cases_24 cores, 2 serial sections, replacing T192 |
|
100-Eur |
US Biomax |
tissue |
| T195 |
Prostate adenocarcinoma tissue array, including TNM and pathology grade, 12 cases_24 cores, 2 serial sections, replaced by T195a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T195a |
Prostate cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T195; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T196 |
Prostate cancer test tissue array (4x (2x3) array)???including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T201 |
Lymphoma test tissue array, with normal lymph node control tissues, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T201 |
Lymphoma test tissue array, with normal lymph node control tissues, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T203 |
Lymphatic tissue tumor test tissue array, with normal tissue, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T203 |
Lymphatic tissue tumor test tissue array, with normal tissue, 12 cases_24 cores, replaced by T203a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T203a |
Lymphatic tissue tumor test tissue array, with normal control tissue, 12 cases_24 cores, replacing T203; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T204 |
Lymphoma test tissue array, with normal tissue as control, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T204 |
Lymphoma test tissue array, with normal tissue as control, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T205 |
Lymphoma tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T211 |
Skin cancer test tissue array, with normal skin control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T211 |
Skin cancer test tissue array, with normal skin control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T212 |
Skin cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T212 |
Skin cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replaced by T212a; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T212a |
Skin tumor tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing T212; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T213 |
Skin cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T213 |
Skin cancer test tissue array, with normal tissue as control, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T214 |
Skin tumor tissue array, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T221 |
Penis cancer test tissue array, with normal penis control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T221 |
Penis cancer test tissue array, with normal penis control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T223 |
Penis cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T223 |
Penis cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T231 |
Testis cancer test tissue array, with normal testis control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T231 |
Testis cancer test tissue array, with normal testis control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T231a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T231a |
Testis tumor tissue array with normal tissue as control, including TNM and clinical stage, 6 cases_24 cores, replacing T231; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T233 |
Testis cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T233 |
Testis cancer test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T241 |
Soft tissue cancer test tissue array, with normal soft tissue control tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T241 |
Soft tissue cancer test tissue array, with normal soft tissue control tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T242 |
Soft tissue cancer test tissue array, with normal tissue, including TNM and clinical stage, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T242 |
Soft tissue cancer test tissue array, with normal tissue, including TNM and clinical stage, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T243 |
Soft tissue tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T243 |
Soft tissue tumor test tissue array, with normal tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T244 |
Soft tissue malignant tumor tissue array, including TNM and clinical stage, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T261 |
Bone and cartilage cancer test tissue array, with normal bone and cartilage tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T261 |
Bone and cartilage cancer test tissue array, with normal bone and cartilage tissue as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T262 |
Bone cancer test tissue array, with normal control tissue, including TNM and clinical stage, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T262 |
Bone cancer test tissue array, with normal control tissue, including TNM and clinical stage, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T263 |
Bone and cartilage tumor tissue array, with normal tissue, including TNM, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T263 |
Bone and cartilage tumor tissue array, with normal tissue, including TNM, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T271 |
Oral cavity tumor test tissue array, with normal oral cavity control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T271 |
Oral cavity tumor test tissue array, with normal oral cavity control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T273 |
Oral cavity cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T273 |
Oral cavity cancer test tissue array, with normal tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T291 |
Multiple myeloma test tissue array, with normal bone marrow tissue as control, 6 cases_24 cores |
|
100-Eur |
US Biomax |
assays |
| T291 |
Multiple myeloma test tissue array, with normal bone marrow tissue as control, 6 cases_24 cores, replaced by T291a; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
assays |
| T291a |
Myeloma tissue array with normal tissue as control, 6 cases_24 cores, replacing T291; ihc Anti-actin |
|
114-Eur |
US Biomax |
tissue |
| T293 |
Bone marrow tumor and normal tissue array, including TNM, 6 cases_24 cores |
|
100-Eur |
US Biomax |
tissue |
| T293 |
Bone marrow tumor and normal tissue array, including TNM, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T301 |
Heart tumor test tissue array, with normal heart tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T301 |
Heart tumor test tissue array, with normal heart tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T303 |
Heart tumor test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T303 |
Heart tumor test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T321 |
Spleen tumor test tissue array, with normal spleen control tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T321 |
Spleen tumor test tissue array, with normal spleen control tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T323 |
Spleen tumor tissue array, with normal tissue, including TNM, 6 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| T323 |
Spleen tumor tissue array, with normal tissue, including TNM, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| T342 |
Head & Neck cancer test tissue array, with normal tongue and epiglottis control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T342 |
Head & Neck cancer test tissue array, with normal tongue and epiglottis control tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| T343 |
Head & Neck cancer tissue array, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| T381 |
Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 6 cases_24 cores, replaced by T385 |
|
88-Eur |
US Biomax |
assays |
| T381 |
Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 6 cases_24 cores, replaced by T385; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T382 |
Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T382 |
Malignant melanoma test tissue array, with normal skin control tissue, including TNM and clinical stage, 12 cases_24 cores; ihc Anti-HMB45 confirmed |
|
105-Eur |
US Biomax |
assays |
| T383 |
Malignant melanoma test tissue array, with normal skin tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T383 |
Malignant melanoma test tissue array, with normal skin tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T385 |
Malignant melanoma test tissue array, with normal skin tissue as control, including TNM and clinical stage, 6 cases_24 cores, replaced by T386 |
|
88-Eur |
US Biomax |
assays |
| T385 |
Malignant melanoma test tissue array, with normal skin tissue as control, including TNM and clinical stage, 6 cases_24 cores, replaced by T385a; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T385a |
Malignant melanoma test tissue array, including TNM and clinical stage, 6 cases_24 cores, replacing T385; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T386 |
Malignant melanoma test tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases_24 cores, replacing T385 |
|
88-Eur |
US Biomax |
assays |
| T386 |
Malignant melanoma test tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases_24 cores, replacing T385; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T388 |
Malignant melanoma test tissue array (4x (2x3)array), including TNM and clinical stage, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T391 |
Mesothelioma test tissue array, with normal mesothelium tissue as control, including TNM and clinical stage, 6 cases_24 cores, replaced by T392 |
|
88-Eur |
US Biomax |
assays |
| T391 |
Mesothelioma test tissue array, with normal mesothelium tissue as control, including TNM and clinical stage, 6 cases_24 cores, replaced by T392; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T392 |
Mesothelioma test tissue array, with normal mesothelial control tissue, including TNM and clinical stage, 6 cases_24 cores, replacing T391 |
|
88-Eur |
US Biomax |
assays |
| T392 |
Mesothelioma test tissue array, with normal mesothelial control tissue, including TNM and clinical stage, 6 cases_24 cores, replacing T391; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T413 |
Appendix cancer test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T413 |
Appendix cancer test tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T421 |
Small intestine cancer test tissue array, with normal small intestine tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T421 |
Small intestine cancer test tissue array, with normal small intestine tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T423 |
Small intestine cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T423 |
Small intestine cancer test tissue array, with normal tissue, including TNM and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
assays |
| T433 |
Adrenal gland cancer test tissue array, with normal tissue, 2 serial sections, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T433 |
Adrenal gland cancer test tissue array, with normal tissue, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| T461 |
Thymus cancer test tissue array, with normal control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| T461 |
Thymus cancer test tissue array, with normal control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| TE2081 |
Testis disease spectrum (testicular cancer progression) tissue array, with TNM data, 104 cases_208 cores |
|
456-Eur |
US Biomax |
assays |
| TE2081 |
Testis disease spectrum (testicular cancer progression) tissue array, with TNM data, 104 cases_208 cores; ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
assays |
| TE241 |
Testis cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TE241 |
Testis cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-leukocyte common antigen confirmed |
|
105-Eur |
US Biomax |
assays |
| TE242 |
Testis cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases_24 cores, replacing TE241 |
|
88-Eur |
US Biomax |
assays |
| TE242 |
Testis cancer tissue array, with adjacent normal tissue, including TNM and pathology grade, 12 cases_24 cores, replacing TE241; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| TE481 |
Testis cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with stage data |
|
160-Eur |
US Biomax |
assays |
| TE481 |
Testis cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with stage data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
assays |
| TE482 |
Testis tumor tissue array, including TNM, 24 cases_48 cores |
|
225-Eur |
US Biomax |
assays |
| TE482 |
Testis tumor tissue array, including TNM, 24 cases_48 cores |
|
189-Eur |
US Biomax |
assays |
| TE482 |
Testis tumor tissue array, including TNM, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
185-Eur |
US Biomax |
assays |
| TE802 |
Testis seminoma and lymphoma tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
assays |
| TE802 |
Testis seminoma and lymphoma tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
assays |
| TE803 |
Testis disease spectrum (testicular cancer progression) tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
assays |
| TE803 |
Testis disease spectrum (testicular cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
assays |
| TET481 |
Human testis cancer tissue array, 24 cases_48 cores |
|
225-Eur |
US Biomax |
assays |
| TET481 |
Human testis cancer tissue array, 24 cases_48 cores; ihc H&E, IHC anti- Cytokeratin |
|
238-Eur |
US Biomax |
assays |
| TH208 |
Thyroid cancer tissue microarray with normal tissue control, high density (60 cases_208 cores), with clinical stage data |
|
456-Eur |
US Biomax |
tissue |
| TH208 |
Thyroid cancer tissue microarray with normal tissue control, high density (60 cases_208 cores), with clinical stage data; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| TH241 |
Thyroid cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| TH241 |
Thyroid cancer tissue array with self-matching normal adjacent tissues, 10 cases_24 cores; ihc Anti-Thyroglobulin (TG) antibody confirmed |
|
105-Eur |
US Biomax |
tissue |
| TH242 |
Thyroid cancer tissue array with matched adjacent thyroid tissue, including TNM and clinical stage, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| TH481 |
Thyroid cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with grade and stage info |
|
160-Eur |
US Biomax |
tissue |
| TH481 |
Thyroid cancer tissue array with unmatched normal adjacent tissues, 48 cases_48 cores, with grade and stage info; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| TH721 |
Thyroid cancer and normal tissue array with clinical stage and grade info, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| TH721 |
Thyroid cancer and normal tissue array with clinical stage and grade info, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TH801 |
Thyroid cancer tissue array, with matched or unmatched adjacent normal tissue, 68 cases_80 cores, no overlaps with TH802 |
|
231-Eur |
US Biomax |
tissue |
| TH801 |
Thyroid cancer tissue array, with matched or unmatched adjacent normal tissue, 68 cases_80 cores, no overlaps with TH802; ihc Anti-Thyroglobulin (TG) antibody confirmed |
|
267-Eur |
US Biomax |
tissue |
| TH8010 |
Thyroid cancer and normal tissue array, with stage and grade info, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| TH8010 |
Thyroid cancer and normal tissue array, with stage and grade info, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TH802 |
Thyroid cancer and adenoma tissue array, 80 cases_80 cores, no overlaps with TH801 |
|
231-Eur |
US Biomax |
tissue |
| TH802 |
Thyroid cancer and adenoma tissue array, 80 cases_80 cores, no overlaps with TH801, replaced by TH802a; ihc Anti-Thyroglobulin (TG) confirmed |
|
267-Eur |
US Biomax |
tissue |
| TH802a |
Thyroid cancer and adenoma tissue array, including TNM and clinical stage, 80 cases_80 cores, replacing TH802; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| TH803 |
Thyroid papillary cancer tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| TH803 |
Thyroid papillary cancer tissue array, 80 cases_80 cores; ihc Anti-Thyroglobulin (Tg) confirmed |
|
267-Eur |
US Biomax |
tissue |
| TH804 |
Normal thyroid gland tissue array, 80 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| TH804 |
Normal thyroid gland tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| TH805 |
Goiter and thyroiditis tissue array, 80 cases_80 cores |
|
231-Eur |
US Biomax |
tissue |
| TH805 |
Goiter and thyroiditis tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
267-Eur |
US Biomax |
tissue |
| TH806 |
Thyroid medullary cancer tissue array and normal tissues, 40 cases_80 cores, with grade and stage data |
|
266-Eur |
US Biomax |
tissue |
| TH806 |
Thyroid medullary cancer tissue array and normal tissues, 40 cases_80 cores, with grade and stage data; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TH807 |
Thyroid disease spectrum tissue array, 75 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| TH807 |
Thyroid disease spectrum tissue array, 75 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TH808 |
Thyroid cancer and normal tissue array, with grade and stage data, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| TH808 |
Thyroid cancer and normal tissue array, with grade and stage data, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TH809 |
Thyroid cancer metastasis tissue array, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| TH809 |
Thyroid cancer metastasis tissue array, 40 cases_80 cores, replaced by TH809a; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TH809a |
Thyroid metastatic carcinoma tissue array with normal thyroid tissue as control, 40 cases_80 cores, replacing TH809; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| THC241 |
Thyroid cancer array, 12 cases_24 cores |
|
189-Eur |
US Biomax |
|
| THC241 |
Thyroid cancer array, 12 cases_24 cores; ihc H&E, IHC Cytokeratin |
|
205-Eur |
US Biomax |
rat |
| THC961 |
Thyroid cancer tissue array, 48 cases_96 cores |
|
225-Eur |
US Biomax |
elisa |
| THC961 |
Thyroid cancer tissue array, 48 cases_96 cores; ihc H&E, IHC anti-Cytokeratin |
|
238-Eur |
US Biomax |
elisa |
| THD181 |
Thyroid disease tissue array, 18 cases_18 cores |
|
142-Eur |
US Biomax |
tissue |
| THD181 |
Multiple organ, normal fetus tissue array, 50 cases_50 cores; ihc Anti-Actin confirmed |
|
138-Eur |
US Biomax |
tissue |
| THY761 |
Thymus disease spectrum (thymic cancer progression) tissue array, 76 cases_76 cores |
|
266-Eur |
US Biomax |
tissue |
| THY761 |
Thymus disease spectrum (thymic cancer progression) tissue array, 76 cases_76 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| TMA2001 |
Multiple organ cancer with normal tissue array, with TNM data, 180 cases_200 cores |
|
397-Eur |
US Biomax |
tissue |
| TMA2001 |
Multiple organ cancer with normal tissue array, with TNM data, 180 cases_200 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| TMA2081 |
High density (156 cases_208 cores) tissue array of normal colon, prostate and breast tissue |
|
456-Eur |
US Biomax |
tissue |
| TMA2081 |
High density (156 cases_208 cores) tissue array of normal colon, prostate and breast tissue; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| TMA2401 |
High density multiple organ (top 4) cancer tissue array (240 cores) |
|
456-Eur |
US Biomax |
tissue |
| TMA2401 |
High density multiple organ (top 4) cancer tissue array (240 cores); ihc Anti-Actin confirmed |
|
429-Eur |
US Biomax |
tissue |
| TOP4-240 |
High density tissue array of top 4 types of cancers with normal tissue control, 220 cases_240 cores |
|
456-Eur |
US Biomax |
tissue |
| TOP4-240 |
High density tissue array of top 4 types of cancers with normal tissue control, 220 cases_240 cores; ihc Anti-Actin confirmed |
|
487-Eur |
US Biomax |
tissue |
| TP241 |
Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM and pathology grade, 12 cases_24 cores |
|
99-Eur |
US Biomax |
tissue |
| TP241 |
Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM and pathology grade, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| TP241 |
Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| TP242 |
Top 4 types of cancer (colon, breast, prostate and lung) 24 core test tissue array, 24 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TP242 |
Top 4 types of cancer (colon, breast, prostate and lung) 24 core test tissue array, 24 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
assays |
| TP481 |
Top 4 types of cancer (colon, breast, prostate and lung) 48 core tissue array, 48 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| TP481 |
Top 4 types of cancer (colon, breast, prostate and lung) 48 core tissue array, 48 cases_48 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
185-Eur |
US Biomax |
tissue |
| TP482 |
Top 4 types of cancer (colon, breast, lung and prostate) tissue microarray, 22 cases_48 cores, plus grade, stage and Gleason Score information |
|
160-Eur |
US Biomax |
tissue |
| TP482 |
Top 4 types of cancer (colon, breast, lung and prostate) tissue microarray, 22 cases_48 cores, plus grade, stage and Gleason Score information; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| TP483 |
Top 4 types of cancer (colon, breast, prostate and lung) tissue microarray, 48 case_48 cores, with grade, Gleason score and stage data |
|
160-Eur |
US Biomax |
tissue |
| TP483 |
Top 4 types of cancer (colon, breast, prostate and lung) tissue microarray, 48 case_48 cores, with grade, Gleason score and stage data; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| TP484 |
Tissue microarray of top 4 types of cancer (colon, breast, prostate and lung) and normal tissue, 24 cases_48 cores |
|
160-Eur |
US Biomax |
tissue |
| TP484 |
Tissue microarray of top 4 types of cancer (colon, breast, prostate and lung) and normal tissue, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| TR011 |
Rat normal stomach test tissue array, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TR011 |
Rat normal stomach test tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| TR031 |
Rat normal liver test tissue array, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TR031 |
Rat normal liver test tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| TR041 |
Rat normal lung test tissue array, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TR041 |
Rat normal lung test tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| TR071 |
Rat normal kidney test tissue array, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TR071 |
Rat normal kidney test tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| TR301 |
Rat normal heart test tissue array, 6 cases_24 cores |
|
88-Eur |
US Biomax |
assays |
| TR301 |
Rat normal heart test tissue array, 6 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
assays |
| UGD381 |
Urinary_genital system disease tissue array, 38 cases_38 cores |
|
166-Eur |
US Biomax |
tissue |
| UGD381 |
Urinary_genital system disease tissue array, 38 cases_38 cores; ihc H&E, IHC anti- Cytokeratin |
|
178-Eur |
US Biomax |
tissue |
| UNC241 |
Universal control tissue array, used for screening of more than 90% routine IHC markers, 12 cases_24 cores |
|
77-Eur |
US Biomax |
tissue |
| UNC241 |
Universal control tissue array, used for screening of more than 90% routine IHC markers, 12 cases_24 cores; ihc H&E, IHC anti-Vimentin_Cytokeratin |
|
85-Eur |
US Biomax |
tissue |
| UR1001 |
Ureter and urethra disease spectrum tissue array, with stage, grade and TNM data, 50 cases_100 cores |
|
199-Eur |
US Biomax |
tissue |
| UR1001 |
Ureter and urethra disease spectrum tissue array, with stage, grade and TNM data, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| UT1001 |
Endometrial cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| UT1001 |
Endometrial cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UT1002 |
Endometrium cancer tissue array for antibody screening, including TNM and pathology grade, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| UT1002 |
Endometrium cancer tissue array for antibody screening, including TNM and pathology grade, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UT1501 |
Uterus cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores; ihc Anti-Actin confirmed |
|
258-Eur |
US Biomax |
tissue |
| UT241 |
Uterine endometrial cancer tissue array with normal tissue from autopsy, 12 cases_24 cores, with TNM data |
|
100-Eur |
US Biomax |
tissue |
| UT241 |
Uterine endometrial cancer tissue array with normal tissue from autopsy, 12 cases_24 cores, with TNM data; ihc Anti-Actin confirmed |
|
114-Eur |
US Biomax |
tissue |
| UT242 |
Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores |
|
189-Eur |
US Biomax |
tissue |
| UT242 |
Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 2 serial sections, 24 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| UT242a |
Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_24 cores |
|
100-Eur |
US Biomax |
tissue |
| UT242a |
Endometrium cancer tissue array, with normal tissue, including TNM and pathology grade, 24 cases_24 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| UT243 |
Endometrium cancer tissue array with matched adjacent endometrium tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores; ihc Anti-Actin confirmed |
|
90-Eur |
US Biomax |
tissue |
| UT481 |
Endometrium cancer tissue array, including TNM and pathology grade, 48 cases_48 cores |
|
278-Eur |
US Biomax |
tissue |
| UT481 |
Endometrium cancer tissue array, including TNM and pathology grade, 48 cases_48 cores; ihc Anti-Actin confirmed |
|
267-Eur |
US Biomax |
tissue |
| UT501 |
Endometrioid adenocarcinoma and normal tissue array with TNM and grade, 50 cases_50 cores |
|
160-Eur |
US Biomax |
tissue |
| UT501 |
Endometrioid adenocarcinoma and normal tissue array with TNM and grade, 50 cases_50 cores; ihc Anti-Actin confirmed |
|
210-Eur |
US Biomax |
tissue |
| UT721 |
Endometrioid adenocarcinoma and normal tissue array with clinical stage and grade information, 24 cases_72 cores |
|
266-Eur |
US Biomax |
tissue |
| UT721 |
Endometrioid adenocarcinoma and normal tissue array with clinical stage and grade information, 24 cases_72 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UT801 |
Endometrial disease spectrum (endometrial cancer progression) tissue array, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| UT801 |
Endometrial disease spectrum (endometrial cancer progression) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
382-Eur |
US Biomax |
tissue |
| UT802 |
Uteral cancer (multi-types of uterine carcinomas and diseases) tissue array, 80 cases_80 cores |
|
278-Eur |
US Biomax |
tissue |
| UT802 |
Uteral cancer (multi-types of uterine carcinomas and diseases) tissue array, 80 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UT803 |
Endometrioid carcinoma, adjacent and normal tissue array, with grade and stage information, 40 cases_80 cores |
|
266-Eur |
US Biomax |
tissue |
| UT803 |
Endometrioid carcinoma, adjacent and normal tissue array, with grade and stage information, 40 cases_80 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UT961 |
Endometrium cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores; ihc Anti-Actin confirmed |
|
228-Eur |
US Biomax |
elisa |
| UTE601 |
Fallopian tube disease spectrum (fallopian tube cancer progression) tissue array, 30 cases_60 cores |
|
266-Eur |
US Biomax |
tissue |
| UTE601 |
Fallopian tube disease spectrum (fallopian tube cancer progression) tissue array, 30 cases_60 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UV1001 |
Vulval disease spectrum (vulva cancer progression) tissue array, 46 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| UV1001 |
Vulval disease spectrum (vulva cancer progression) tissue array, 46 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| UV241 |
Vulvar (vulva) cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores |
|
88-Eur |
US Biomax |
tissue |
| UV241 |
Vulvar (vulva) cancer tissue array with unmatched normal adjacent tissues, 12 cases_24 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
105-Eur |
US Biomax |
tissue |
| UV801 |
Vulva malignant tumor tissue array, 39 cases_78 cores |
|
266-Eur |
US Biomax |
tissue |
| UV801 |
Vulva malignant tumor tissue array, 39 cases_78 cores; ihc Anti-Cytokeratin (CK) confirmed |
|
258-Eur |
US Biomax |
tissue |
| VA1001 |
Vermiform appendix disease spectrum (vermiform appendix tumor progression) tissue array, 50 cases_100 cores |
|
266-Eur |
US Biomax |
tissue |
| VA1001 |
Vermiform appendix disease spectrum (vermiform appendix tumor progression) tissue array, 50 cases_100 cores; ihc Anti-Actin confirmed |
|
296-Eur |
US Biomax |
tissue |
| VLC11 |
Lung cancer tissue array, with TNM and grade info, 11 cases_11 cores |
|
88-Eur |
US Biomax |
tissue |
| VLC11 |
Lung cancer tissue array, with TNM and grade info, 11 cases_11 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
| VLC12 |
Lung cancer tissue array, with TNM and grade info, 12 cases_12 cores |
|
88-Eur |
US Biomax |
tissue |
| VLC12 |
Lung cancer tissue array, with TNM and grade info, 12 cases_12 cores; ihc Anti-Actin confirmed |
|
105-Eur |
US Biomax |
tissue |
GENTAUR Europe BVBA
GENTAUR France SARL
GENTAUR GmbH 
GENTAUR Ltd. 
GENTAUR Poland Sp. z o.o. 
GENTAUR Nederland BV
GENTAUR SRL IVA IT03841300167
GENTAUR Spain
GENTAUR BULGARIA